APPROVED DRUG PRODUCTS
With Therapeutic Equivalence Evaluations

The "Orange Book"

FDA data supplied by DrugPatentWatch.com

CUMULATIVE SUPPLEMENT 7
July 2005



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

25th EDITION

Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs

2005

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

25th EDITION

Cumulative Supplement 7

July 2005

CONTENTS

PAGE

Note:
Historically, the Electronic Orange Book (EOB) and Cumulative Supplement (CS) have been updated monthly, each month updated by the end of the third working week of the following month.

As of February 2005, we are also providing daily EOB product information for new generic drug approvals. Daily generic updates will provide the consumer with the most current listing of approved generic products. Previously, a first-time-generic approved early in the month would not be published in the CS for several weeks. Daily generic updates are especially important since the Orange Book listing may be relevant for substitution.

As a result, the monthly CS will include generic approvals and related product changes current to the day of publication (e.g., the June CS will include generic approvals up to the third week of July). Patent information is also current to the day of publication.

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

25th EDITION

CUMULATIVE SUPPLEMENT 7
July 2005

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 25th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 25th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 26th Edition. The current edition

Section 2. How To Use The Drug Product Lists describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >**A**>. The Patent and Exclusivity List new additions are indicated by the symbol **>A>** to the left of Patent Number or Exclusivity Code. The **>A>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>D>** (DELETE) to the left of the line. The information line with the **>D>** symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
CELLTECH PHARMACEUTICALS INC (CELLTECH PHARMS	UCB PHARMA INC (UCB)
FUJISAWA HEALTHCARE	ASTELLAS PHARMA US INC

(FUJISAWA HLTHCARE)	(ASTELLAS)
SHIRE LABORATORIES INC	SHIRE DEVELOPMENT INC
(SHIRE LABS)	(SHIRE)
SHIRE PHARMACEUTICAL DEVELOPMENT INC	SHIRE DEVELOPMENT INC
(SHIRE PHARM)	(SHIRE)
YAMANOUCHI PHARMA AMERICA INC	ASTELLAS PHARMA US INC
(YAMANOUCHI)	(ASTELLAS)

1.3 LEVOTHYROXINE SODIUM

The Description of Special Situations, Levothyroxine Sodium, published in the 25th Annual Edition of the Orange Book, has been modified in the Cumulative Supplement to include information on Genpharm ANDA 76752 approved in 2005. The full discussion as published in the 25th Annual Edition is repeated in the Cumulative Supplement and includes recent approval information on levothyroxine sodium.

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210) and Levothyroxine Sodium (Genpharm ANDA 76752)tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210) and Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King/Jones Pharma NDA 021301) tablets.

Novothyrox (Genpharm NDA 021292) requires further investigation and review to establish therapeutic equivalence to corresponding strengths of any other levothyroxine sodium drug products and is rated BX.

Thyro-Tabs (Lloyd NDA 021116) requires further investigation and review to establish therapeutic equivalence to corresponding strengths of any other levothyroxine sodium drug products and is rated BX.

Levolet (Vintage NDA 021137) requires further investigation and review to establish therapeutic equivalence to corresponding strengths of any other levothyroxine sodium drug products and is rated BX.

The chart outlines TE codes for all 0.025mg products with other products being similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	JONES PHARMA	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOTHYROXINE SODIUM	GENPHARM	0.025MG	AB2	76752	001
LEVOXYL	JONES PHARMA	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
NOVOTHYROX	GENPHARM	0.025MG	BX	21292	001
THYRO-TABS	LLOYD	0.025MG	BX	21116	001
LEVOLET	VINTAGE PHARMS	0.025MG	BX	21137	001

1.4 AVAILABILITY OF THE EDITION

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements will not be available in a published paper version. Since 1997, the Electronic Orange Book (EOB http://www.fda.gov/cder/ob/default.htm, has been available on the internet and has become the updated-every-month Orange Book.

The 25th edition and current monthly supplement are available in an electronic downloadable Portable Document Format (PDF) at the EOB home page by clicking on the Annual Edition. The PDF annual and cumulative supplements will duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The Electronic Orange Book Query (EOB) is at http://www.fda.gov/cder/ob/default.htm. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product. Currently, In addition to monthly updates, in the public interest, the EOB is updated on a daily basis with new generic product approval information and new patent information. Current month updates are accomplished by the third week of the following month.

The Internet version of the Orange Book annual edition is at http://www.fda.gov/cder/ob/docs/preface/ectablec.htm The Internet version of the monthly supplement is at http://www.fda.gov/cder/orange/supplement/cspreface.htm_.

There are historical lists of Orange Book cumulative supplement product monthly changes at http://www.fda.gov/cder/rxotcdpl/pdplarchive.htm

There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at http://www.fda.gov/cder/orange/obreadme.htm . The drug product text files are zipped into eobzip.exe. The files are updated concurrently with the monthly cumulative supplements. Appendix A and Appendix B text files of the annual Orange Book Edition are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, http://www.fda.gov/opacom/morechoices/fdaforms/default.html.

The current listing of the Orphan Product Designations and Approvals is available at http://www.fda.gov/orphan/designat/list.htm.

1.5 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2004) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2004	MAR 2005	JUN 2005	SEP 2005
DRUG PRODUCTS LISTED	11082	11184	11167	
SINGLE SOURCE	2427 (21.9%)	2437 (21.8%)	2428 (21.7%)	
MULTISOURCE	8547 (77.1%)	8637 (77.2%)	8630 (77.3%)	
THERAPEUTICALLY EQUIVALENT	8327 (75.1%)	8428 (75.4%)	8421 (75.4%)	
NOT THERAPEUTICALLY EQUIVALENT	220 (2.0%)	209 (1.9%)	209 (1.9%)	
EXCEPTIONS[1]	108 (1.0%)	110 (1.0%)	109 (1.0%)	
NEW MOLECULAR ENTITIES APPROVED	9	2	4	
NUMBER OF APPLICANTS	625	631	627	

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.6 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.

DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.
WDAG	Withdrawn. The applicant holder has notified the FDA in writing that the product in no longer being marketed resulting in the product approval being withdrawn by mutual agreement. The product will be listed in the Discontinued Section.
WDRP	Withdrawn. The application approval has been withdrawn for failure to provide Annual Reports. The product will be moved to the Discontinued Section in the next edition

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

		@ ABLE	325MG;50MG;40MG	N40390	001	Jul 23, 2001	May		DISC
		@	500MG;50MG;40MG	N40394	001	Jul 23, 2001	May		DISC

BUTALBITAL, ACETAMINOPHEN, CAFFEINE

>A>	AB	MUTUAL PHARM	325MG;50MG;40MG	N40601	001	Jul 29, 2005	Jul		NEWA

BUTALBITAL, APAP, AND CAFFEINE

	AB	WATSON LABS	325MG;50MG;40MG	N89536	001	Feb 16, 1988	Feb		CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL; ACETAMINOPHEN; CAFFEINE AND CODEINE PHOSPHATE

		@ ABLE	325MG;50MG;40MG;30MG	N76528	001	Aug 21, 2003	May		DISC

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

		@ ABLE	300MG;30MG	N40452	001	Aug 01, 2002	May		DISC
		@	300MG;60MG	N40459	001	Aug 01, 2002	May		DISC
>A>	AA	VINTAGE	300MG;15MG	N89990	001	Sep 30, 1988	Jul		CAHN
>D>	AA	VINTAGE PHARMS	300MG;15MG	N89990	001	Sep 30, 1988	Jul		CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

		@ ABLE	325MG;5MG	N40478	001	Nov 08, 2002	May		DISC
		@	325MG;7.5MG	N40464	001	Oct 23, 2002	May		DISC
		@	325MG;10MG	N40464	002	Oct 23, 2002	May		DISC
		@	500MG;5MG	N40477	001	Nov 06, 2002	May		DISC
		@	500MG;7.5MG	N40490	001	May 21, 2003	May		DISC
		@	500MG;10MG	N40473	001	Nov 06, 2002	May		DISC
		@	650MG;7.5MG	N40474	001	Jan 02, 2003	May		DISC
		@	650MG;10MG	N40476	001	Oct 23, 2002	May		DISC
		@	750MG;7.5MG	N40469	001	Oct 25, 2002	May		DISC

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

DARVOCET-N 100

>D>	AB	+ AAIPHARMA LLC	650MG;100MG	N17122	002		Jul		CAHN
>A>	AB	+ XANODYNE PHARM	650MG;100MG	N17122	002		Jul		CAHN

DARVOCET-N 50

>D>	AB	AAIPHARMA LLC	325MG;50MG	N17122	001		Jul		CAHN
>A>	AB	XANODYNE PHARM	325MG;50MG	N17122	001		Jul		CAHN

PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

		@ ABLE	650MG;100MG	N75838	001	Jul 11, 2001	May		DISC
	AB	ANDRX PHARMS	500MG;100MG	N77196	001	Jun 28, 2005	Jun		NEWA

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

ACETAMINOPHEN AND TRAMADOL HCL

	AB	KALI LABS	325MG;37.5MG	N76475	001	Apr 21, 2005	Mar		NEWA

		TABLET; ORAL						
		ULTRACET						
AB	+	ORTHO MCNEIL PHARM	325MG;37.5MG	N21123	001	Aug 15, 2001	Mar	CFTG
		ACETIC ACID, GLACIAL						
		SOLUTION/DROPS; OTIC						
		ACETIC ACID						
AT	+	MORTON GROVE	2%	N40166	001	Jul 26, 1996	Jan	CRLD
AT		VINTAGE	2%	N40607	001	Feb 24, 2005	Feb	NEWA
		VOSOL						
		@ MEDPOINTE PHARM HLC	2%	N12179	001		Jan	DISC
		ACETYLCYSTEINE						
		SOLUTION; INHALATION, ORAL						
		MUCOSIL-10						
		@ DEY	10%	N70575	001	Oct 14, 1986	May	DISC
		MUCOSIL-20						
		@ DEY	20%	N70576	001	Oct 14, 1986	May	DISC
		ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE						
		CAPSULE; ORAL						
		SEMPREX-D						
	+	UCB	8MG;60MG	N19806	001	Mar 25, 1994	Mar	CAHN
		ACYCLOVIR						
		CAPSULE; ORAL						
		ACYCLOVIR						
AB		TEVA PHARMS	200MG	N74914	001	Nov 26, 1997	Mar	CAHN
		SUSPENSION; ORAL						
		ACYCLOVIR						
AB		HI TECH PHARMA	200MG/5ML	N77026	001	Jun 07, 2005	May	NEWA
		TABLET; ORAL						
		ACYCLOVIR						
AB		TEVA PHARMS	400MG	N75021	001	Mar 18, 1998	Mar	CAHN
AB			800MG	N75021	002	Mar 18, 1998	Mar	CAHN
		ACYCLOVIR SODIUM						
		INJECTABLE; INJECTION						
		ACYCLOVIR						
		@ ABBOTT	EQ 50MG BASE/ML	N75114	001	Jul 26, 1999	Feb	DISC
		ADAPALENE						
		SOLUTION; TOPICAL						
		DIFFERIN						
		@ GALDERMA LABS LP	0.1%	N20338	001	May 31, 1996	Jun	DISC
		ADENOSINE						
		INJECTABLE; INJECTION						
		ADENSOINE						
AP		AM PHARM	3MG/ML	N77133	001	Apr 27, 2005	Apr	NEWA
		ALBUTEROL SULFATE						
		SOLUTION; INHALATION						
		ALBUTEROL SULFATE						
AN	+	DEY	EQ 0.083% BASE	N72652	001	Feb 21, 1992	Jan	CRLD

TABLET, EXTENDED RELEASE; ORAL
ALBUTEROL SULFATE

>A>		ODYSSEY PHARMS	EQ 4MG BASE	N76130	002	Sep 26, 2002	Jul	CAHN
>A>	+		EQ 8MG BASE	N76130	003	Sep 26, 2002	Jul	CAHN
>D>		PLIVA	EQ 4MG BASE	N76130	002	Sep 26, 2002	Jul	CAHN
>D>	+		EQ 8MG BASE	N76130	003	Sep 26, 2002	Jul	CAHN

TABLET; ORAL
ALBUTEROL SULFATE

AB	+	MYLAN	EQ 2MG BASE	N72894	002	Jan 17, 1991	Apr	CMS1

ALCLOMETASONE DIPROPIONATE

CREAM; TOPICAL
ACLOVATE

AB	+	GLAXOSMITHKLINE	0.05%	N18707	001	Dec 14, 1982	Jun	CFTG

ALCLOMETASONE DIPROPIONATE

AB		ALTANA	0.05%	N76973	001	Jul 12, 2005	Jun	NEWA

OINTMENT; TOPICAL
ALCLOMETASONE DIPROPIONATE

AB		ALTANA	0.05%	N76884	001	Jul 18, 2005	Jun	NEWA

ALENDRONATE SODIUM

SOLUTION; ORAL
FOSAMAX

	+	MERCK	EQ 70MG BASE/75ML	N21575	001	Sep 17, 2003	Apr	CPOT

ALENDRONATE SODIUM; CHOLECALCIFEROL

TABLET; ORAL
FOSAMAX PLUS D

	+	MERCK	EQ 70MG BASE;2,800 IU	N21762	001	Apr 07, 2005	Apr	NEWA

ALPRAZOLAM

TABLET, ORALLY DISINTEGRATING; ORAL
NIRAVAM

		SCHWARZ PHARMA	0.25MG	N21726	001	Jan 19, 2005	Jan	NEWA
			0.5MG	N21726	002	Jan 19, 2005	Jan	NEWA
			1MG	N21726	003	Jan 19, 2005	Jan	NEWA
	+		2MG	N21726	004	Jan 19, 2005	Jan	NEWA

ALPROSTADIL

INJECTABLE; INJECTION
EDEX

AP	+	SCHWARZ PHARMA	0.01MG/VIAL	N20649	005	Jul 30, 1998	Apr	CTEC
AP	+		0.02MG/VIAL	N20649	006	Jul 30, 1998	Apr	CTEC
AP	+		0.04MG/VIAL	N20649	007	Jul 30, 1998	Apr	CTEC

AMANTADINE HYDROCHLORIDE

SYRUP; ORAL
AMANTADINE HCL

AA		TEVA PHARMS	50MG/5ML	N73115	001	Aug 23, 1991	Mar	CAHN

AMIKACIN SULFATE

INJECTABLE; INJECTION
AMIKACIN SULFATE

		@ MAYNE PHARMA USA	EQ 50MG BASE/ML	N63350	001	Jul 30, 1993	Jun	DISC
		@	EQ 250MG BASE/ML	N63350	002	Jul 30, 1993	Jun	DISC

AMINO ACIDS

INJECTABLE; INJECTION

AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE

		@ HOSPIRA	5.2% (5.2GM/100ML)	N18901	001	Apr 06, 1984	May	DISC

AMINOSYN 7%

		HOSPIRA	7% (7GM/100ML)	N17673	002		Mar	CMFD

AMINOSYN 8.5%

		HOSPIRA	8.5% (8.5GM/100ML)	N17673	004		Mar	CMFD

AMIODARONE

INJECTABLE; INTRAVENOUS

AMIODARONE HCL

AP		APOTEX	50MG/ML	N77161	001	Apr 20, 2005	Mar	NEWA

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HCL

AP	+	AM PHARM PARTNERS	50MG/ML	N75761	001	Oct 15, 2002	Mar	CRLD
AP	+	APOTEX	50MG/ML	N76394	001	Apr 25, 2003	Mar	CRLD
AP	+	BEDFORD	50MG/ML	N76018	001	Oct 15, 2002	Mar	CRLD
AP	+	BEDFORD LABS	50MG/ML	N76299	001	Oct 24, 2002	Mar	CRLD
AP	+	BEN VENUE	50MG/ML	N76088	001	Oct 15, 2002	Mar	CRLD
AP	+	BIONICHE (CANADA)	50MG/ML	N76217	001	Oct 15, 2002	Mar	CRLD
AP	+	MAYNE PHARMA USA	50MG/ML	N76108	001	Oct 15, 2002	Mar	CRLD
AP	+	SICOR PHARMS	50MG/ML	N76163	001	Sep 05, 2003	Mar	CRLD

TABLET; ORAL

AMIODARONE HCL

AB		AUROSAL PHARMS	200MG	N77069	001	Apr 08, 2005	Mar	NEWA
AB			400MG	N77069	002	Apr 08, 2005	Mar	NEWA
AB		TARO	100MG	N75424	002	Dec 18, 2002	Mar	CTEC
AB		TEVA PHARMS	200MG	N74739	001	Nov 30, 1998	Mar	CAHN

PACERONE

AB		UPSHER SMITH	100MG	N75135	002	Apr 12, 2005	Mar	NEWA

AMOXICILLIN

FOR SUSPENSION; ORAL

TRIMOX

AB		APOTHECON	50MG/ML	N61886	001		Apr	CMFD
AB			125MG/5ML	N61886	002		Apr	CMFD
AB			250MG/5ML	N61886	003		Apr	CMFD

TABLET; ORAL

AMOXICILLIN

AB		SANDOZ	500MG	N65228	001	Jul 13, 2005	Jun	NEWA
AB			875MG	N65228	002	Jul 13, 2005	Jun	NEWA

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB		HIKMA PHARMS	200MG/5ML;EQ 28.5MG BASE/5ML	N65191	002	Jan 25, 2005	Jan	NEWA
AB			400MG/5ML;EQ 57MG BASE/5ML	N65191	001	Jan 25, 2005	Jan	NEWA

AUGMENTIN '400'

>D>	AB	GLAXOSMITHKLINE	400MG/5ML;EQ 57MG BASE/5ML	N50725	002	May 31, 1996	Jul	CRLD
>A>	AB	+	400MG/5ML;EQ 57MG BASE/5ML	N50725	002	May 31, 1996	Jul	CRLD

TABLET, CHEWABLE; ORAL
AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	TEVA	200MG;EQ 28.5MG BASE	N65205	001	Feb 09, 2005	Jan	NEWA
AB		400MG;EQ 57MG BASE	N65205	002	Feb 09, 2005	Jan	NEWA

AMPHOTERICIN B

INJECTABLE, LIPID COMPLEX; INJECTION
AMPHOTEC

+	THREE RIVERS PHARMS	50MG/VIAL	N50729	001	Nov 22, 1996	May	CAHN
+		100MG/VIAL	N50729	002	Nov 22, 1996	May	CAHN

AMPICILLIN SODIUM

INJECTABLE; INJECTION
AMPICILLIN SODIUM

AP	INSTITUTO BIOCHEMICO	EQ 125MG BASE/VIAL	N62797	001	Jul 12, 1993	Jan	CMFD
AP		EQ 2GM BASE/VIAL	N62797	002	Jul 12, 1993	Jan	CAHN

AMPRENAVIR

CAPSULE; ORAL
AGENERASE

+	GLAXOSMITHKLINE	50MG	N21007	001	Apr 15, 1999	May	CRLD
@		150MG	N21007	002	Apr 15, 1999	May	DISC

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL
AGRYLIN

AB	SHIRE	EQ 0.5MG BASE	N20333	001	Mar 14, 1997	Mar	CFTG
AB +		EQ 1MG BASE	N20333	002	Mar 14, 1997	Mar	CFTG

ANAGRELIDE HCL

AB	BARR	EQ 0.5MG BASE	N76530	001	Apr 18, 2005	Mar	NEWA
AB		EQ 1MG BASE	N76530	002	Apr 18, 2005	Mar	NEWA
AB	EON	EQ 0.5MG BASE	N76683	001	Apr 18, 2005	Mar	NEWA
AB		EQ 1MG BASE	N76683	002	Apr 18, 2005	Mar	NEWA
AB	IMPAX LABS	EQ 0.5MG BASE	N76910	001	Apr 18, 2005	Mar	NEWA
AB		EQ 1MG BASE	N76910	002	Apr 18, 2005	Mar	NEWA
AB	IVAX PHARMS	EQ 0.5MG BASE	N76468	001	Apr 18, 2005	Mar	NEWA
AB		EQ 1MG BASE	N76468	002	Apr 18, 2005	Mar	NEWA
AB	MYLAN	EQ 0.5MG BASE	N76811	001	Apr 18, 2005	Mar	NEWA
AB		EQ 1MG BASE	N76811	002	Apr 18, 2005	Mar	NEWA
AB	ROXANE	EQ 0.5MG BASE	N76489	001	Apr 18, 2005	Mar	NEWA
AB		EQ 1MG BASE	N76489	002	Apr 18, 2005	Mar	NEWA
AB	WATSON LABS	EQ 0.5MG BASE	N76417	001	Apr 18, 2005	Mar	NEWA
AB		EQ 1MG BASE	N76417	002	Apr 18, 2005	Mar	NEWA

ARSENIC TRIOXIDE

INJECTABLE; INJECTION
TRISENOX

>D> +	CELL THERAP	1MG/ML	N21248	001	Sep 25, 2000	Jul	CAHN
>A> +	CEPHALON	1MG/ML	N21248	001	Sep 25, 2000	Jul	CAHN

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12

			@ MAYNE PHARMA USA	10MG/ML;0.006MG/ML;0.5UGM/ML;1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.36MG/ML;0.3MG/ML;330 UNITS/ML;1 IU/ML	N08809	004	Aug 08, 1985	Jun DISC

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12

			@ MAYNE PHARMA USA	20MG/ML;0.006MG/ML;0.5UGM/ML;1.5MG/ML;20 IU/ML;0.6MG/ML;4MG/ML;0.4MG/ML;0.36MG/ML;0.6MG/ML;330 UNITS/ML;1 IU/ML	N08809	005	Apr 22, 2004	Jun DISC

ASPIRIN; BUTALBITAL; CAFFEINE

TABLET; ORAL

BUTALBITAL W/ ASPIRIN & CAFFEINE

			@ PHARMERAL	325MG;50MG;40MG	N87048	002	Dec 09, 1983	May DISC	

BUTALBITAL, ASPIRIN AND CAFFEINE

	AB	+	WEST WARD	325MG;50MG;40MG	N86162	002	Feb 16, 1984	May CRLD	

FIORINAL

			@ WATSON PHARMS	325MG;50MG;40MG	N17534	003	Apr 16, 1986	May DISC	

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

DARVON COMPOUND

>D>			@ AAIPHARMA LLC	389MG;32.4MG;32MG	N10996	006	Mar 08, 1983	Jul CAHN	
>A>			@ XANODYNE PHARM	389MG;32.4MG;32MG	N10996	006	Mar 08, 1983	Jul CAHN	

DARVON COMPOUND-65

>D>	AA	+	AAIPHARMA LLC	389MG;32.4MG;65MG	N10996	007	Mar 08, 1983	Jul CAHN	
>A>	AA	+	XANODYNE PHARM	389MG;32.4MG;65MG	N10996	007	Mar 08, 1983	Jul CAHN	

ASPIRIN; HYDROCODONE BITARTRATE

TABLET; ORAL

AZDONE

		+	SCHWARZ PHARMA	500MG;5MG	N89420	001	Jan 25, 1988	May CAHN	

ASPIRIN; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

DARVON W/ ASA

>D>			@ AAIPHARMA LLC	325MG;65MG	N10996	005		Jul CAHN	
>A>			@ XANODYNE PHARM	325MG;65MG	N10996	005		Jul CAHN	

ATENOLOL

TABLET; ORAL

ATENOLOL

			@ ABLE	25MG	N76907	001	Jul 30, 2004	May DISC	
			@	50MG	N76907	002	Jul 30, 2004	May DISC	
			@	100MG	N76907	003	Jul 30, 2004	May DISC	
	AB		MYLAN	25MG	N73457	002	Apr 26, 1999	Mar CTEC	
	AB		TEVA PHARMS	50MG	N74120	001	Feb 24, 1995	Mar CAHN	
	AB			100MG	N74120	002	Feb 24, 1995	Mar CAHN	

TABLET; ORAL
ATENOLOL

AB	ZYDUS PHARMS USA	25MG	N76900	001	Jan 28, 2005	Jan	NEWA
AB		50MG	N76900	002	Jan 28, 2005	Jan	NEWA
AB		100MG	N76900	003	Jan 28, 2005	Jan	NEWA

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL
STRATTERA

LILLY	80MG	N21411	007	Feb 14, 2005	Feb	NEWA
	100MG	N21411	008	Feb 14, 2005	Feb	NEWA

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL
DIPHENOXYLATE HCL AND ATROPINE SULFATE

@ ABLE	0.025MG;2.5MG	N40395	001	Nov 27, 2000	May	DISC

AZELAIC ACID

GEL; TOPICAL
FINACEA

+ INTENDIS	15%	N21470	001	Dec 24, 2002	May	CAHN

AZITHROMYCIN

FOR SUSPENSION, EXTENDED RELEASE; ORAL
ZMAX

+ PFIZER GLOBAL	EQ 2GM BASE/BOT	N50797	001	Jun 10, 2005	Jun	NEWA

BACLOFEN

TABLET; ORAL
BACLOFEN

>A>	AB	ALPHAPHARM	10MG	N77181	001	Jul 29, 2005	Jul	NEWA
>A>	AB		20MG	N77121	002	Jul 29, 2005	Jul	NEWA

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; INHALATION
VANCERIL

@ SCHERING	0.042MG/INH	N17573	001		Apr	DISC

BENZYL PENICILLOYL-POLYLYSINE

INJECTABLE; INJECTION
PRE-PEN

>A>	@ ALLERQUEST	60UMOLAR	N50114	001		Jul	CAHN
>D>	@ HOLLISTER STIER LABS	60UMOLAR	N50114	001		Jul	CAHN
	@	60UMOLAR	N50114	001		Mar	DISC

BETAMETHASONE DIPROPIONATE

LOTION; TOPICAL
BETAMETHASONE DIPROPIONATE

AB	TEVA PHARMS	EQ 0.05% BASE	N71882	001	Jun 06, 1988	Mar	CAHN

OINTMENT; TOPICAL
ALPHATREX

@ SAVAGE LABS	EQ 0.05% BASE	N19143	001	Sep 04, 1984	Jan	DISC

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

LOTION; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB	ALTANA PHARMA	EQ 0.05% BASE;1%	N76516	001	Jun 16, 2005	May	NEWA

BETAMETHASONE VALERATE

LOTION; TOPICAL

BETAMETHASONE VALERATE

AB	TEVA PHARMS	EQ 0.1% BASE	N71883	001	Apr 22, 1988	Mar	CAHN

BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDE

	@ ABLE	5MG	N40492	001	Jul 27, 2004	May	DISC
	@	10MG	N40483	001	Jul 27, 2004	May	DISC
	@	25MG	N40485	001	Jul 27, 2004	May	DISC
	@	50MG	N40509	001	Jul 27, 2004	May	DISC
AA	UPSHER SMITH	5MG	N40633	001	Jun 01, 2005	May	NEWA
AA		10MG	N40634	001	Jun 01, 2005	May	NEWA
AA		25MG	N40635	001	Jun 01, 2005	May	NEWA
AA		50MG	N40636	001	Jun 01, 2005	May	NEWA

DUVOID

AA	WELLSPRING PHARM	50MG	N85882	003		Apr	CMFD

BISOPROLOL FUMARATE

TABLET; ORAL

BISOPROLOL FUMARATE

AB	TEVA PHARMS	5MG	N75644	001	Jun 26, 2001	Mar	CAHN
AB		10MG	N75644	002	Jun 26, 2001	Mar	CAHN

BROMFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

XIBROM

+	ISTA PHARMS	0.09%	N21664	001	Mar 24, 2005	Mar	NEWA

BROMOCRIPTINE MESYLATE

CAPSULE; ORAL

BROMOCRIPTINE MESYLATE

AB	MYLAN	EQ 5MG BASE	N77226	001	Apr 04, 2005	Mar	NEWA

PARLODEL

AB +	NOVARTIS	EQ 5MG BASE	N17962	002	Mar 01, 1982	Mar	CTEC

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL

BROMFED-DM

AA	BRIGHTON PHARMS INC	2MG/5ML;10MG/5ML;30MG/5ML	N89681	001	Dec 22, 1988	May	CAHN

BUPRENORPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPRENORPHINE HCL

AP	BEDFORD	EQ 0.3MG BASE/ML	N76931	001	Mar 02, 2005	Feb	NEWA

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HCL

AB1		EON	200MG	N75932	003	Jun 22, 2005	May	NEWA
AB1		SANDOZ	100MG	N76845	001	Jul 14, 2005	Jun	NEWA
AB2			150MG	N76834	001	Jul 14, 2005	Jun	NEWA
AB1			150MG	N76845	002	Jul 14, 2005	Jun	NEWA

BUTENAFINE HYDROCHLORIDE

CREAM; TOPICAL

MENTAX

+		MYLAN BERTEK	1%	N20524	001	Oct 18, 1996	Apr	CAHN

MENTAX-TC

+		MYLAN BERTEK	1%	N21408	001	Oct 17, 2002	Jun	CAHN

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

BUTORPHANOL TARTRATE

AP		MAYNE PHARMA USA	1MG/ML	N75342	001	Nov 04, 1999	Jun	CAHN
AP			2MG/ML	N75342	002	Nov 04, 1999	Jun	CAHN

SPRAY, METERED; NASAL

BUTORPHANOL TARTRATE

AB	+	MYLAN	1MG/SPRAY	N75759	001	Aug 08, 2001	Jun	CRLD

STADOL

	@	BRISTOL MYERS SQUIBB	1MG/SPRAY	N19890	001	Dec 12, 1991	Jun	DISC

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY; RECTAL

MIGERGOT

BR		G AND W LABS	100MG;2MG	N86557	001	Oct 04, 1983	Feb	CMFD

CALCITRIOL

INJECTABLE; INJECTION

CALCITRIOL

	@	MAYNE PHARMA USA	0.001MG/ML	N75816	001	Jan 16, 2004	Jun	DISC
	@		0.002MG/ML	N75816	002	Jan 16, 2004	Jun	DISC

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

AB		TEVA PHARMS	12.5MG	N74462	001	Feb 13, 1996	Mar	CAHN
AB			25MG	N74462	002	Feb 13, 1996	Mar	CAHN
AB			50MG	N74462	003	Feb 13, 1996	Mar	CAHN
AB			100MG	N74462	004	Feb 13, 1996	Mar	CAHN

CARBAMAZEPINE

SUSPENSION; ORAL

CARBAMAZEPINE

	@	TARO	100MG/5ML	N75875	001	Dec 21, 2000	Mar	DISC

CARBIDOPA; LEVODOPA

TABLET, FOR SUSPENSION; ORAL

CARBILEV

		RANBAXY	10MG;100MG	N76643	001	Jun 10, 2005	May	NEWA
			25MG;100MG	N76643	002	Jun 10, 2005	May	NEWA

TABLET, FOR SUSPENSION; ORAL
CARBILEV
\+ RANBAXY 25MG;250MG N76643 003 Jun 10, 2005 May NEWA

CARBOPLATIN

INJECTABLE; INJECTION
CARBOPLATIN
AP EON 50MG/VIAL N76959 001 Mar 18, 2005 Mar NEWA
AP 150MG/VIAL N76959 002 Mar 18, 2005 Mar NEWA
AP 450MG/VIAL N76959 003 Mar 18, 2005 Mar NEWA
@ MAYNE PHARMA USA 50MG/VIAL N76473 001 Oct 27, 2004 Jun DISC
@ 150MG/VIAL N76473 002 Oct 27, 2004 Jun DISC
@ 450MG/VIAL N76473 003 Oct 27, 2004 Jun DISC
INJECTABLE; IV (INFUSION)
CARBOPLATIN
AP SPECTRUM PHARMS EQ 50MG/5ML(10MG/ML) N77096 001 Jun 14, 2005 May NEWA
AP EQ 150MG/15ML(10MG/ML) N77096 002 Jun 14, 2005 May NEWA
AP EQ 450MG/45ML(10MG/ML) N77096 003 Jun 14, 2005 May NEWA

CARISOPRODOL

TABLET; ORAL
CARISOPRODOL
@ ABLE 350MG N40421 001 Jun 21, 2001 May DISC
AA NEIL 350MG N40576 001 Jun 07, 2005 May NEWA

CEFACLOR

CAPSULE; ORAL
CECLOR
@ LILLY EQ 250MG BASE N50521 001 Mar DISC
@ EQ 500MG BASE N50521 002 Mar DISC
CEFACLOR
AB \+ RANBAXY EQ 500MG BASE N64156 002 Aug 28, 1997 Mar CRLD
FOR SUSPENSION; ORAL
CECLOR
AB CEPH INTL EQ 375MG BASE/5ML N62206 004 Apr 20, 1988 Mar CRLD
@ LILLY EQ 125MG BASE/5ML N50522 001 Mar DISC
@ EQ 250MG BASE/5ML N50522 002 Mar DISC
CEFACLOR
AB CEPH INTL EQ 125MG BASE/5ML N62206 001 Apr CTNA
AB EQ 187MG BASE/5ML N62206 003 Apr 20, 1988 Apr CTNA
AB EQ 250MG BASE/5ML N62206 002 Apr CTNA
AB EQ 375MG BASE/5ML N62206 004 Apr 20, 1988 Apr CTNA
AB \+ RANBAXY EQ 375MG BASE/5ML N64155 001 Oct 02, 1997 Mar CRLD

CEFADROXIL/CEFADROXIL HEMIHYDRATE

TABLET; ORAL
CEFADROXIL
AB IVAX PHARMS EQ 1GM BASE N62774 001 Apr 08, 1987 Apr CMFD

CEFAZOLIN SODIUM

INJECTABLE; INJECTION
>A> CEFAZOLIN
>A> AP ORCHID HLTHCARE EQ 1GM BASE N65244 001 Aug 12, 2005 Jul NEWA
>A> AP EQ 10GM BASE N65247 001 Aug 12, 2005 Jul NEWA
CEFAZOLIN SODIUM
AP \+ AM PHARM PARTNERS EQ 500MG BASE/VIAL N64169 001 Aug 14, 1998 Mar CRLD

INJECTABLE; INJECTION
CEFAZOLIN SODIUM

AP	+	AM PHARM PARTNERS	EQ 1GM BASE/VIAL	N64169	002	Aug 14, 1998	Mar	CRLD
AP	+		EQ 10GM BASE/VIAL	N64170	001	Mar 18, 1998	Mar	CRLD
AP		ORCHID HLTHCARE	EQ 500MG BASE/VIAL	N65226	001	Apr 21, 2005	Apr	NEWA
AP			EQ 1GM BASE/VIAL	N65226	002	Apr 21, 2005	Apr	NEWA

CEFOXITIN SODIUM

INJECTABLE; INJECTION
CEFOXITIN

AP	+	AM PHARM PARTNERS	EQ 1GM BASE/VIAL	N65012	001	Jul 03, 2000	Jun	CRLD
AP	+		EQ 2GM BASE/2VIAL	N65012	002	Jul 03, 2000	Jun	CRLD
AP	+		EQ 10GM BASE/VIAL	N65011	001	Jul 03, 2000	Jun	CRLD

MEFOXIN

	@	MERCK	EQ 1GM BASE/VIAL	N50517	001		Jun	DISC
	@		EQ 2GM BASE/VIAL	N50517	002		Jun	DISC
	@		EQ 10GM BASE/VIAL	N50517	003		Jun	DISC

CEFTIBUTEN DIHYDRATE

FOR SUSPENSION; ORAL
CEDAX

	+	SHIONOGI	EQ 90MG BASE/5ML	N50686	001	Dec 20, 1995	Jun	CRLD
	@		EQ 180MG BASE/5ML	N50686	002	Dec 20, 1995	Jun	DISC

CEFTRIAXONE SODIUM

INJECTABLE; IM-IV
CEFTRIAXONE

>A>	AP	ORCHID HLTHCARE	EQ 250MG BASE/VIAL	N65230	001	Aug 02, 2005	Jul	NEWA
>A>	AP		EQ 500MG BASE/VIAL	N65230	002	Aug 02, 2005	Jul	NEWA
>A>	AP		EQ 1GM BASE/VIAL	N65230	003	Aug 02, 2005	Jul	NEWA
>A>	AP		EQ 2GM BASE/VIAL	N65230	004	Aug 02, 2005	Jul	NEWA
	AP	SANDOZ	EQ 250MG BASE/VIAL	N65169	001	May 09, 2005	Apr	NEWA
	AP		EQ 500MG BASE/VIAL	N65169	002	May 09, 2005	Apr	NEWA
	AP		EQ 1GM BASE/VIAL	N65169	003	May 09, 2005	Apr	NEWA
	AP		EQ 2GM BASE/VIAL	N65169	004	May 09, 2005	Apr	NEWA

INJECTABLE; INJECTION
CEFTRIAXONE

>A>	AP	ORCHID HLTHCARE	EQ 1GM BASE/VIAL	N65231	001	Aug 02, 2005	Jul	NEWA
>A>	AP		EQ 2GM BASE/VIAL	N65231	002	Aug 02, 2005	Jul	NEWA
>A>	AP		EQ 10GM BASE/VIAL	N65232	001	Aug 02, 2005	Jul	NEWA
	AP	SANDOZ	EQ 1GM BASE/VIAL	N65204	001	May 03, 2005	Apr	NEWA
	AP		EQ 2GM BASE/VIAL	N65204	002	May 03, 2005	Apr	NEWA
	AP		EQ 10GM BASE/VIAL	N65168	001	May 17, 2005	Apr	NEWA

CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER

AP	+	B BRAUN	EQ 1GM BASE/VIAL	N50796	001	Apr 20, 2005	Apr	NEWA
AP	+		EQ 2GM BASE/VIAL	N50796	002	Apr 20, 2005	Apr	NEWA

ROCEPHIN

	@	HLR	EQ 250MG BASE/VIAL	N63239	001	Aug 13, 1993	Apr	DISC
	@		EQ 500MG BASE/VIAL	N63239	002	Aug 13, 1993	Apr	DISC
	+		EQ 1GM BASE/VIAL	N62654	002	Apr 30, 1987	Mar	CRLD
AP	+		EQ 1GM BASE/VIAL	N62654	002	Apr 30, 1987	Apr	CFTG
	@		EQ 1GM BASE/VIAL	N63239	003	Aug 13, 1993	Apr	DISC
AP	+		EQ 2GM BASE/VIAL	N62654	003	Apr 30, 1987	Apr	CFTG
AP	+		EQ 10GM BASE/VIAL	N50585	005	Dec 21, 1984	Apr	CFTG

CEFUROXIME AXETIL

TABLET; ORAL

CEFUROXIME AXETIL

>A>	AB	WOCKHARDT	EQ 125MG BASE	N65166	001	Jul 29, 2005	Jul	NEWA
>A>	AB		EQ 250MG BASE	N65166	002	Jul 29, 2005	Jul	NEWA
>A>	AB		EQ 500MG BASE	N65166	003	Jul 29, 2005	Jul	NEWA

CEFUROXIME SODIUM

INJECTABLE; INJECTION

CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER

AP	+	B BRAUN	EQ 750MG BASE/VIAL	N50780	001	Feb 21, 2001	Apr	CPOT
AP	+		EQ 1.5GM BASE/VIAL	N50780	002	Feb 21, 2001	Apr	CPOT

CEPHALEXIN

CAPSULE; ORAL

CEPHALEXIN

		@ APOTHECON	EQ 250MG BASE	N63186	001	Dec 30, 1994	Mar	DISC
		@	EQ 500MG BASE	N63186	002	Dec 30, 1994	Mar	DISC
AB		BELCHER	EQ 250MG BASE	N62713	001	Jul 15, 1988	Jan	CAHN
AB			EQ 500MG BASE	N62713	002	Jul 15, 1988	Jan	CAHN
AB		ORCHID HLTHCARE	EQ 250MG BASE	N65248	001	Jun 28, 2005	Jun	NEWA
AB			EQ 500MG BASE	N65248	002	Jun 28, 2005	Jun	NEWA
AB		SUN PHARM INDS (IN)	EQ 250MG BASE	N62791	001	Jun 11, 1987	Jan	CAHN
AB			EQ 500MG BASE	N62791	002	Jun 11, 1987	Jan	CAHN
AB		YUNG SHIN PHARM	EQ 250MG BASE	N65152	001	Feb 24, 2005	Feb	NEWA
AB			EQ 500MG BASE	N65152	002	Feb 24, 2005	Feb	NEWA

FOR SUSPENSION; ORAL

CEPHALEXIN

>A>	AB	LUPIN	EQ 125MG BASE/5ML	N65234	001	Aug 17, 2005	Jul	NEWA
>A>	AB		EQ 250MG BASE/5ML	N65234	002	Aug 17, 2005	Jul	NEWA

CHLOROTHIAZIDE

SUSPENSION; ORAL

DIURIL

	+	MERCK	250MG/5ML	N11870	001		May	CMFD

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

CODEPREX

	+	UCB	EQ 4MG MALEATE/5ML;EQ 20MG BASE/5ML	N21369	001	Jun 21, 2004	Mar	CAHN

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

TUSSIONEX

	+	UCB	EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML	N19111	001	Dec 31, 1987	Mar	CAHN

CHLORPROMAZINE HYDROCHLORIDE

TABLET; ORAL

CHLORPROMAZINE HCL

BP		SANDOZ	10MG	N80439	001		May	CRLD
BP	+		10MG	N80439	001		Apr	CRLD
BP	+		100MG	N80439	004		Apr	CRLD

THORAZINE

		@ GLAXOSMITHKLINE	10MG	N09149	002		Apr	DISC

	TABLET; ORAL							
	THORAZINE							
	@ GLAXOSMITHKLINE	25MG	N09149	007			Apr	DISC
	@	50MG	N09149	013			Apr	DISC
	@	100MG	N09149	018			Apr	DISC
	@	200MG	N09149	020			Apr	DISC
	CHOLESTYRAMINE							
	POWDER; ORAL							
	CHOLESTYRAMINE							
AB	TEVA PHARMS	EQ 4GM RESIN/PACKET	N74554	001	Oct 02, 1996		Mar	CAHN
AB		EQ 4GM RESIN/SCOOPFUL	N74554	002	Oct 02, 1996		Mar	CAHN
	CHOLESTYRAMINE LIGHT							
AB	TEVA PHARMS	EQ 4GM RESIN/SCOOPFUL	N74555	002	Sep 30, 1998		Mar	CAHN
AB		EQ 4GM RESIN/PACKET	N74555	001	Sep 30, 1998		Mar	CAHN
	CICLOPIROX							
	CREAM; TOPICAL							
	CICLOPIROX							
AB	TARO	0.77%	N76790	001	Apr 12, 2005		Mar	NEWA
	SUSPENSION; TOPICAL							
	CICLOPIROX							
>A> AB	TARO	0.77%	N77092	001	Aug 10, 2005		Jul	NEWA
	CILOSTAZOL							
	TABLET; ORAL							
	CILOSTAZOL							
AB	COREPHARMA	50MG	N77150	001	Mar 11, 2005		Feb	NEWA
AB	IVAX PHARMS	100MG	N77020	002	Mar 01, 2005		Feb	NEWA
AB	ROXANE	50MG	N77024	001	May 17, 2005		Apr	NEWA
AB		100MG	N77024	002	May 17, 2005		Apr	NEWA
	CIMETIDINE HYDROCHLORIDE							
	INJECTABLE; INJECTION							
	CIMETIDINE HCL							
	@ HOSPIRA	EQ 300MG BASE/2ML	N74296	001	Mar 28, 1997		Jun	DISC
	@	EQ 300MG BASE/2ML	N74412	001	Mar 28, 1997		Jun	DISC
	@	EQ 300MG BASE/2ML	N74422	001	Jan 31, 1995		Jun	DISC
	@ LUITPOLD	EQ 300MG BASE/2ML	N74353	001	Dec 20, 1994		May	DISC
	CIMETIDINE HCL IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
+	HOSPIRA	EQ 6MG BASE/ML	N74269	001	Dec 27, 1994		May	CRLD
	@	EQ 90MG BASE/100ML	N74468	005	Dec 29, 1994		Jun	DISC
	@	EQ 120MG BASE/100ML	N74468	006	Dec 29, 1994		Jun	DISC
	@	EQ 180MG BASE/100ML	N74468	003	Dec 29, 1994		Jun	DISC
	@	EQ 240MG BASE/100ML	N74468	004	Dec 29, 1994		Jun	DISC
	@	EQ 360MG BASE/100ML	N74468	001	Dec 29, 1994		Jun	DISC
	@	EQ 480MG BASE/100ML	N74468	002	Dec 29, 1994		Jun	DISC
	TAGAMET							
	@ GLAXOSMITHKLINE	EQ 300MG BASE/2ML	N17939	002			May	DISC
	TAGAMET HCL IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
	@ GLAXOSMITHKLINE	EQ 6MG BASE/ML	N19434	001	Oct 31, 1985		May	DISC
	SOLUTION; ORAL							
	CIMETIDINE HCL							
AA	TEVA PHARMS	EQ 300MG BASE/5ML	N74859	001	Jul 09, 1998		Mar	CAHN

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
CIPROFLOXACIN

AT	HITECH PHARMA	EQ 0.3% BASE	N76673	001	Jan 21, 2005	Jan	NEWA

TABLET, EXTENDED RELEASE; ORAL
PROQUIN XR

+	DEPOMED INC	EQ 500MG BASE	N21744	001	May 19, 2005	May	NEWA

TABLET; ORAL
CIPROFLOXACIN

AB	COBALT	EQ 100MG BASE	N76794	001	Feb 10, 2005	Jan	NEWA
AB	PLIVA	EQ 100MG BASE	N76426	001	Jun 15, 2005	May	NEWA
AB		EQ 250MG BASE	N76426	002	Jun 15, 2005	May	NEWA
AB		EQ 500MG BASE	N76426	003	Jun 15, 2005	May	NEWA
AB		EQ 750MG BASE	N76426	004	Jun 15, 2005	May	NEWA
AB	SANDOZ	EQ 100MG BASE	N75939	001	Mar 03, 2005	Feb	NEWA
AB	TARO	EQ 100MG BASE	N76912	001	Feb 18, 2005	Jan	NEWA

CITALOPRAM HYDROBROMIDE

TABLET; ORAL
CITALOPRAM HYDROBROMIDE

AB	AKYMA PHARMS	EQ 10MG BASE	N77045	003	Apr 29, 2005	Apr	NEWA
AB		EQ 20MG BASE	N77045	002	Apr 29, 2005	Apr	NEWA
AB		EQ 40MG BASE	N77045	001	Apr 29, 2005	Apr	NEWA
AB	COBALT	EQ 10MG BASE	N77034	001	Jun 30, 2005	Jun	NEWA
AB		EQ 20MG BASE	N77034	002	Jun 30, 2005	Jun	NEWA
AB		EQ 40MG BASE	N77034	003	Jun 30, 2005	Jun	NEWA
AB	MYLAN	EQ 10MG BASE	N77039	001	Feb 03, 2005	Jan	NEWA
AB		EQ 20MG BASE	N77039	002	Feb 03, 2005	Jan	NEWA
AB		EQ 40MG BASE	N77039	003	Feb 03, 2005	Jan	NEWA
>A> AB	SANDOZ	EQ 10MG BASE	N77040	001	Aug 17, 2005	Jul	NEWA
>A> AB		EQ 20MG BASE	N77040	002	Aug 17, 2005	Jul	NEWA
>A> AB		EQ 40MG BASE	N77040	003	Aug 17, 2005	Jul	NEWA

CLARITHROMYCIN

TABLET, EXTENDED RELEASE; ORAL
CLARITHROMYCIN

	RANBAXY	1GM	N65210	001	Jan 26, 2005	Jan	NEWA
AB	TEVA	500MG	N65154	001	May 18, 2005	Apr	NEWA

TABLET; ORAL
CLARITHROMYCIN

AB	GENPHARM	250MG	N65195	001	Mar 11, 2005	Feb	NEWA
AB		500MG	N65195	002	Mar 11, 2005	Feb	NEWA
AB	IVAX PHARMS	250MG	N65137	001	May 31, 2005	May	NEWA
AB		500MG	N65137	002	May 31, 2005	May	NEWA
AB	TEVA	250MG	N65155	001	May 31, 2005	May	NEWA
AB		500MG	N65155	002	May 31, 2005	May	NEWA

CLEMASTINE FUMARATE

SYRUP; ORAL
CLEMASTINE FUMARATE

AA	TEVA PHARMS	EQ 0.5MG BASE/5ML	N73095	001	Apr 21, 1992	Mar	CAHN

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLINDAMYCIN HCL

>A>	AB	LANNETT	EQ 75MG BASE	N65242	001	Aug 12, 2005	Jul	NEWA
>A>	AB		EQ 150MG BASE	N65242	002	Aug 12, 2005	Jul	NEWA
>A>	AB		EQ 300MG BASE	N65243	001	Aug 12, 2005	Jul	NEWA
>A>	AB	TEVA	EQ 300MG BASE	N63029	002	Aug 05, 2005	Jul	NEWA

CLINDAMYCIN HYDROCHLORIDE

	AB	ZYDUS PHARMS USA	EQ 75MG BASE	N65217	001	Jan 31, 2005	Jan	NEWA
	AB		EQ 150MG BASE	N65217	002	Jan 31, 2005	Jan	NEWA
	AB		EQ 300MG BASE	N65217	003	Jan 31, 2005	Jan	NEWA

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

CLINDAMYCIN PHOSPHATE

	AP	HOSPIRA	EQ 150MG BASE/ML	N62943	001	Sep 29, 1988	Mar	CMFD

CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER

		@ BAXTER HLTHCARE	EQ 6MG BASE/ML	N50648	001	Dec 29, 1989	May	DISC
		@	EQ 12MG BASE/ML	N50648	002	Dec 29, 1989	May	DISC
		@	EQ 900MG BASE/100ML	N50648	003	Dec 29, 1989	May	DISC

CLOBETASOL PROPIONATE

CREAM; TOPICAL

CLOBETASOL PROPIONATE

	AB1	TEVA PHARMS	0.05%	N74087	001	Feb 16, 1994	Mar	CAHN

OINTMENT; TOPICAL

CLOBETASOL PROPIONATE

	AB	TEVA PHARMS	0.05%	N74089	001	Feb 16, 1994	Mar	CAHN

SOLUTION; TOPICAL

CLOBETASOL PROPIONATE

>A>	AT	ATRIX	0.05%	N76977	001	Aug 05, 2005	Jul	NEWA

CLONAZEPAM

TABLET, ORALLY DISINTEGRATING; ORAL

CLONAZEPAM

>A>	AB	BARR	0.125MG	N77194	001	Aug 10, 2005	Jul	NEWA
>A>	AB		0.25MG	N77194	002	Aug 10, 2005	Jul	NEWA
>A>	AB		0.5MG	N77194	003	Aug 10, 2005	Jul	NEWA
>A>	AB		1MG	N77194	004	Aug 10, 2005	Jul	NEWA
>A>	AB		2MG	N77194	005	Aug 10, 2005	Jul	NEWA
>A>	AB	KALI LABS	0.125MG	N77171	001	Aug 03, 2005	Jul	NEWA
>A>	AB		0.25MG	N77171	002	Aug 03, 2005	Jul	NEWA
>A>	AB		0.5MG	N77171	003	Aug 03, 2005	Jul	NEWA
>A>	AB		1MG	N77171	004	Aug 03, 2005	Jul	NEWA
>A>	AB		2MG	N77171	005	Aug 03, 2005	Jul	NEWA

KLONOPIN RAPIDLY DISINTEGRATING

>D>		ROCHE	0.125MG	N20813	001	Dec 23, 1997	Jul	CFTG
>A>	AB		0.125MG	N20813	001	Dec 23, 1997	Jul	CFTG
>D>			0.25MG	N20813	002	Dec 23, 1997	Jul	CFTG
>A>	AB		0.25MG	N20813	002	Dec 23, 1997	Jul	CFTG
>D>			0.5MG	N20813	003	Dec 23, 1997	Jul	CFTG
>A>	AB		0.5MG	N20813	003	Dec 23, 1997	Jul	CFTG
>D>		+	1MG	N20813	004	Dec 23, 1997	Jul	CFTG
>A>	AB	+	1MG	N20813	004	Dec 23, 1997	Jul	CFTG
>D>			2MG	N20813	005	Dec 23, 1997	Jul	CFTG

TABLET, ORALLY DISINTEGRATING; ORAL
KLONOPIN RAPIDLY DISINTEGRATING

>A>	AB	ROCHE	2MG	N20813	005	Dec 23, 1997	Jul	CFTG

TABLET; ORAL
CLONAZEPAM

	AB	KALI LABS	0.5MG	N77147	001	May 02, 2005	Apr	NEWA
	AB		1MG	N77147	002	May 02, 2005	Apr	NEWA
	AB		2MG	N77147	003	May 02, 2005	Apr	NEWA

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
DURACLON

>D>		AAIPHARMA	0.1MG/ML	N20615	001	Oct 02, 1996	Jul	CAHN
>D>	+		0.5MG/ML	N20615	002	Apr 27, 1999	Jul	CAHN
>A>		XANODYNE PHARM	0.1MG/ML	N20615	001	Oct 02, 1996	Jul	CAHN
>A>	+		0.5MG/ML	N20615	002	Apr 27, 1999	Jul	CAHN

TABLET; ORAL
CLONIDINE HCL

	AB	MUTUAL PHARM	0.2MG	N70924	001	Sep 04, 1987	Jun	CMFD
	AB		0.3MG	N70923	001	Sep 04, 1987	Jun	CMFD

CLORAZEPATE DIPOTASSIUM

TABLET; ORAL
CLORAZEPATE DIPOTASSIUM

		@ ABLE	3.75MG	N71780	001	Jun 26, 1987	May	DISC
		@	7.5MG	N71781	001	Jun 26, 1987	May	DISC
		@	15MG	N71782	001	Jun 26, 1987	May	DISC

CLOTRIMAZOLE

CREAM; TOPICAL
CLOTRIMAZOLE

	+	TARO	1%	N72640	001	Aug 31, 1993	Feb	CRLD

LOTRIMIN

		@ SCHERING PLOUGH	1%	N17619	001		Feb	DISC

MYCELEX

		@ BAYER PHARMS	1%	N18183	001		Feb	DISC

CLOZAPINE

TABLET, ORALLY DISINTEGRATING; ORAL
FAZACLO ODT

		ALAMO PHARMS	50MG	N21590	003	Jun 03, 2005	Jun	NEWA

TABLET; ORAL
CLOZAPINE

		IVAX PHARMS	50MG	N74949	004	Apr 25, 2005	Apr	NEWA
	AB	TEVA	25MG	N75162	001	Apr 26, 2005	Apr	NEWA
	AB		100MG	N75162	002	Apr 26, 2005	Apr	NEWA

CROMOLYN SODIUM

SOLUTION, CONCENTRATE; ORAL
GASTROCROM

	+	UCB	100MG/5ML	N20479	001	Feb 29, 1996	Mar	CAHN

SOLUTION; INHALATION
CROMOLYN SODIUM

	AN	BREATH LTD	10MG/ML	N76469	001	Jun 17, 2005	May	NEWA

CYANOCOBALAMIN

SPRAY, METERED; NASAL

NASCOBAL

+	NASTECH PHARM	0.5MG/SPRAY	N21642	001	Jan 31, 2005	Jan	NEWA
+	QUESTCOR PHARMS	0.5MG/SPRAY	N21642	001	Jan 31, 2005	Feb	CAHN

CYCLOSPORINE

CAPSULE; ORAL

CYCLOSPORINE

AB1	IVAX PHARMS	25MG	N65110	003	Mar 29, 2005	Mar	NEWA
AB1		50MG	N65110	001	Mar 29, 2005	Mar	NEWA
AB1		100MG	N65110	002	Mar 29, 2005	Mar	NEWA

GENGRAF

AB1	ABBOTT	50MG	N65003	002	May 12, 2000	Mar	CTEC

SOLUTION; ORAL

CYCLOSPORINE

AB1	IVAX PHARMS	100MG/ML	N65078	001	Mar 25, 2005	Mar	NEWA

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL

CYPROHEPTADINE HCL

@	ABC HOLDING	4MG	N88212	001	May 26, 1983	Feb	DISC

DALTEPARIN SODIUM

INJECTABLE; INJECTION

FRAGMIN

+	PHARMACIA AND UPJOHN	7,500 IU/0.3ML	N20287	005	Apr 04, 2002	Jan	NEWA
@		7,500 IU/0.75ML	N20287	008	Apr 04, 2002	Apr	DISC
+		95,000IU/3.8ML(25,000IU/ML)	N20287	006	Apr 04, 2002	Apr	NEWA
+		95,000IU/9.5ML(10,000IU/ML)	N20287	007	Apr 04, 2002	Apr	NEWA

DANTROLENE SODIUM

CAPSULE; ORAL

DANTRIUM

AB	PROCTER AND GAMBLE	25MG	N17443	001		Feb	CFTG
AB		50MG	N17443	003		Feb	CFTG
AB +		100MG	N17443	002		Feb	CFTG

DANTROLENE SODIUM

AB	IMPAX LABS	25MG	N76856	001	Mar 01, 2005	Feb	NEWA
AB		50MG	N76856	002	Mar 01, 2005	Feb	NEWA
AB		100MG	N76856	003	Mar 01, 2005	Feb	NEWA

DAPSONE

GEL; TOPICAL

ACZONE

>A> +	QLT USA	5%	N21794	001	Jul 07, 2005	Jul	NEWA

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

DAUNORUBICIN HCL

>A> AP	AM PHARM	EQ 5MG BASE/VIAL	N65034	001	Nov 20, 2001	Jul	CAHN
>A> AP	AM PHARM PARTNERS	EQ 20MG BASE/VIAL	N65000	001	May 25, 1999	Jul	CAHN
>D> AP	BIGMAR BIOREN PHARMS	EQ 20MG BASE/VIAL	N65000	001	May 25, 1999	Jul	CAHN
>D> AP	SUPERGEN	EQ 5MG BASE/VIAL	N65034	001	Nov 20, 2001	Jul	CAHN

DESIRUDIN RECOMBINANT

INJECTABLE; SUBCUTANEOUS
IPRIVASK

+	CANYON	15MG/VIAL	N21271	001	Apr 04, 2003	Mar	CAIN

DESLORATADINE

TABLET, ORALLY DISINTEGRATING; ORAL
CLARINEX

>A>	SCHERING	2.5MG	N21312	002	Jul 14, 2005	Jul	NEWA

DESLORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL
CLARINEX D 24 HOUR

+	SCHERING	5MG;240MG	N21605	001	Mar 03, 2005	Mar	NEWA

DESMOPRESSIN ACETATE

SPRAY, METERED; NASAL
DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION)

AB	APOTEX	0.01MG/SPRAY	N76703	001	Jan 27, 2005	Jan	NEWA

TABLET; ORAL
DDAVP

AB	AVENTIS	0.1MG	N19955	001	Sep 06, 1995	Jun	CFTG
AB	+	0.2MG	N19955	002	Sep 06, 1995	Jun	CFTG

DESMOPRESSIN ACETATE

AB	BARR	0.1MG	N76470	001	Jul 01, 2005	Jun	NEWA
AB		0.2MG	N76470	002	Jul 01, 2005	Jun	NEWA

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28
DESOGESTREL AND ETHINYL ESTRADIOL

>A>	AB	WATSON LABS	0.15MG;0.03MG	N76915	001	Jul 29, 2005	Jul	NEWA

DESONIDE

CREAM; TOPICAL
DESONIDE

AB	TEVA PHARMS	0.05%	N74027	001	Sep 28, 1992	Mar	CAHN

DEXAMETHASONE

TABLET; ORAL
DEXAMETHASONE

	PAR PHARM	0.25MG	N88149	001	Apr 28, 1983	Mar	CRLD
BP	ROXANE	1.5MG	N84610	001		Mar	CRLD

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION
DEXAMETHASONE SODIUM PHOSPHATE

AP	AM PHARM	EQ 10MG PHOSPHATE/ML	N40572	001	Apr 22, 2005	Apr	NEWA

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
FOCALIN XR

	NOVARTIS	5MG	N21802	001	May 26, 2005	May	NEWA
		10MG	N21802	002	May 26, 2005	May	NEWA
+		20MG	N21802	003	May 26, 2005	May	NEWA

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

	DEXTROAMPHETAMINE SULFATE							
	@ ABLE	5MG	N76814	001	Aug 25, 2004	May	DISC	
	@	10MG	N76814	002	Aug 25, 2004	May	DISC	
	@	15MG	N76814	003	Aug 25, 2004	May	DISC	

DEXTROSE

INJECTABLE; INJECTION

	DEXTROSE 50% IN PLASTIC CONTAINER							
AP	HOSPIRA	500MG/ML	N19445	001	Jun 03, 1986	Mar	CMFD	

DIAZEPAM

GEL; RECTAL

	DIASTAT							
	VALEANT	2.5MG/0.5ML	N20648	001	Jul 29, 1997	Apr	CAHN	
		5MG/ML	N20648	002	Jul 29, 1997	Apr	CAHN	
		10MG/2ML	N20648	003	Jul 29, 1997	Apr	CAHN	
		15MG/3ML	N20648	004	Jul 29, 1997	Apr	CAHN	
+		20MG/4ML	N20648	005	Jul 29, 1997	Apr	CAHN	

DICLOFENAC SODIUM

TABLET, DELAYED RELEASE; ORAL

	DICLOFENAC SODIUM							
AB	TEVA PHARMS	25MG	N74459	001	Jun 25, 1997	Mar	CAHN	
AB		50MG	N74459	002	Jun 25, 1997	Mar	CAHN	
AB		75MG	N74459	003	Jun 25, 1997	Mar	CAHN	
	VOLTAREN							
	@ NOVARTIS	25MG	N19201	001	Jul 28, 1988	May	DISC	
	@	50MG	N19201	002	Jul 28, 1988	May	DISC	

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE; ORAL

	ARTHROTEC							
	GD SEARLE LLC	50MG;0.2MG	N20607	001	Dec 24, 1997	May	CRLD	

DICYCLOMINE HYDROCHLORIDE

SYRUP; ORAL

	BENTYL							
AA	+ AXCAN SCANDIPHARM	10MG/5ML	N07961	002	Oct 15, 1984	Mar	CTEC	
	DICYCLOMINE HCL							
AA	MIKART	10MG/5ML	N40169	001	Mar 24, 2005	Mar	NEWA	

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL

	DIETHYLPROPION HCL							
	@ ABC HOLDING	25MG	N88267	001	Aug 25, 1983	Feb	DISC	
	@	25MG	N88268	001	Aug 25, 1983	Feb	DISC	
	TENUATE							
+	AVENTIS PHARMS	25MG	N11722	002		Feb	CTEC	

DIHYDROERGOTAMINE MESYLATE

INJECTABLE; INJECTION

	D.H.E. 45							
AP	+ VALEANT	1MG/ML	N05929	001		Apr	CAHN	

SPRAY, METERED; NASAL
MIGRANAL
+ VALEANT 0.5MG/INH N20148 001 Dec 08, 1997 Apr CAHN

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
CARDIZEM CD
AB3 BIOVAIL 120MG N20062 001 Aug 10, 1992 May CRLD
AB3 180MG N20062 002 Dec 27, 1991 May CRLD
AB3 240MG N20062 003 Dec 27, 1991 May CRLD
AB3 300MG N20062 004 Dec 27, 1991 May CRLD
DILACOR XR
AB2 WATSON LABS 120MG N20092 001 May 29, 1992 May CRLD
AB2 180MG N20092 002 May 29, 1992 May CRLD
DILTIAZEM HCL
MYLAN 60MG N74910 001 May 02, 1997 May CRLD
90MG N74910 002 May 02, 1997 May CRLD

INJECTABLE; INJECTION
CARDIZEM
AP + BIOVAIL LABS INTL 5MG/ML N20027 001 Oct 24, 1991 Mar CAHN
+ 25MG/VIAL N20027 003 Aug 18, 1995 Mar CAHN
DILTIAZEM HCL
AP MAYNE PHARMA USA 5MG/ML N75106 001 Apr 29, 1999 Jun CAHN

TABLET, EXTENDED RELEASE; ORAL
CARDIZEM LA
BIOVAIL LABS INTL 120MG N21392 001 Feb 06, 2003 Mar CAHN
180MG N21392 002 Feb 06, 2003 Mar CAHN
240MG N21392 003 Feb 06, 2003 Mar CAHN
300MG N21392 004 Feb 06, 2003 Mar CAHN
360MG N21392 005 Feb 06, 2003 Mar CAHN
+ 420MG N21392 006 Feb 06, 2003 Mar CAHN

TABLET; ORAL
CARDIZEM
AB BIOVAIL LABS INTL 30MG N18602 001 Nov 05, 1982 Mar CAHN
AB 60MG N18602 002 Nov 05, 1982 Mar CAHN
AB 90MG N18602 003 Dec 08, 1986 Mar CAHN
AB + 120MG N18602 004 Dec 08, 1986 Mar CAHN
DILTIAZEM HCL
AB TEVA PHARMS 30MG N74067 001 Nov 05, 1992 Mar CAHN
AB 60MG N74067 002 Nov 05, 1992 Mar CAHN
AB 90MG N74067 003 Nov 05, 1992 Mar CAHN
AB 120MG N74067 004 Nov 05, 1992 Mar CAHN

DIMYRISTOYL LECITHIN; PERFLEXANE

INJECTABLE; INTRAVENOUS
IMAGENT
@ IMCOR PH 0.92MG/VIAL;0.092MG/VIAL N21191 001 May 31, 2002 Jun DISC

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DIPHENHYDRAMINE HCL
AP BIONICHE PHARMA 50MG/ML N40498 001 Jul 12, 2005 Jun NEWA

DIPYRIDAMOLE

TABLET; ORAL
PERSANTINE
AB BOEHRINGER INGELHEIM 50MG N12836 004 Feb 06, 1987 May CRLD

		TABLET; ORAL							
		PERSANTINE							
AB	+	BOEHRINGER INGELHEIM	75MG	N12836	005	Feb 06, 1987	May	CRLD	
		DONEPEZIL HYDROCHLORIDE							
>D>		SOLUTION; ORAL							
>D>		ARICEPT							
>D>	+	EISAI MEDCL RES	5MG/5ML	N21719	001	Oct 18, 2004	Jul	DISC	
>A>		@	5MG/5ML	N21719	001	Oct 18, 2004	Jul	DISC	
		DOPAMINE HYDROCHLORIDE							
		INJECTABLE; INJECTION							
		DOPAMINE HCL							
AP	+	HOSPIRA	40MG/ML	N74403	001	May 23, 1996	Jun	CRLD	
AP	+	LUITPOLD	40MG/ML	N70799	001	Feb 11, 1987	Jun	CRLD	
AP	+		80MG/ML	N70820	001	Feb 11, 1987	Jun	CRLD	
AP	+		160MG/ML	N70826	001	Feb 11, 1987	Jun	CRLD	
AP	+	SICOR PHARMS	40MG/ML	N72999	001	Oct 23, 1991	Jun	CRLD	
AP	+		80MG/ML	N73000	001	Oct 23, 1991	Jun	CRLD	
		INTROPIN							
		@ MAYNE PHARMA USA	40MG/ML	N17395	001		Jun	DISC	
		@	80MG/ML	N17395	002		Jun	DISC	
		@	160MG/ML	N17395	003		Jun	DISC	
		DOXACURIUM CHLORIDE							
		INJECTABLE; INJECTION							
		NUROMAX							
		@ ABBOTT	EQ 1MG BASE/ML	N19946	001	Mar 07, 1991	Jun	DISC	
		DOXAZOSIN MESYLATE							
		TABLET, EXTENDED RELEASE; ORAL							
		CARDURA XL							
		PFIZER	EQ 4MG BASE	N21269	001	Feb 22, 2005	Feb	NEWA	
	+		EQ 8MG BASE	N21269	002	Feb 22, 2005	Feb	NEWA	
		DOXEPIN HYDROCHLORIDE							
		CONCENTRATE; ORAL							
		DOXEPIN HCL							
AA		TEVA PHARMS	EQ 10MG BASE/ML	N71609	001	Nov 09, 1987	Mar	CAHN	
		DOXERCALCIFEROL							
		CAPSULE; ORAL							
		HECTOROL							
>D>		BONE CARE	0.5UGM	N20862	002	Apr 23, 2004	Jul	CAHN	
>D>	+		2.5UGM	N20862	001	Jun 09, 1999	Jul	CAHN	
>A>		GENZYME	0.5UGM	N20862	002	Apr 23, 2004	Jul	CAHN	
>A>	+		2.5UGM	N20862	001	Jun 09, 1999	Jul	CAHN	
		INJECTABLE; INJECTION							
		HECTOROL							
>D>	+	BONE CARE	2UGM/ML	N21027	001	Apr 06, 2000	Jul	CAHN	
>A>	+	GENZYME	2UGM/ML	N21027	001	Apr 06, 2000	Jul	CAHN	
		DOXYCYCLINE							
		CAPSULE; ORAL							
		DOXYCYCLINE							
AB		PAR PHARM	EQ 75MG BASE	N65055	004	Apr 18, 2005	Mar	NEWA	

CAPSULE; ORAL
DOXYCYCLINE

	PAR PHARM	EQ 150MG BASE	N65055	003	Jul 15, 2005	Jun	NEWA
AB	RANBAXY	EQ 75MG BASE	N65053	003	Sep 10, 2003	Mar	CTEC

TABLET; ORAL
DOXYCYCLINE

	PAR PHARM	EQ 150MG BASE	N65070	004	Jul 14, 2005	Jun	NEWA

DOXYCYCLINE HYCLATE

CAPSULE; ORAL
DOXYCYCLINE HYCLATE

+	WEST WARD	EQ 20MG BASE	N65103	001	May 13, 2005	Apr	NEWA

TABLET, DELAYED RELEASE; ORAL
DORYX

	FAULDING	EQ 75MG BASE	N50795	001	May 06, 2005	May	NEWA
+		EQ 100MG BASE	N50795	002	May 06, 2005	May	NEWA

TABLET; ORAL
DOXYCYCLINE HYCLATE

AB	COREPHARMA	EQ 20MG BASE	N65182	001	May 13, 2005	Apr	NEWA
AB	IVAX PHARMS	EQ 20MG BASE	N65163	001	May 13, 2005	Apr	NEWA
AB	MUTUAL PHARMA	EQ 20MG BASE	N65134	001	May 13, 2005	Apr	NEWA

PERIOSTAT

AB +	COLLAGENEX PHARMS	EQ 20MG BASE	N50783	001	Feb 02, 2001	Apr	CFTG

DROPERIDOL

INJECTABLE; INJECTION
DROPERIDOL

	@ MAYNE PHARMA USA	2.5MG/ML	N71645	001	Apr 07, 1988	Jun	DISC

ENALAPRIL MALEATE

TABLET; ORAL
ENALAPRIL MALEATE

	@ APOTHECON	2.5MG	N75583	001	Aug 22, 2000	Feb	DISC
	@	5MG	N75583	002	Aug 22, 2000	Feb	DISC
	@	10MG	N75583	003	Aug 22, 2000	Feb	DISC
	@	20MG	N75583	004	Aug 22, 2000	Feb	DISC

VASOTEC

AB	BIOVAIL LABS INTL	2.5MG	N18998	005	Jul 26, 1988	Mar	CAHN
AB		5MG	N18998	001	Dec 24, 1985	Mar	CAHN
AB		10MG	N18998	002	Dec 24, 1985	Mar	CAHN
AB +		20MG	N18998	003	Dec 24, 1985	Mar	CAHN

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL
VASERETIC

AB	BIOVAIL LABS INTL	5MG;12.5MG	N19221	003	Jul 12, 1995	Mar	CAHN
AB +		10MG;25MG	N19221	001	Oct 31, 1986	Mar	CAHN

ENALAPRILAT

INJECTABLE; INJECTION
VASOTEC

AP +	BIOVAIL LABS INTL	1.25MG/ML	N19309	001	Feb 09, 1988	Mar	CAHN

ENTECAVIR

SOLUTION; ORAL
BARACLUDE
\+ BRISTOL MYERS SQUIBB 0.05MG/ML N21798 001 Mar 29, 2005 Mar NEWA

TABLET; ORAL
BARACLUDE
BRISTOL MYERS SQUIBB 0.5MG N21797 001 Mar 29, 2005 Mar NEWA
\+ 1MG N21797 002 Mar 29, 2005 Mar NEWA

EPINEPHRINE

INJECTABLE; IM-SC
TWINJECT 0.30
\+ HOLLISTER STIER LABS EQ 0.3MG /DELIVERY N20800 001 May 30, 2003 Feb CTNA

EPROSARTAN MESYLATE

TABLET; ORAL
TEVETEN
KOS LIFE EQ 300MG BASE N20738 004 Dec 22, 1997 May CAHN
@ EQ 300MG BASE N20738 004 Dec 22, 1997 Jun DISC
EQ 400MG BASE N20738 005 Dec 22, 1997 May CAHN
\+ EQ 600MG BASE N20738 006 May 27, 1999 May CAHN

EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL
TEVETEN HCT
KOS LIFE 600MG;12.5MG N21268 001 Nov 01, 2001 May CAHN
\+ 600MG;25MG N21268 002 Nov 01, 2001 May CAHN

ERYTHROMYCIN

SOLUTION; TOPICAL
ERYMAX
AT MERZ PHARMS 2% N62508 002 Jul 11, 1985 Jan CAHN
ERYTHROMYCIN
@ ALPHARMA US PHARMS 2% N62326 001 Apr 19, 1982 Jun DISC
AT + ALTANA 2% N64187 001 Sep 30, 1997 Jun CRLD
@ BAUSCH AND LOMB 2% N64039 001 Jan 27, 1994 Jun DISC
@ STIEFEL 2% N64127 001 Feb 14, 1997 Jun DISC
ERYTHRO-STATIN
@ HI TECH PHARMA 2% N64101 001 Oct 22, 1996 Jun DISC
SANSAC
@ HEALTHPOINT 2% N62522 001 Jan 24, 1985 Jun DISC
STATICIN
@ WESTWOOD SQUIBB 1.5% N50526 001 Jun DISC
T-STAT
@ WESTWOOD SQUIBB 2% N62436 001 Mar 09, 1983 Jun DISC

SWAB; TOPICAL
T-STAT
@ WESTWOOD SQUIBB 2% N62748 001 Jul 23, 1987 Jun DISC

ERYTHROMYCIN ESTOLATE

CAPSULE; ORAL
ERYTHROMYCIN ESTOLATE
@ BARR EQ 250MG BASE N62162 002 Feb DISC

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

ESMOLOL HCL

AP		AM PHARM	10MG/ML	N76573	001	May 02, 2005	Apr NEWA
AP		PHARMAFORCE	10MG/ML	N76474	001	May 02, 2005	Apr NEWA

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS; ORAL

NEXIUM

		ASTRAZENECA	EQ 20MG BASE	N21153	001	Feb 20, 2001	Jan CRLD

ESOMEPRAZOLE SODIUM

INJECTABLE; INTRAVENOUS

NEXIUM IV

+		ASTRAZENECA	EQ 20MG BASE/VIAL	N21689	001	Mar 31, 2005	Mar NEWA
+			EQ 40MG BASE/VIAL	N21689	002	Mar 31, 2005	Mar NEWA

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL

CLIMARA

AB2	+	BERLEX	0.025MG/24HR	N20375	004	Mar 05, 1999	Jan CFTG
AB2	+		0.075MG/24HR	N20375	003	Mar 23, 1998	Jan CFTG

ESCLIM

	@	WOMEN FIRST HLTHCARE	0.025MG/24HR	N20847	001	Aug 04, 1998	Jan DISC
	@		0.0375MG/24HR	N20847	002	Aug 04, 1998	Jan DISC
	@		0.05MG/24HR	N20847	003	Aug 04, 1998	Jan DISC
	@		0.075MG/24HR	N20847	004	Aug 04, 1998	Jan DISC
	@		0.1MG/24HR	N20847	005	Aug 04, 1998	Jan DISC

ESTRADIOL

AB2		MYLAN TECHNOLOGIES	0.025MG/24HR	N75182	003	Jan 26, 2005	Jan NEWA
AB2			0.075MG/24HR	N75182	002	Jan 26, 2005	Jan NEWA

VIVELLE

	@	NOVARTIS	0.025MG/24HR	N20323	005	Aug 16, 2000	Jan DISC
AB1			0.05MG/24HR	N20323	002	Oct 28, 1994	Jan CRLD
AB1			0.1MG/24HR	N20323	004	Oct 28, 1994	Jan CRLD

VIVELLE-DOT

BX	+	NOVARTIS	0.025MG/24HR	N20538	009	May 03, 2002	Jan CRLD
BX	+		0.0375MG/24HR	N20538	005	Jan 08, 1999	Jan CRLD
AB1	+		0.05MG/24HR	N20538	006	Jan 08, 1999	Jan CRLD
BX	+		0.075MG/24HR	N20538	007	Jan 08, 1999	Jan CRLD
AB1	+		0.1MG/24HR	N20538	008	Jan 08, 1999	Jan CRLD

ESTRADIOL; NORGESTIMATE

TABLET; ORAL

ESTRADIOL AND NORGESTIMATE

AB		BARR	1MG,1MG;N/A,0.09MG	N76812	001	Apr 29, 2005	Apr NEWA

PREFEST

AB	+	DURAMED	1MG,1MG;N/A,0.09MG	N21040	001	Oct 22, 1999	Apr CFTG

ESTROGENS, CONJUGATED SYNTHETIC B

TABLET; ORAL

ENJUVIA

	@	DURAMED	0.3MG	N21443	001	Dec 20, 2004	Mar DISC
	@		0.45MG	N21443	002	Dec 20, 2004	Mar DISC

ESTROPIPATE

TABLET; ORAL

ORTHO-EST

AB	SUN PHARM INDS (IN)	0.75MG	N89567	001	Feb 27, 1991	May	CAHN
AB		1.5MG	N89582	001	Jul 17, 1991	May	CAHN

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET; ORAL-28

KELNOR

AB	BARR	0.035MG;1MG	N76785	001	May 23, 2005	May	NEWA

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-21

NORDETTE-21

>D>									
>D>	AB	+	DURAMED	0.03MG;0.15MG	N18668	001	May 10, 1982	Jul	DISC
>A>			@	0.03MG;0.15MG	N18668	001	May 10, 1982	Jul	DISC

TABLET; ORAL-28

NORDETTE-28

>D>	AB		DURAMED	0.03MG;0.15MG	N18782	001	Jul 21, 1982	Jul	CRLD
>A>	AB	+		0.03MG;0.15MG	N18782	001	Jul 21, 1982	Jul	CRLD

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

BALZIVA-21

		+	BARR	0.035MG;0.4MG	N76198	001	Apr 22, 2004	May	CRLD

NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)

		+	WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	N71041	001	Sep 24, 1991	Mar	CTEC

NORTREL 7/7/7

			BARR	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	N75478	001	Aug 30, 2002	Mar	CTEC

OVCON-35

			@ WARNER CHILCOTT	0.035MG;0.4MG	N18127	001		May	DISC

TABLET; ORAL-28

NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)

			WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	N71042	001	Sep 24, 1991	Mar	CTEC

ORTHO-NOVUM 10/11-28

AB		+	ORTHO MCNEIL PHARM	0.035MG,0.035MG;0.5MG,1MG	N18354	002	Jan 11, 1982	Mar	CRLD

ORTHO-NOVUM 7/14-28

			@ ORTHO MCNEIL PHARM	0.035MG,0.035MG;0.5MG,1MG	N19004	002	Apr 04, 1984	Feb	DISC

OVCON-35

AB			WARNER CHILCOTT	0.035MG;0.4MG	N17716	001		Mar	CRLD

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

FEMHRT

>A>			WARNER CHILCOTT	0.0025MG;0.5MG	N21065	001	Jan 14, 2005	Jul	NEWA

TABLET; ORAL-28

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB			ANDRX PHARMS	0.02MG;1MG	N77077	001	May 20, 2005	May	NEWA
AB				0.03MG;1.5MG	N77075	001	Apr 28, 2005	Apr	NEWA

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-28

OGESTREL 0.5/50-28

		+	WATSON LABS	0.05MG;0.5MG	N75406	002	Dec 15, 1999	Jun	CTEC

		TABLET; ORAL-28							
		OVRAL-28							
		@ WYETH PHARMS INC	0.05MG;0.5MG	N16806	001			Jun	DISC
		ETHOSUXIMIDE							
		SYRUP; ORAL							
		ETHOSUXIMIDE							
	AA	TEVA PHARMS	250MG/5ML	N81306	001	Jul 30, 1993		Mar	CAHN
		ETODOLAC							
		CAPSULE; ORAL							
		LODINE							
		@ WYETH PHARMS INC	200MG	N18922	002	Jan 31, 1991		May	DISC
		TABLET, EXTENDED RELEASE; ORAL							
		ETODOLAC							
		@ POINT HOLDINGS	400MG	N75696	001	Jul 31, 2000		Jun	DISC
	AB	+ TEVA	600MG	N75665	001	Jul 31, 2000		Jun	CRLD
		LODINE XL							
		@ WYETH PHARMS INC	400MG	N20584	001	Oct 25, 1996		May	DISC
		@	500MG	N20584	003	Jan 20, 1998		May	DISC
		TABLET; ORAL							
		ETODOLAC							
>D>	AB	TARO PHARM INDS	500MG	N75074	002	Apr 25, 2000		Jul	CRLD
>A>	AB	+	500MG	N75074	002	Apr 25, 2000		Jul	CRLD
		LODINE							
		@ WYETH PHARMS INC	400MG	N18922	004	Jul 29, 1993		May	DISC
		@	500MG	N18922	005	Jun 28, 1996		May	DISC
		EXENATIDE SYNTHETIC							
		INJECTABLE; SUBCUTANEOUS							
		BYETTA							
		+ AMYLIN	300UGM/1.2ML(250UGM/ML)	N21773	001	Apr 28, 2005		Apr	NEWA
		+	600UGM/2.4ML(250UGM/ML)	N21773	002	Apr 28, 2005		Apr	NEWA
		FAMOTIDINE							
		INJECTABLE; INJECTION							
		FAMOTIDINE							
		@ MAYNE PHARMA USA	10MG/ML	N75705	001	Apr 16, 2001		Jun	DISC
		FAMOTIDINE PRESERVATIVE FREE							
		@ MAYNE PHARMA USA	10MG/ML	N75669	001	Apr 16, 2001		Jun	DISC
		TABLET; ORAL							
		FAMOTIDINE							
>A>	AB	PERRIGO	20MG	N77352	002	Jul 27, 2005		Jul	NEWA
>A>	AB		40MG	N77352	001	Jul 27, 2005		Jul	NEWA
		FENOFIBRATE							
		TABLET; ORAL							
		FENOFIBRATE							
	AB	TEVA	54MG	N76433	001	May 13, 2005		Apr	NEWA
	AB		160MG	N76433	002	May 13, 2005		Apr	NEWA
		TRICOR							
	AB	ABBOTT	54MG	N21203	001	Sep 04, 2001		Apr	CFTG
	AB	+	160MG	N21203	003	Sep 04, 2001		Apr	CFTG
		TRIGLIDE							
		SKYEPHARMA	50MG	N21350	001	May 07, 2005		May	NEWA
	BX		160MG	N21350	002	May 07, 2005		May	NEWA

FENOLDOPAM MESYLATE

INJECTABLE; INJECTION

FENOLDOPAM MESYLATE

AP	SABEX 2002	EQ 10MG BASE/ML	N77155	001	Feb 15, 2005	Jan	NEWA

FENOPROFEN CALCIUM

CAPSULE; ORAL

NALFON

AB	+ PEDINOL	EQ 300MG BASE	N17604	002		Apr	CAHN

NALFON 200

AB	PEDINOL	EQ 200MG BASE	N17604	003		Apr	CAHN

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

DURAGESIC-100

AB	ALZA	100UGM/HR	N19813	001	Aug 07, 1990	Jan	CFTG

DURAGESIC-12

	ALZA	12.5UGM/HR	N19813	005	Feb 04, 2005	Feb	NEWA

DURAGESIC-25

AB	+ ALZA	25UGM/HR	N19813	004	Aug 07, 1990	Jan	CFTG

DURAGESIC-50

AB	ALZA	50UGM/HR	N19813	003	Aug 07, 1990	Jan	CFTG

DURAGESIC-75

AB	ALZA	75UGM/HR	N19813	002	Aug 07, 1990	Jan	CFTG

FENTANYL

AB	MYLAN TECHNOLOGIES	25UGM/HR	N76258	001	Jan 28, 2005	Jan	NEWA
AB		50UGM/HR	N76258	002	Jan 28, 2005	Jan	NEWA
AB		75UGM/HR	N76258	003	Jan 28, 2005	Jan	NEWA
AB		100UGM/HR	N76258	004	Jan 28, 2005	Jan	NEWA

FEXOFENADINE HYDROCHLORIDE

CAPSULE; ORAL

ALLEGRA

AB	+ AVENTIS PHARMS	60MG	N20625	001	Jul 25, 1996	Jun	CFTG

FEXOFENADINE HCL

AB	BARR	60MG	N76169	001	Jul 13, 2005	Jun	NEWA

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALLEGRA-D 12 HOUR

AB	+ AVENTIS PHARMS	60MG;120MG	N20786	001	Dec 24, 1997	Mar	CFTG

FEXOFENADINE HCL AND PSEUDOEPHEDRINE HCL

AB	BARR	60MG;120MG	N76236	001	Apr 14, 2005	Mar	NEWA

FLUCONAZOLE

INJECTABLE; INJECTION

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	APOTEX	200MG/100ML	N76888	001	Mar 25, 2005	Mar	NEWA

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	APOTEX	200MG/100ML	N76889	001	Mar 25, 2005	Mar	NEWA

FLUCYTOSINE

CAPSULE; ORAL

ANCOBON

	VALEANT	250MG	N17001	001		Apr	CAHN

CAPSULE; ORAL
ANCOBON
\+ VALEANT 500MG N17001 002 Apr CAHN

FLUMAZENIL

INJECTABLE; INJECTION
FLUMAZENIL
AP SABEX 2002 1MG/10ML (0.1MG/ML) N77071 002 May 03, 2005 Apr NEWA
AP 0.5MG/5ML (0.1MG/ML) N77071 001 May 03, 2005 Apr NEWA

FLUOCINOLONE ACETONIDE

IMPLANT; INTRAVITREAL
RETISERT
\+ BAUSCH AND LOMB 0.59MG N21737 001 Apr 08, 2005 Apr NEWA

FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN

CREAM; TOPICAL
TRI-LUMA
\+ GALDERMA LABS LP 0.01%;4%;0.05% N21112 001 Jan 18, 2002 May CAHN

FLUOCINONIDE

CREAM; TOPICAL
VANOS
\+ MEDICIS 0.1% N21758 001 Feb 11, 2005 Feb NEWA

SOLUTION; TOPICAL
FLUOCINONIDE
AT TEVA PHARMS 0.05% N72522 001 Sep 28, 1990 Mar CAHN

FLUOROURACIL

INJECTABLE; INJECTION
FLUOROURACIL
>A> AP AM PHARM 50MG/ML N40291 001 Mar 24, 1999 Jul CAHN
>A> AP AM PHARM PARTNERS 50MG/ML N40379 001 Nov 15, 2000 Jul CAHN
>D> AP BIGMAR BIOREN PHARMS 50MG/ML N40291 001 Mar 24, 1999 Jul CAHN
>D> AP 50MG/ML N40379 001 Nov 15, 2000 Jul CAHN
AP \+ VALEANT 50MG/ML N12209 001 Apr CAHN

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL
FLUOXETINE
AB BARR EQ 40MG BASE N76251 001 May 18, 2005 Apr NEWA
AB RANBAXY EQ 40MG BASE N76990 001 Dec 13, 2004 May CAIN

FLUPHENAZINE HYDROCHLORIDE

CONCENTRATE; ORAL
FLUPHENAZINE HCL
AA TEVA PHARMS 5MG/ML N73058 001 Aug 30, 1991 Mar CAHN

ELIXIR; ORAL
FLUPHENAZINE HCL
AA TEVA PHARMS 2.5MG/5ML N81310 001 Apr 29, 1993 Mar CAHN

FLUTICASONE PROPIONATE

AEROSOL, METERED; INHALATION
FLOVENT
\+ GLAXOSMITHKLINE 0.044MG/INH N20548 001 Mar 27, 1996 Jan CRLD
\+ 0.11MG/INH N20548 002 Mar 27, 1996 Jan CRLD

AEROSOL, METERED; INHALATION
FLOVENT HFA
\+ GLAXOSMITHKLINE 0.044MG/INH N21433 003 May 14, 2004 Jan CRLD
\+ 0.11MG/INH N21433 002 May 14, 2004 Jan CRLD

LOTION; TOPICAL
CUTIVATE
\+ GLAXOSMITHKLINE 0.05% N21152 001 Mar 31, 2005 Mar NEWA

OINTMENT; TOPICAL
FLUTICASONE PROPIONATE
AB TARO PHARM INDS 0.005% N77145 001 Jun 14, 2005 May NEWA

FOLIC ACID

TABLET; ORAL
FOLIC ACID
AA MUTUAL PHARM 1MG N40582 001 Jul 18, 2005 Jun NEWA
>A> AA PHARMAX 1MG N40625 001 Jul 21, 2005 Jul NEWA
AA TRIGEN 1MG N40514 001 Jun 14, 2005 May NEWA

FOLLITROPIN ALFA/BETA

INJECTABLE; SUBCUTANEOUS
FOLLISTIM AQ
\+ ORGANON USA INC 150 IU/0.18ML N21211 003 Feb 11, 2004 Feb NEWA
\+ 300 IU/0.36ML N21211 001 Mar 23, 2004 Jan CPOT
\+ 600 IU/0.72ML N21211 002 Mar 23, 2004 Jan CPOT
\+ 900 IU/1.08ML N21211 004 Feb 11, 2005 Feb NEWA
>D> GONAL-F
>D> \+ SERONO INC 75 IU/VIAL N21765 002 Mar 25, 2004 Jul CTNA
@ 1,050 IU/VIAL N20378 004 Feb 28, 2001 Jun DISC
>A> GONAL-F RFF
>A> \+ SERONO INC 75 IU/VIAL N21765 002 Mar 25, 2004 Jul CTNA

FOMIVIRSEN SODIUM

INJECTABLE; INJECTION
VITRAVENE PRESERVATIVE FREE
@ NOVARTIS 6.6MG/ML N20961 001 Aug 26, 1998 Feb DISC

FOSCARNET SODIUM

INJECTABLE; INJECTION
FOSCARNET SODIUM
AP PHARMAFORCE 2.4GM/100ML N77174 001 May 31, 2005 May NEWA
FOSCAVIR
AP \+ ASTRAZENECA 2.4GM/100ML N20068 001 Sep 27, 1991 May CFTG

FOSINOPRIL SODIUM

TABLET; ORAL
FOSINOPRIL SODIUM
AB APOTEX 10MG N76906 001 May 17, 2005 Apr NEWA
AB 20MG N76906 002 May 17, 2005 Apr NEWA
AB 40MG N76906 003 May 17, 2005 Apr NEWA
AB INVAGEN PHARMS 10MG N77222 001 Apr 20, 2005 Mar NEWA
AB 20MG N77222 002 Apr 20, 2005 Mar NEWA
AB 40MG N77222 003 Apr 20, 2005 Mar NEWA

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

>A>	AB		WATSON LABS	10MG;12.5MG	N77144	001	Aug 16, 2005	Jul	NEWA
>A>	AB			20MG;12.5MG	N77144	002	Aug 16, 2005	Jul	NEWA

FUROSEMIDE

INJECTABLE; INJECTION
FUROSEMIDE

	AP	+	LUITPOLD	10MG/ML	N18579	001	Nov 30, 1983	Feb	CRLD

LASIX

		@	AVENTIS PHARMS	10MG/ML	N16363	001		Feb	DISC

GABAPENTIN

CAPSULE; ORAL
GABAPENTIN

	AB		APOTEX	100MG	N75360	001	Apr 06, 2005	Mar	NEWA
	AB			300MG	N75360	002	Apr 06, 2005	Mar	NEWA
	AB			400MG	N75360	003	Apr 06, 2005	Mar	NEWA
	AB		EON	100MG	N75539	001	Apr 06, 2005	Mar	NEWA
	AB			300MG	N75539	002	Apr 06, 2005	Mar	NEWA
	AB			400MG	N75539	003	Apr 06, 2005	Mar	NEWA
	AB		IVAX PHARMS	100MG	N75477	001	Mar 23, 2005	Mar	NEWA
	AB			300MG	N75477	002	Mar 23, 2005	Mar	NEWA
	AB			400MG	N75477	003	Mar 23, 2005	Mar	NEWA
	AB		MUTUAL PHARM	100MG	N76537	001	Jun 30, 2005	Jun	NEWA
	AB			300MG	N76537	002	Jun 30, 2005	Jun	NEWA
	AB			400MG	N76537	003	Jun 30, 2005	Jun	NEWA

TABLET; ORAL
GABAPENTIN

	AB		IVAX PHARMS	600MG	N76017	004	Apr 29, 2005	Apr	NEWA
	AB			800MG	N76017	005	Apr 29, 2005	Apr	NEWA

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE; ORAL
REMINYL

		+	JOHNSON AND JOHNSON	EQ 8MG BASE	N21615	001	Dec 22, 2004	Jan	CRLD
				EQ 24MG BASE	N21615	003	Dec 22, 2004	Jan	CRLD

GATIFLOXACIN

INJECTABLE; INJECTION
TEQUIN

		+	BRISTOL MYERS SQUIBB	400MG/40ML(10MG/ML)	N21062	004	Dec 17, 1999	Mar	CPOT

TEQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER

		+	BRISTOL MYERS SQUIBB	200MG/100ML(2MG/ML)	N21062	001	Dec 17, 1999	Mar	CPOT
		+		400MG/200ML(2MG/ML)	N21062	002	Dec 17, 1999	Mar	CPOT

GENTAMICIN SULFATE

SOLUTION/DROPS; OPHTHALMIC
GARAMYCIN

		@	SCHERING	EQ 0.3% BASE	N50039	002		May	DISC

GENTAMICIN SULFATE

	AT		ALTANA	EQ 0.3% BASE	N65121	001	Jan 30, 2004	May	CPOT
	AT	+	BAUSCH AND LOMB	EQ 0.3% BASE	N64048	001	May 11, 1994	Jun	CRLD

GLYBURIDE; METFORMIN HYDROCHLORIDE

		TABLET; ORAL							
		GLYBURIDE AND METFORMIN HCL							
AB		PUREPAC PHARM	1.25MG;250MG	N76716	001	Jun 28, 2005	Jun	NEWA
AB			2.5MG;500MG	N76716	002	Jun 28, 2005	Jun	NEWA
AB			5MG;500MG	N76716	003	Jun 28, 2005	Jun	NEWA
AB		TEVA	1.25MG;250MG	N76821	001	Jan 27, 2005	Jan	NEWA
AB			2.5MG;500MG	N76821	002	Jan 27, 2005	Jan	NEWA
AB			5MG;500MG	N76821	003	Jan 27, 2005	Jan	NEWA

GLYCOPYRROLATE

		TABLET; ORAL							
		GLYCOPYRROLATE							
AA		COREPHARMA	1MG	N40568	001	Dec 22, 2004	Apr	CTEC
AA			2MG	N40568	002	Dec 22, 2004	Apr	CTEC
		ROBINUL							
AA	+	FIRST HORIZON	1MG	N12827	001		Apr	CTEC
		ROBINUL FORTE							
AA	+	FIRST HORIZON	2MG	N12827	002		Apr	CTEC

GONADOTROPIN, CHORIONIC

		INJECTABLE; INJECTION							
		CHORIONIC GONADOTROPIN							
		@ WATSON LABS (UTAH)	2,000 UNITS/VIAL	N17016	009	Dec 27, 1984	Feb	CAHN
		@	2,000 UNITS/VIAL	N17016	011	Feb 16, 1990	Feb	CAHN
		@	5,000 UNITS/VIAL	N17016	006		Feb	CAHN
AP	+		10,000 UNITS/VIAL	N17016	007		Feb	CAHN
		@	15,000 UNITS/VIAL	N17016	010	Feb 15, 1985	Feb	CAHN
		@	20,000 UNITS/VIAL	N17016	004		Feb	CAHN

GRISEOFULVIN, MICROCRYSTALLINE

		SUSPENSION; ORAL							
		GRIFULVIN V							
AB	+	J AND J	125MG/5ML	N62483	001	Jan 26, 1984	Feb	CFTG
		GRISEOFULVIN							
AB		STIEFEL	125MG/5ML	N65200	001	Mar 02, 2005	Feb	NEWA

GUANABENZ ACETATE

		TABLET; ORAL							
		GUANABENZ ACETATE							
AB		TEVA PHARMS	EQ 4MG BASE	N74267	001	Jun 01, 1994	Mar	CAHN
AB			EQ 8MG BASE	N74267	002	Jun 01, 1994	Mar	CAHN

HALCINONIDE

		CREAM; TOPICAL							
		HALOG-E							
		@ WESTWOOD SQUIBB	0.1%	N18234	001		Jun	DISC

HALOBETASOL PROPIONATE

		CREAM; TOPICAL							
		HALOBESTASOL PROPIONATE							
>A>	AB	TARO	0.05%	N77227	001	Aug 04, 2005	Jul	NEWA
		OINTMENT; TOPICAL							
		HALOBETASOL PROPIONATE							
	AB	ALPHARMA US PHARMS	0.05%	N77109	001	Jun 14, 2005	May	NEWA

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

	HALOPERIDOL DECANOATE							
AO	SABEX 2002	EQ 50MG BASE/ML	N76463	001	Jun 24, 2005	Jun		NEWA
AO		EQ 100MG BASE/ML	N76463	002	Jun 24, 2005	Jun		NEWA

HALOPERIDOL LACTATE

CONCENTRATE; ORAL

	HALOPERIDOL							
AA	+ TEVA PHARMS	EQ 2MG BASE/ML	N71617	001	Dec 01, 1988	Mar		CAHN

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

	HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE							
AA	IVAX PHARMS	1.5MG/5ML;5MG/5ML	N40285	001	Jul 19, 1999	Jan		CAHN

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

	HYDRALAZINE HCL							
	@ ABC HOLDING	10MG	N88846	001	Feb 26, 1985	Feb		DISC
	@	25MG	N88847	001	Feb 26, 1985	Feb		DISC
	@	50MG	N88848	001	Feb 26, 1985	Feb		DISC
	@	100MG	N88849	001	Feb 26, 1985	Feb		DISC

HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE

TABLET; ORAL

	BIDIL							
	+ NITROMED	37.5MG;20MG	N20727	001	Jun 23, 2005	Jun		NEWA

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

	HYDROCHLOROTHIAZIDE							
AB	IVAX PHARMS	12.5MG	N77005	001	Jul 13, 2005	Jun		NEWA

TABLET; ORAL

	HYDROCHLOROTHIAZIDE							
	@ ABC HOLDING	25MG	N85683	001		Feb		DISC
	@	50MG	N83965	001		Feb		DISC
	@	50MG	N85672	001		Feb		DISC
AB	+ IVAX PHARMS	50MG	N83177	002		Apr		CRLD
	@	100MG	N85022	001		Apr		DISC

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

	AVALIDE							
	SANOFI SYNTHELABO	12.5MG;300MG	N20758	003	Aug 31, 1998	Mar		CRLD
	+	25MG;300MG	N20758	004	Mar 15, 2005	Mar		NEWA

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

	INDERIDE-40/25							
AB	+ WYETH PHARMS INC	25MG;40MG	N18031	001		May		CRLD
	INDERIDE-80/25							
	@ WYETH PHARMS INC	25MG;80MG	N18031	002		May		DISC

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL
QUINAPRIL HCL AND HYDROCHLOROTHIAZIDE

AB	MYLAN	12.5MG;EQ 10MG BASE	N77093	001	Mar 28, 2005	Mar	NEWA
AB		12.5MG;EQ 20MG BASE	N77093	002	Mar 28, 2005	Mar	NEWA
AB		25MG;EQ 20MG BASE	N77093	003	Mar 28, 2005	Mar	NEWA

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL
DIOVAN HCT

NOVARTIS	12.5MG;160MG	N20818	002	Mar 06, 1998	Mar	CRLD
+	25MG;160MG	N20818	003	Jan 17, 2002	Mar	CRLD

HYDROCORTISONE

ENEMA; RECTAL
HYDROCORTISONE

AB	TEVA PHARMS	100MG/60ML	N74171	001	May 27, 1994	Mar	CAHN

OINTMENT; TOPICAL
CORTRIL

@ PFIZER GLOBAL	1%	N09176	001		May	DISC
@	2.5%	N09176	002		May	DISC

HYDROCORTISONE BUTYRATE

CREAM; TOPICAL
HYDROCORTISONE BUTYRATE

>A>	AB	TARO PHARM INDS	0.1%	N76654	001	Aug 03, 2005	Jul	NEWA

LOCOID

>D>	+	FERNDALE LABS	0.1%	N18514	001	Mar 31, 1982	Jul	CFTG
>A>	AB	+	0.1%	N18514	001	Mar 31, 1982	Jul	CFTG

HYDROCORTISONE VALERATE

CREAM; TOPICAL
HYDROCORTISONE VALERATE

AB	TEVA PHARMS	0.2%	N74489	001	Aug 12, 1998	Mar	CAHN

HYDROMORPHONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
PALLADONE

PURDUE PHARMA LP	16MG	N21044	002	Sep 24, 2004	Feb	CRLD
+	32MG	N21044	004	Sep 24, 2004	Feb	CRLD

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL
HYDROXYCHLOROQUINE SULFATE

AB	TEVA PHARMS	200MG	N40081	001	Sep 30, 1994	Mar	CAHN

HYDROXYPROGESTERONE CAPROATE

INJECTABLE; INJECTION
HYDROXYPROGESTERONE CAPROATE

@ WATSON LABS	125MG/ML	N17439	001		Mar	CAHN
@	250MG/ML	N17439	002		Mar	CAHN

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL
HYDROXYZINE HCL

	@ ABLE	10MG	N40559	001	Jul 22, 2004	May	DISC
	@	25MG	N40562	001	Jul 22, 2004	May	DISC
	@	50MG	N40563	001	Jul 22, 2004	May	DISC
AB	VINTAGE PHARMS	10MG	N40579	001	May 27, 2005	May	NEWA
AB		25MG	N40574	001	May 27, 2005	May	NEWA
AB		50MG	N40580	001	May 27, 2005	May	NEWA

IBANDRONATE SODIUM

TABLET; ORAL
BONIVA

+	ROCHE	EQ 2.5MG BASE	N21455	001	May 16, 2003	Feb	CMFD
		EQ 150MG BASE	N21455	002	Mar 24, 2005	Mar	NEWA
+		EQ 150MG BASE	N21455	002	Mar 24, 2005	Apr	CRLD

IBUPROFEN

TABLET; ORAL
IBU

	@ BASF	600MG	N70088	001	Feb 08, 1985	Jun	DISC

IBUPROFEN

AB	PERRIGO R AND D	400MG	N77114	001	Jul 18, 2005	Jun	NEWA
AB		600MG	N77114	002	Jul 18, 2005	Jun	NEWA
AB		800MG	N77114	003	Jul 18, 2005	Jun	NEWA

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL
IMIPRAMINE HCL

	@ TEVA	10MG	N83729	001		Feb	DISC
	@	25MG	N83729	004		Feb	DISC
	@	50MG	N83729	003		Feb	DISC

INDOCYANINE GREEN

INJECTABLE; INJECTION
IC-GREEN

	@ AKORN	10MG/VIAL	N11525	003		Jun	CTNA
+		25MG/VIAL	N11525	001		Jun	CTNA
	@	40MG/VIAL	N11525	004		Jun	CTNA
	@	50MG/VIAL	N11525	002		Jun	CTNA

INDOMETHACIN

CAPSULE, EXTENDED RELEASE; ORAL
INDOMETHACIN

	@ ABLE	75MG	N76114	001	Feb 06, 2002	May	DISC

CAPSULE; ORAL
INDOMETHACIN

	@ ABLE	25MG	N76666	001	Dec 17, 2003	May	DISC
	@	50MG	N76666	002	Dec 17, 2003	May	DISC

INSULIN DETEMIR RECOMBINANT

INJECTABLE; SUBCUTANEOUS
LEVEMIR

+	NOVO NORDISK INC	100 UNITS/ML	N21536	001	Jun 16, 2005	Jun	NEWA

IPRATROPIUM BROMIDE

SOLUTION; INHALATION

IPRATROPIUM BROMIDE

AN		BREATH LTD	0.02%	N76291	001	May 09, 2005	Apr	NEWA
AN		RXELITE	0.02%	N77072	001	Jul 19, 2005	Jun	NEWA

IRON DEXTRAN

INJECTABLE; INJECTION

INFED

BP	+	WATSON LABS (UTAH)	EQ 50MG IRON/ML	N17441	001		Feb	CAHN

IRON SUCROSE

INJECTABLE; INTRAVENOUS

VENOFER

	+	LUITPOLD	EQ 100MG BASE/5ML(EQ 20MG BASE/ML)	N21135	001	Nov 06, 2000	Mar	CPOT
			EQ 50MG BASE/2.5ML(EQ 20MG BASE/ML)	N21135	002	Mar 20, 2005	Mar	NEWA
			EQ 75MG BASE/3.75ML(EQ 20MG BASE/ML)	N21135	003	Mar 29, 2005	Mar	NEWA

ISONIAZID

INJECTABLE; INJECTION

ISONIAZID

AP		SABEX 2002	100MG/ML	N40648	001	Jul 05, 2005	Jun	NEWA

NYDRAZID

AP	+	SANDOZ	100MG/ML	N08662	001		Jun	CFTG

ISONIAZID; RIFAMPIN

CAPSULE; ORAL

RIFAMATE

>D>		+ AVENTIS PHARMS	150MG;300MG	N61884	001		Jul	CFTG
>A>	AB	+	150MG;300MG	N61884	001		Jul	CFTG

>A> RIFAMPIN AND ISONIAZID

>A>	AB	WESTWARD	150MG;300MG	N65221	001	Jul 29, 2005	Jul	NEWA

ISOTRETINOIN

CAPSULE; ORAL

>D> ISOTRETINOIN

>D>	AB	RANBAXY	10MG	N76041	001	Dec 24, 2002	Jul	CTNA
>D>	AB		20MG	N76041	002	Dec 24, 2002	Jul	CTNA
>D>	AB		40MG	N76041	003	Dec 24, 2002	Jul	CTNA

>A> SOTRET

>A>	AB	RANBAXY	10MG	N76041	001	Dec 24, 2002	Jul	CTNA
>A>	AB		20MG	N76041	002	Dec 24, 2002	Jul	CTNA
>A>	AB		40MG	N76041	003	Dec 24, 2002	Jul	CTNA

ISRADIPINE

TABLET, EXTENDED RELEASE; ORAL

DYNACIRC CR

		RELIANT PHARMS	5MG	N20336	001	Jun 01, 1994	Mar	CRLD

KANAMYCIN SULFATE

CAPSULE; ORAL

KANTREX

		@ APOTHECON	EQ 500MG BASE	N62726	001	Mar 06, 1987	Feb	DISC

KETOCONAZOLE

SHAMPOO; TOPICAL
KETOCONAZOLE

AB		QLT USA	2%	N76942	001	Apr 11, 2005	Mar	NEWA

KETOPROFEN

CAPSULE, EXTENDED RELEASE; ORAL
ORUVAIL

		@ WYETH PHARMS INC	100MG	N19816	003	Feb 08, 1995	May	DISC
		@	150MG	N19816	002	Feb 08, 1995	May	DISC

LACTULOSE

SOLUTION; ORAL
EVALOSE

AA		TEVA PHARMS	10GM/15ML	N73497	001	May 28, 1993	Mar	CAHN

SOLUTION; ORAL, RECTAL
HEPTALAC

AA		TEVA PHARMS	10GM/15ML	N73504	001	May 28, 1993	Mar	CAHN

LANTHANUM CARBONATE

TABLET, CHEWABLE; ORAL
FOSRENOL

>D>		SHIRE	250MG	N21468	001	Oct 26, 2004	Jul	CPOT
>A>			EQ 250MG BASE	N21468	001	Oct 26, 2004	Jul	CPOT
>D>	+		500MG	N21468	002	Oct 26, 2004	Jul	CPOT
>A>	+		EQ 500MG BASE	N21468	002	Oct 26, 2004	Jul	CPOT

LEPIRUDIN RECOMBINANT

INJECTABLE; INJECTION
REFLUDAN

	+	BERLEX	50MG/VIAL	N20807	001	Mar 06, 1998	Mar	CAIN

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION
LEUCOVORIN CALCIUM

		@ MAYNE PHARMA USA	EQ 50MG BASE/VIAL	N08107	002		Jun	DISC
		@	EQ 100MG BASE/VIAL	N08107	004	May 23, 1988	Jun	DISC

LEUCOVORIN CALCIUM PRESERVATIVE FREE

>A>	AP	AM PHARM PARTNERS	EQ 200MG BASE/VIAL	N40258	001	Feb 26, 1999	Jul	CAHN
>A>	+		EQ 500MG BASE/VIAL	N40286	001	Feb 26, 1999	Jul	CAHN
	AP	+ BEDFORD	EQ 10MG BASE/ML	N40347	001	Apr 25, 2000	Apr	CRLD
>D>	AP	BIGMAR BIOREN PHARMS	EQ 200MG BASE/VIAL	N40258	001	Feb 26, 1999	Jul	CAHN
>D>	+		EQ 500MG BASE/VIAL	N40286	001	Feb 26, 1999	Jul	CAHN
		@ HOSPIRA	EQ 10MG BASE/ML	N40147	001	Jun 25, 1997	Apr	DISC

LEUPROLIDE ACETATE

INJECTABLE; SUBCUTANEOUS
ELIGARD

	+	QLT USA	22.5MG/VIAL	N21379	001	Jul 24, 2002	Jan	CAHN

LEVALBUTEROL TARTRATE

AEROSOL, METERED; INHALATION
XOPENEX HFA

	+	SEPRACOR	EQ 0.045MG BASE/INH	N21730	001	Mar 11, 2005	Mar	NEWA

LEVOFLOXACIN

TABLET; ORAL

LEVAQUIN

	ORTHO MCNEIL PHARM	250MG	N20634	001	Dec 20, 1996	Mar	CTEC
		500MG	N20634	002	Dec 20, 1996	Mar	CTEC
AB +		750MG	N20634	003	Sep 08, 2000	Jan	CFTG

LEVOFLOXACIN

AB	TEVA	750MG	N76361	003	Jan 26, 2005	Jan	NEWA

LEVOMETHADYL ACETATE HYDROCHLORIDE

CONCENTRATE; ORAL

ORLAAM

	@ ROXANE	10MG/ML	N20315	001	Jul 09, 1993	Jun	DISC

LEVOTHYROXINE SODIUM**

**Refer to Preface Section 1.3 Levothyroxine Sodium for amplifying information

TABLET; ORAL

LEVOTHYROXINE SODIUM

AB2	GENPHARM	0.025MG	N76752	001	Jun 16, 2005	May	NEWA
AB2		0.05MG	N76752	002	Jun 16, 2005	May	NEWA
AB2		0.075MG	N76752	003	Jun 16, 2005	May	NEWA
AB2		0.088MG	N76752	004	Jun 16, 2005	May	NEWA
AB2		0.1MG	N76752	005	Jun 16, 2005	May	NEWA
AB2		0.112MG	N76752	006	Jun 16, 2005	May	NEWA
AB2		0.125MG	N76752	007	Jun 16, 2005	May	NEWA
AB2		0.15MG	N76752	008	Jun 16, 2005	May	NEWA
AB2		0.175MG	N76752	009	Jun 16, 2005	May	NEWA
AB2		0.2MG	N76752	010	Jun 16, 2005	May	NEWA
AB2		0.3MG	N76752	011	Jun 16, 2005	May	NEWA

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HCL PRESERVATIVE FREE

AP	AM PHARM	2%	N17584	001		Apr	CAHN
AP		4%	N17584	002		Apr	CAHN

XYLOCAINE PRESERVATIVE FREE

AP +	ASTRAZENECA	2%	N16801	001		Jun	CRLD

JELLY; TOPICAL

LIDOCAINE HCL

AT	TEVA PHARMS	2%	N81318	001	Apr 29, 1993	Mar	CAHN

LIDOCAINE; TETRACAINE

PATCH; TOPICAL

SYNERA

+	ZARS	70MG;70MG	N21623	001	Jun 23, 2005	Jun	NEWA

LIOTHYRONINE SODIUM

TABLET; ORAL

CYTOMEL

	KING PHARMS	EQ 0.005MG BASE	N10379	001		May	CAHN
		EQ 0.025MG BASE	N10379	002		May	CAHN
+		EQ 0.05MG BASE	N10379	003		May	CAHN

LITHIUM CARBONATE

CAPSULE; ORAL

		LITHIUM CARBONATE						
	@	ABLE	150MG	N76823	001	Jun 29, 2004	May	DISC
	@		300MG	N76121	001	Sep 27, 2001	May	DISC
	@		300MG	N76823	002	Jun 29, 2004	May	DISC
	@		600MG	N76823	003	Jun 29, 2004	May	DISC
	+	ROXANE	600MG	N17812	003	Jan 28, 1987	May	CTEC

TABLET, EXTENDED RELEASE; ORAL

		LITHIUM CARBONATE						
	@	ABLE	300MG	N76382	001	Apr 21, 2003	May	DISC

LORAZEPAM

INJECTABLE; INJECTION

		LORAZEPAM						
	@	AKORN	2MG/ML	N74974	001	Jul 23, 1998	Jun	DISC
AP		BEDFORD	2MG/ML	N77076	001	Jul 13, 2005	Jun	NEWA
AP			4MG/ML	N77076	002	Jul 13, 2005	Jun	NEWA
	@	CLONMEL HLTHCARE	2MG/ML	N74793	001	Mar 16, 2000	Jun	DISC
	@		4MG/ML	N74793	002	Mar 16, 2000	Jun	DISC
	@	MARSAM PHARMS LLC	1MG/0.5ML	N74551	003	Sep 12, 1996	Jun	DISC
	@		2MG/ML	N74535	001	Sep 12, 1996	Jun	DISC
	@		2MG/ML	N74551	001	Sep 12, 1996	Jun	DISC
	@		4MG/ML	N74535	002	Sep 12, 1996	Jun	DISC
	@		4MG/ML	N74551	002	Sep 12, 1996	Jun	DISC
	@	TAYLOR	2MG/ML	N75025	001	Jul 23, 1998	Jun	DISC
		LORAZEPAM PRESERVATIVE FREE						
AP		BEDFORD LABS	2MG/ML	N77074	001	Jul 13, 2005	Jun	NEWA
AP			4MG/ML	N77074	002	Jul 13, 2005	Jun	NEWA

SOLUTION; ORAL

		LORAZEPAM						
		ROXANE	0.5MG/5ML	N74648	001	Mar 18, 1997	Jan	CMFD

LOVASTATIN; NIACIN

TABLET, EXTENDED RELEASE; ORAL

		ADVICOR						
	+	KOS LIFE	20MG;500MG	N21249	001	Dec 17, 2001	Jun	CAHN
	@		20MG;750MG	N21249	002	Dec 17, 2001	Jun	CAHN
	+		20MG;1GM	N21249	003	Dec 17, 2001	Jun	CAHN

LOXAPINE SUCCINATE

CAPSULE; ORAL

		LOXAPINE SUCCINATE						
>A>	AB	AMIDE PHARM	EQ 5MG BASE	N76868	001	Aug 04, 2005	Jul	NEWA
>A>	AB		EQ 10MG BASE	N76868	002	Aug 04, 2005	Jul	NEWA
>A>	AB		EQ 25MG BASE	N76868	003	Aug 04, 2005	Jul	NEWA
>A>	AB		EQ 50MG BASE	N76868	004	Aug 04, 2005	Jul	NEWA

MAFENIDE ACETATE

CREAM; TOPICAL

		SULFAMYLON						
	+	MYLAN BERTEK	EQ 85MG BASE/GM	N16763	001		Apr	CAHN

MANGAFODIPIR TRISODIUM

INJECTABLE; INJECTION
TESLASCAN
@ GE HEALTHCARE 37.9MG/ML N20652 001 Nov 26, 1997 Jan DISC

MEBENDAZOLE

TABLET, CHEWABLE; ORAL
MEBENDAZOLE
AB TEVA PHARMS 100MG N73580 001 Jan 04, 1995 Mar CAHN

MECLIZINE HYDROCHLORIDE

TABLET; ORAL
MECLIZINE HCL
@ ABC HOLDING 12.5MG N85253 001 Feb DISC
@ 25MG N85252 001 Feb DISC

MEDROXYPROGESTERONE ACETATE

>D> INJECTABLE; INJECTION
>D> DEPO-SUBQ PROVERA 104
>D> + PFIZER 104MG/0.65ML N21583 001 Dec 17, 2004 Jul CDFR
>A> INJECTABLE; SUBCUTANEOUS
>A> DEPO-SUBQ PROVERA 104
>A> + PFIZER 104MG/0.65ML N21583 001 Dec 17, 2004 Jul CDFR

MEGESTROL ACETATE

SUSPENSION; ORAL
MEGACE ES
>A> + PAR PHARM 125MG/ML N21778 001 Jul 05, 2005 Jul NEWA
MEGESTROL ACETATE
AB TEVA PHARMS 40MG/ML N75681 001 May 05, 2003 Mar CAHN

MEMANTINE HYDROCHLORIDE

SOLUTION; ORAL
NAMENDA
+ FOREST LABS 2MG/ML N21627 001 Apr 18, 2005 Apr NEWA

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
MEPERIDINE HCL PRESERVATIVE FREE
@ MAYNE PHARMA USA 10MG/ML N40305 001 Mar 10, 1999 Jun DISC

MEQUINOL; TRETINOIN

SOLUTION; TOPICAL
SOLAGE
+ BARRIER 2%;0.01% N20922 001 Dec 10, 1999 Feb CAHN

MERCAPTOPURINE ANHYDROUS

TABLET; ORAL
MERCAPTOPURINE
AB MYLAN 50MG N40594 001 Jul 01, 2005 Jun NEWA

METAPROTERENOL SULFATE

SYRUP; ORAL
METAPROTERENOL SULFATE
@ TEVA PHARMS 10MG/5ML N73034 001 Aug 30, 1991 Mar CAHN

METAXALONE

TABLET; ORAL

		SKELAXIN							
	@	JONES PHARMA INC	400MG	N13217	001			May	DISC

METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

		FORTAMET							
BX	+	ANDRX LABS LLC	1GM	N21574	002	Apr 27, 2004		Jun	CTEC
		GLUMETZA							
BX		BIOVAIL	500MG	N21748	001	Jun 03, 2005		Jun	NEWA
BX			1GM	N21748	002	Jun 03, 2005		Jun	NEWA
		METFORMIN HCL							
AB		ANDRX PHARMS	750MG	N76869	001	Apr 12, 2005		Mar	NEWA
AB		PUREPAC PHARM	750MG	N76878	001	Apr 13, 2005		Mar	NEWA
AB		RANBAXY	750MG	N77211	001	Jun 29, 2005		Jun	NEWA
AB		TEVA	750MG	N76864	001	Apr 12, 2005		Mar	NEWA
AB		ZYDUS PHARMS USA	500MG	N77060	001	Apr 20, 2005		Mar	NEWA
AB			750MG	N77078	001	Apr 21, 2005		Apr	NEWA

TABLET; ORAL

		METFORMIN HCL							
AB		ZYDUS PHARMS USA	500MG	N77064	001	Apr 18, 2005		Mar	NEWA
AB			850MG	N77064	002	Apr 18, 2005		Mar	NEWA
AB			1GM	N77064	003	Apr 18, 2005		Mar	NEWA

METHADONE HYDROCHLORIDE

INJECTABLE; INJECTION

		DOLOPHINE HCL							
>D>	+	AAIPHARMA LLC	10MG/ML	N21624	001			Jul	CAHN
>A>	+	XANODYNE PHARM	10MG/ML	N21624	001			Jul	CAHN

TABLET; ORAL

		METHADONE HCL							
AA		MALLINCKRODT	40MG	N77142	001	Jul 12, 2005		Jun	NEWA

METHAMPHETAMINE HYDROCHLORIDE

TABLET; ORAL

		DESOXYN							
	+	OVATION PHARMS	5MG	N05378	002			May	CTEC
		METHAMPHETAMINE HCL							
	@	ABLE	5MG	N40529	001	Feb 25, 2004		May	DISC

METHAZOLAMIDE

TABLET; ORAL

		METHAZOLAMIDE							
AB		TEVA PHARMS	25MG	N40001	001	Jun 30, 1993		Mar	CAHN
AB			50MG	N40001	002	Jun 30, 1993		Mar	CAHN

METHIMAZOLE

TABLET; ORAL

		METHIMAZOLE							
AB		CEDAR PHARMS	5MG	N40547	001	Feb 18, 2005		Jan	NEWA
AB			10MG	N40547	002	Feb 18, 2005		Jan	NEWA
			15MG	N40619	003	Jul 12, 2005		Jun	NEWA
AB			20MG	N40547	004	Feb 18, 2005		Jan	NEWA
AB	+	GENPHARM	10MG	N40350	002	Mar 29, 2000		Jun	CRLD

TABLET; ORAL
METHIMAZOLE

	@	GENPHARM	20MG	N40350	003	Jun 07, 2001	Apr	DISC
AB	+		20MG	N40350	003	Jun 07, 2001	Jan	CFTG

METHOCARBAMOL

TABLET; ORAL
METHOCARBAMOL

	@	ABLE	500MG	N40413	001	Mar 17, 2003	May	DISC
	@		750MG	N40413	002	Mar 17, 2003	May	DISC

METHOTREXATE

INJECTABLE; INJECTION
METHOTREXATE PRESERVATIVE FREE

>A>	+	BEDFORD	EQ 1GM BASE/VIAL	N40632	001	Aug 12, 2005	Jul	NEWA

METHOTREXATE SODIUM

INJECTABLE; INJECTION
METHOTREXATE

>A>	@	AM PHARM	EQ 25MG BASE/ML	N40263	001	Feb 26, 1999	Jul	CAHN
>D>	@	BIGMAR BIOREN PHARMS	EQ 25MG BASE/ML	N40263	001	Feb 26, 1999	Jul	CAHN
	@		EQ 25MG BASE/ML	N40263	001	Feb 26, 1999	Apr	DISC
AP	+	MAYNE PHARMA USA	EQ 50MG BASE/2ML (25 MG/ML)	N11719	010	Dec 15, 2004	Apr	NEWA

METHOTREXATE LPF

	@	MAYNE PHARMA USA	EQ 25MG BASE/ML	N11719	007	Mar 31, 1982	Apr	DISC

METHOTREXATE PRESERVATIVE FREE

>A>	@	AM PHARM PARTNERS	EQ 25MG BASE/ML	N40265	001	Feb 26, 1999	Jul	CAHN
>D>	@		EQ 1GM BASE/VIAL	N40266	001	Feb 26, 1999	Jul	CAHN
>A>	@		EQ 1GM BASE/VIAL	N40266	001	Feb 26, 1999	Jul	CAHN
	@		EQ 1GM BASE/VIAL	N40266	001	Feb 26, 1999	Apr	DISC
>D>	@	BIGMAR BIOREN PHARMS	EQ 25MG BASE/ML	N40265	001	Feb 26, 1999	Jul	CAHN
	@		EQ 25MG BASE/ML	N40265	001	Feb 26, 1999	Apr	DISC
	+	MAYNE PHARMA USA	EQ 20MG BASE/2ML (10 MG/ML)	N11719	014	Apr 13, 2005	Apr	NEWA
	@		EQ 20MG BASE/2ML (10 MG/ML)	N11719	014	Apr 13, 2005	Jun	DISC
AP	+		EQ 500MG BASE/20ML (25 MG/ML)	N11719	013	Apr 13, 2005	Apr	NEWA
	@		EQ 500MG BASE/20ML (25 MG/ML)	N11719	013	Apr 13, 2005	Jun	DISC
AP	+		ED 1GM BASE/40ML (25 MG/ML)	N11719	012	Apr 13, 2005	Apr	NEWA
AP	+		EQ 2.5GM BASE/100ML (25 MG/ML)	N11719	011	Apr 13, 2005	Apr	NEWA
	@		EQ 2.5GM BASE/100ML (25 MG/ML)	N11719	011	Apr 13, 2005	Jun	DISC

METHOTREXATE SODIUM

AP		BEDFORD	EQ 50 MG BASE/2ML (25 ML/ML)	N89340	001	Sep 16, 1986	Apr	CPOT
AP			EQ 100MG BASE/4ML (25 MG/ML)	N89341	001	Sep 16, 1986	Apr	CPOT
AP			EQ 200MG BASE/8ML (25 MG/ML)	N89342	001	Sep 16, 1986	Apr	CPOT
AP			EQ 250MG BASE/10ML (25 MG/ML)	N89343	001	Sep 16, 1986	Apr	CPOT
	@	MAYNE PHARMA USA	EQ 20MG BASE/VIAL	N11719	001		Mar	DISC
	@		EQ 25MG BASE/ML	N11719	005		Apr	DISC
	@	NORBROOK	EQ 25MG BASE/ML	N88648	001	May 09, 1986	Apr	DISC
	@	PHARMACHEMIE USA	EQ 25MG BASE/ML	N89158	001	Jul 08, 1988	Apr	DISC

METHOTREXATE SODIUM PRESERVATIVE FREE

	@	MAYNE PHARMA USA	EQ 1GM BASE/VIAL	N11719	009	Apr 07, 1988	Jun	DISC

MEXATE-AQ

	@	BRISTOL MYERS	EQ 25MG BASE/ML	N88760	001	Feb 14, 1985	Apr	DISC

METHYL AMINOLEVULINATE HYDROCHLORIDE

CREAM; TOPICAL
METVIXIA

	+	PHOTOCURE ASA	EQ 16.8% BASE	N21415	001	Jul 27, 2004	May	CTNA

METHYLDOPA

TABLET; ORAL

		ALDOMET						
		@ MERCK	500MG	N13400	002		Jan	DISC
		METHYLDOPA						
AB	+	MYLAN	500MG	N70076	001	Apr 18, 1985	Jan	CRLD

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

		ALDOMET						
		@ MERCK	50MG/ML	N13401	001		Jan	DISC
		METHYLDOPATE HCL						
AP	+	LUITPOLD	50MG/ML	N71279	001	Oct 02, 1987	Jan	CRLD

METHYLERGONOVINE MALEATE

TABLET; ORAL

		METHERGINE						
	+	NOVARTIS	0.2MG	N06035	003		Jan	CRLD

METHYLPHENIDATE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

		METHYLPHENIDATE HCL						
		@ ABLE	20MG	N76032	001	May 09, 2001	May	DISC

TABLET; ORAL

		METHYLPHENIDATE HCL						
		@ ABLE	5MG	N40404	001	Mar 29, 2001	May	DISC
		@	10MG	N40404	002	Mar 29, 2001	May	DISC
		@	20MG	N40404	003	Mar 29, 2001	May	DISC

METHYLPREDNISOLONE ACETATE

INJECTABLE; INJECTION

		DEPO-MEDROL						
AB	+	PHARMACIA AND UPJOHN	40MG/ML	N11757	001		Feb	CFTG
AB	+		80MG/ML	N11757	004		Feb	CFTG
		METHYLPREDNISOLONE ACETATE						
AB		SICOR PHARMS	40MG/ML	N40557	001	Feb 23, 2005	Feb	NEWA
AB			80MG/ML	N40557	002	Feb 23, 2005	Feb	NEWA

METOCLOPRAMIDE HYDROCHLORIDE

TABLET, ORALLY DISINTEGRATING; ORAL

		METOCLOPRAMIDE						
		SCHWARZ PHARMA	EQ 5MG BASE	N21793	001	Jun 10, 2005	Jun	NEWA
	+		EQ 10MG BASE	N21793	002	Jun 10, 2005	Jun	NEWA

METOLAZONE

TABLET; ORAL

		ZAROXOLYN						
AB		UCB	2.5MG	N17386	001		Mar	CAHN
AB	+		5MG	N17386	002		Mar	CAHN
AB	+		10MG	N17386	003		Mar	CAHN

METOPROLOL TARTRATE

TABLET; ORAL

		METOPROLOL TARTRATE						
AB		TEVA PHARMS	50MG	N74333	001	Jan 27, 1994	Mar	CAHN

TABLET; ORAL
METOPROLOL TARTRATE

AB	TEVA PHARMS	100MG	N74333	002	Jan 27, 1994	Mar	CAHN

METRONIDAZOLE

CAPSULE; ORAL
METRONIDAZOLE

	@ ABLE	375MG	N76505	001	Nov 13, 2003	May	DISC

GEL; TOPICAL
METROGEL

>D>	+ DOW PHARM SCI	1%	N21789	001	Jun 30, 2005	Jul	CAHN
	+	1%	N21789	001	Jun 30, 2005	Jun	NEWA
>A>	+ GALDERMA LABS LP	1%	N21789	001	Jun 30, 2005	Jul	CAHN

GEL; VAGINAL
METROGEL-VAGINAL

BX	+ 3M	0.75%	N20208	001	Aug 17, 1992	May	CTEC

METRONIDAZOLE

BX	TEVA PHARMS	0.75%	N21806	001	May 20, 2005	May	NEWA

TABLET, EXTENDED RELEASE; ORAL
FLAGYL ER

	+ GD SEARLE LLC	750MG	N20868	001	Nov 26, 1997	May	CTEC

METRONIDAZOLE

	@ ABLE	750MG	N76462	001	Jun 25, 2003	May	DISC

TABLET; ORAL
METRONIDAZOLE

	@ ABLE	250MG	N76519	001	Jun 27, 2003	May	DISC
	@	500MG	N76519	002	Jun 27, 2003	May	DISC

MICAFUNGIN SODIUM

INJECTABLE; IV (INFUSION)
MYCAMINE

	+ ASTELLAS	50MG/VIAL	N21506	002	Mar 16, 2005	Mar	NEWA

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION
MIDAZOLAM HCL

AP	HOSPIRA	EQ 1MG BASE/ML	N75293	001	Jun 20, 2000	Mar	CMFD
AP		EQ 5MG BASE/ML	N75293	002	Jun 20, 2000	Mar	CMFD
AP	INTL MEDICATED	EQ 1MG BASE/ML	N76144	001	Jan 26, 2005	Jan	NEWA
AP		EQ 5MG BASE/ML	N76144	002	Jan 26, 2005	Jan	NEWA

SYRUP; ORAL
MIDAZOLAM HCL

AA	PADDOCK	EQ 2MG BASE/ML	N76379	001	May 02, 2005	Apr	NEWA

MILRINONE LACTATE

INJECTABLE; INJECTION
MILRINONE LACTATE IN 5% DEXTROSE IN PLASTIC CONTAINER

AP	APOTEX	EQ 20MG BASE/100ML	N77151	001	Jul 20, 2005	Jun	NEWA

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL
MINOCIN

	@ WYETH PHARMS INC	EQ 75MG BASE	N50649	003	Feb 12, 2001	May	DISC

INJECTABLE; INJECTION
MINOCIN

	@ WYETH PHARMS INC	EQ 100MG BASE/VIAL	N50444	001		May	DISC

MIRTAZAPINE

TABLET, ORALLY DISINTEGRATING; ORAL

MIRTAZAPINE

AB		TEVA	15MG	N76901	001	Jun 28, 2005	Jun	NEWA
AB			30MG	N76901	002	Jun 28, 2005	Jun	NEWA
AB			45MG	N76901	003	Jun 28, 2005	Jun	NEWA

REMERON SOLTAB

AB		ORGANON USA INC	45MG	N21208	003	Jan 12, 2001	Jun	CTEC

MITOMYCIN

INJECTABLE; INJECTION

MITOMYCIN

	@	MAYNE PHARMA USA	20MG/VIAL	N64106	001	Nov 29, 1995	Jun	DISC

MOMETASONE FUROATE

CREAM; TOPICAL

ELOCON

AB	+	SCHERING	0.1%	N19625	001	May 06, 1987	Jan	CFTG

MOMETASONE FUROATE

AB		ALTANA	0.1%	N76171	001	Apr 08, 2005	Mar	NEWA
AB		TARO	0.1%	N76679	001	Dec 21, 2004	Jan	NEWA

LOTION; TOPICAL

ELOCON

AB	+	SCHERING	0.1%	N19796	001	Mar 30, 1989	Mar	CFTG

MOMETASONE FUROATE

AB		AGIS INDS	0.1%	N77180	001	Apr 06, 2005	Mar	NEWA

OINTMENT; TOPICAL

MOMETASONE FUROATE

AB		ALTANA	0.1%	N77061	001	Mar 28, 2005	Mar	NEWA

POWDER; INHALATION

ASMANEX TWISTHALER

	+	SCHERING	0.22MG/INH	N21067	001	Mar 30, 2005	Mar	NEWA

MOMETASONE FUROATE MONOHYDRATE

SPRAY, METERED; NASAL

NASONEX

	+	SCHERING PLOUGH	EQ 0.05MG BASE/SPRAY	N20762	001	Oct 01, 1997	Apr	CAHN
	+	SHIRE	EQ 0.05MG BASE/SPRAY	N20762	001	Oct 01, 1997	Mar	CAHN

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

AVINZA

BX		LIGAND	30MG	N21260	001	Mar 20, 2002	Mar	CRLD
BX			60MG	N21260	002	Mar 20, 2002	Mar	CRLD
			90MG	N21260	003	Mar 20, 2002	Mar	CRLD

KADIAN

		ALPHARMA US PHARMS	20MG	N20616	001	Jul 03, 1996	Mar	CRLD
BX			30MG	N20616	004	Mar 09, 2001	Mar	CRLD
			50MG	N20616	002	Jul 03, 1996	Mar	CRLD
BX			60MG	N20616	005	Mar 09, 2001	Mar	CRLD

TABLET, EXTENDED RELEASE; ORAL

ORAMORPH SR

>D>	BC	AAIPHARMA	15MG	N19977	004	Nov 23, 1994	Jul	CAHN
>D>	BC		30MG	N19977	001	Aug 15, 1991	Jul	CAHN
>D>	BC	+	60MG	N19977	002	Aug 15, 1991	Jul	CAHN
>D>	BC		100MG	N19977	003	Aug 15, 1991	Jul	CAHN

TABLET, EXTENDED RELEASE; ORAL
ORAMORPH SR

>A>	BC		XANODYNE PHARM	15MG	N19977	004	Nov 23, 1994	Jul	CAHN
>A>	BC			30MG	N19977	001	Aug 15, 1991	Jul	CAHN
>A>	BC	+		60MG	N19977	002	Aug 15, 1991	Jul	CAHN
>A>	BC			100MG	N19977	003	Aug 15, 1991	Jul	CAHN

NADOLOL

TABLET; ORAL
NADOLOL

	AB		TEVA PHARMS	80MG	N74368	001	Aug 31, 1994	Mar	CAHN
	AB			120MG	N74368	002	Aug 31, 1994	Mar	CAHN
	AB			160MG	N74368	003	Aug 31, 1994	Mar	CAHN

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION
NALBUPHINE HCL

	AP		MAYNE PHARMA USA	10MG/ML	N74471	001	Mar 19, 1998	Jun	CMFD
	AP			20MG/ML	N74471	002	Mar 19, 1998	Jun	CMFD

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION
NALOXONE HCL

	AP		HOSPIRA	0.4MG/ML	N70172	001	Sep 24, 1986	Mar	CMFD

NAPROXEN

TABLET, DELAYED RELEASE; ORAL
NAPROXEN

	AB		ALPHAPHARM	375MG	N75390	001	Apr 19, 2001	May	CDFR
	AB			500MG	N75390	002	Apr 19, 2001	May	CDFR

TABLET; ORAL
NAPROXEN

	AB		PERRIGO R AND D	250MG	N77339	001	Apr 27, 2005	Apr	NEWA
	AB			375MG	N77339	002	Apr 27, 2005	Apr	NEWA
	AB			500MG	N77339	003	Apr 27, 2005	Apr	NEWA
	AB		TEVA PHARMS	250MG	N74207	001	Dec 21, 1993	Mar	CAHN
	AB			375MG	N74207	002	Dec 21, 1993	Mar	CAHN
	AB			500MG	N74207	003	Dec 21, 1993	Mar	CAHN

NAPROXEN SODIUM

TABLET; ORAL
NAPROXEN SODIUM

			@ ABLE	EQ 250MG BASE	N76544	001	Aug 22, 2003	May	DISC
			@	EQ 500MG BASE	N76544	002	Aug 22, 2003	May	DISC
	AB		TEVA PHARMS	EQ 250MG BASE	N74289	001	Jan 27, 1994	Mar	CAHN
	AB			EQ 500MG BASE	N74289	002	Jan 27, 1994	Mar	CAHN

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL
NEFAZODONE HCL

	AB	+	TEVA	250MG	N76037	005	Sep 16, 2003	May	CRLD
			SERZONE						
			@ BRISTOL MYERS SQUIBB	50MG	N20152	001	Dec 22, 1994	May	DISC
			@	100MG	N20152	002	Dec 22, 1994	May	DISC
			@	150MG	N20152	003	Dec 22, 1994	May	DISC
			@	200MG	N20152	004	Dec 22, 1994	May	DISC

TABLET; ORAL
SERZONE
@ BRISTOL MYERS SQUIBB 250MG N20152 005 Dec 22, 1994 May DISC

NESIRITIDE RECOMBINANT

FOR SOLUTION; INTRAVENOUS
NATRECOR
\+ SCIOS 1.5MG/VIAL N20920 001 Aug 10, 2001 Apr CAIN

NIACIN

TABLET, EXTENDED RELEASE; ORAL
NIACIN
AB BARR 500MG N76378 001 Apr 26, 2005 Apr NEWA
AB 750MG N76378 002 Apr 26, 2005 Apr NEWA
AB 1GM N76250 001 Apr 14, 2005 Mar NEWA
NIASPAN
AB + KOS 500MG N20381 002 Jul 28, 1997 Apr CFTG
AB + 750MG N20381 003 Jul 28, 1997 Apr CFTG
AB + 1GM N20381 004 Jul 28, 1997 Mar CFTG
@ KOS LIFE 375MG N20381 001 Jul 28, 1997 Jun CAHN
AB + 500MG N20381 002 Jul 28, 1997 Jun CAHN
AB + 750MG N20381 003 Jul 28, 1997 Jun CAHN
AB + 1GM N20381 004 Jul 28, 1997 Jun CAHN
NIASPAN TITRATION STARTER PACK
@ KOS LIFE 375MG;500MG;750MG N20381 005 Jul 28, 1997 Jun CAHN

NICARDIPINE HYDROCHLORIDE

INJECTABLE; INJECTION
CARDENE
\+ ESP PHARMA 2.5MG/ML N19734 001 Jan 30, 1992 Mar CAHN

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)
AB EON 75MG;25MG N77066 001 Apr 05, 2005 Mar NEWA
AB RANBAXY 75MG;25MG N76951 001 Mar 30, 2005 Mar NEWA

NIZATIDINE

SOLUTION; ORAL
AXID
\+ BRAINTREE 15MG/ML N21494 001 May 25, 2004 Jun CAHN

NORGESTREL

TABLET; ORAL
OVRETTE
@ WYETH PHARMS INC 0.075MG N17031 001 Jun DISC

NYSTATIN

POWDER; TOPICAL
NYSTATIN
AT UPSHER SMITH 100,000 UNITS/GM N65183 001 May 03, 2005 Apr NEWA
SUSPENSION; ORAL
NYSTATIN
AA VINTAGE PHARMS 100,000 UNITS/ML N65148 001 Jun 28, 2005 Jun NEWA

NYSTATIN; TRIAMCINOLONE ACETONIDE

		CREAM; TOPICAL						
		MYCOLOG-II						
		@ APOTHECON	100,000 UNITS/GM;0.1%	N62606	001	May 15, 1985	Jun	DISC
		MYCO-TRIACET II						
		@ TEVA	100,000 UNITS/GM;0.1%	N61954	002	Sep 20, 1985	Jun	DISC
		MYTREX F						
		@ SAVAGE LABS	100,000 UNITS/GM;0.1%	N62597	001	Oct 08, 1985	Jun	DISC
		NYSTATIN AND TRIAMCINOLONE ACETONIDE						
		@ TARO	100,000 UNITS/GM;0.1%	N62347	001	Mar 30, 1987	Jun	DISC
AT	+		100,000 UNITS/GM;0.1%	N62364	001	Dec 22, 1987	Jun	CRLD
		OINTMENT; TOPICAL						
		MYCOLOG-II						
		@ APOTHECON	100,000 UNITS/GM;0.1%	N60572	001	Jun 28, 1985	Jun	DISC
		MYTREX F						
		@ SAVAGE LABS	100,000 UNITS/GM;0.1%	N62601	001	Oct 09, 1985	Jun	DISC
		NYSTATIN AND TRIAMCINOLONE ACETONIDE						
AT	+	TARO	100,000 UNITS/GM;0.1%	N63305	001	Mar 29, 1993	Jun	CRLD

OCTREOTIDE ACETATE

		INJECTABLE; INJECTION						
		OCTREOTIDE ACETATE						
AP		BEDFORD	EQ 0.2MG BASE/ML	N76330	001	Apr 08, 2005	Mar	NEWA
AP			EQ 1MG BASE/ML	N76330	002	Apr 08, 2005	Mar	NEWA
		OCTREOTIDE ACETATE (PRESERVATIVE FREE)						
AP		BEDFORD	EQ 0.05MG BASE/ML	N76313	001	Mar 28, 2005	Mar	NEWA
AP			EQ 0.1MG BASE/ML	N76313	003	Mar 28, 2005	Mar	NEWA
AP			EQ 0.5MG BASE/ML	N76313	002	Mar 28, 2005	Mar	NEWA
		SANDOSTATIN						
AP	+	NOVARTIS	EQ 0.05MG BASE/ML	N19667	001	Oct 21, 1988	Mar	CFTG
AP	+		EQ 0.1MG BASE/ML	N19667	002	Oct 21, 1988	Mar	CFTG
AP	+		EQ 0.2MG BASE/ML	N19667	004	Jun 12, 1991	Mar	CFTG
AP	+		EQ 0.5MG BASE/ML	N19667	003	Oct 21, 1988	Mar	CFTG
AP	+		EQ 1MG BASE/ML	N19667	005	Jun 12, 1991	Mar	CFTG

OLSALAZINE SODIUM

		CAPSULE; ORAL						
		DIPENTUM						
	+	UCB	250MG	N19715	001	Jul 31, 1990	Mar	CAHN

OMEPRAZOLE

		CAPSULE, DELAYED REL PELLETS; ORAL						
		PRILOSEC						
	+	ASTRAZENECA	40MG	N19810	002	Jan 15, 1998	Apr	CRLD
			40MG	N19810	002	Jan 15, 1998	Mar	CTEC

OXALIPLATIN

		INJECTABLE; IV (INFUSION)						
		ELOXATIN						
	+	SANOFI SYNTHELABO	50MG/VIAL	N21492	001	Aug 09, 2002	Mar	CRLD
	+		50MG/10ML (5MG/ML)	N21759	001	Jan 31, 2005	Jan	NEWA
	+		100MG/20ML (5MG/ML)	N21759	002	Jan 31, 2005	Jan	NEWA

OXAZEPAM

CAPSULE; ORAL

OXAZEPAM

	AB	+	IVAX PHARMS	30MG	N70945	001	Aug 03, 1987	Apr	CRLD

SERAX

		@	ALPHARMA US PHARMS	10MG	N15539	002		Apr	DISC
		@		15MG	N15539	004		Apr	DISC
		@		30MG	N15539	006		Apr	DISC

OXYCODONE HYDROCHLORIDE

TABLET; ORAL

ROXICODONE

>D>	AB	+	AAIPHARMA	15MG	N21011	001	Aug 31, 2000	Jul	CAHN
>D>	AB			30MG	N21011	002	Aug 31, 2000	Jul	CAHN
>A>	AB	+	XANODYNE PHARM	15MG	N21011	001	Aug 31, 2000	Jul	CAHN
>A>	AB			30MG	N21011	002	Aug 31, 2000	Jul	CAHN

OXYMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

NUMORPHAN

		@	ENDO PHARMS	1.5MG/ML	N11707	001		May	DISC

SUPPOSITORY; RECTAL

NUMORPHAN

		@	ENDO PHARMS	5MG	N11738	004		May	DISC

PACLITAXEL

FOR SUSPENSION; IV (INFUSION)

ABRAXANE

		+	AM BIOSCIENCE	100MG/VIAL	N21660	001	Jan 07, 2005	Jan	NEWA

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

AREDIA

		@	NOVARTIS	60MG/VIAL	N20036	003	May 06, 1993	Jun	DISC

PAMIDRONATE DISODIUM

	AP	+	BEDFORD	30MG /10ML(3MG/ML)	N21113	001	Mar 04, 2002	May	CRLD
	AP	+	MAYNE PHARMA USA	30MG/10ML(3MG/ML)	N75841	001	Jun 27, 2002	May	CRLD
	AP	+		60MG/10ML(6MG/ML)	N75841	002	Jun 27, 2002	May	CRLD
	AP	+		90MG/10ML(9MG/ML)	N75841	003	Jun 27, 2002	May	CRLD

PARICALCITOL

CAPSULE; ORAL

ZEMPLAR

			ABBOTT	1UGM	N21606	001	May 26, 2005	May	NEWA
				2UGM	N21606	002	May 26, 2005	May	NEWA
		+		4UGM	N21606	003	May 26, 2005	May	NEWA

PAROXETINE HYDROCHLORIDE

TABLET; ORAL

PAROXETINE HCL

>A>	AB		TEVA	EQ 10MG BASE	N76618	001	Aug 15, 2005	Jul	NEWA
>A>	AB			EQ 20MG BASE	N76618	002	Aug 15, 2005	Jul	NEWA
>A>	AB			EQ 30MG BASE	N76618	003	Aug 15, 2005	Jul	NEWA
>A>	AB			EQ 40MG BASE	N76618	004	Aug 15, 2005	Jul	NEWA

PEMOLINE

TABLET, CHEWABLE; ORAL

PEMOLINE

AB		TEVA PHARMS	37.5MG	N75555	001	Feb 18, 2000	Mar	CAHN

TABLET; ORAL

PEMOLINE

AB		TEVA PHARMS	18.75MG	N75030	003	Feb 22, 2000	Mar	CAHN
AB			37.5MG	N75030	001	Jan 29, 1999	Mar	CAHN
AB			75MG	N75030	002	Jan 29, 1999	Mar	CAHN

PENTOBARBITAL SODIUM

CAPSULE; ORAL

SODIUM PENTOBARBITAL

		@ VALEANT PHARM INTL	100MG	N83264	001		Jan	DISC

PERGOLIDE MESYLATE

TABLET; ORAL

PERMAX

>D>	AB	+	LILLY	EQ 0.05MG BASE	N19385	001	Dec 30, 1988	Jul	CAHN
>D>	AB			EQ 0.25MG BASE	N19385	002	Dec 30, 1988	Jul	CAHN
>D>	AB			EQ 1MG BASE	N19385	003	Dec 30, 1988	Jul	CAHN
>A>	AB	+	VALEANT	EQ 0.05MG BASE	N19385	001	Dec 30, 1988	Jul	CAHN
>A>	AB			EQ 0.25MG BASE	N19385	002	Dec 30, 1988	Jul	CAHN
>A>	AB			EQ 1MG BASE	N19385	003	Dec 30, 1988	Jul	CAHN

PERPHENAZINE

INJECTABLE; INJECTION

TRILAFON

>D>		+	SCHERING	5MG/ML	N11213	002		Jul	DISC
>A>			@	5MG/ML	N11213	002		Jul	DISC

PHENDIMETRAZINE TARTRATE

TABLET; ORAL

BONTRIL PDM

AA	+	VALEANT	35MG	N85272	001		Feb	CRLD

CAM-METRAZINE

		@ ABC HOLDING	35MG	N83922	001		Feb	DISC
		@	35MG	N85318	001		Feb	DISC
		@	35MG	N85320	001		Feb	DISC
		@	35MG	N85321	001		Feb	DISC
		@	35MG	N85511	001		Feb	DISC
		@ CAMALL	35MG	N85756	001		Feb	DISC

PHENDIMETRAZINE TARTRATE

		@ ABC HOLDING	35MG	N85761	001		Feb	DISC
		@	35MG	N85941	001	Jun 27, 1983	Feb	DISC
		@ EON	35MG	N85830	001		Feb	DISC

X-TROZINE

		@ SHIRE RICHWOOD	35MG	N86553	001		Feb	DISC
		@	35MG	N86554	001		Feb	DISC

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

ONA-MAST

		@ MAST MM	30MG	N86511	001		Feb	DISC
		@	30MG	N86516	001		Feb	DISC

	CAPSULE; ORAL							
	PHENTERMINE HCL							
	@ ABC HOLDING	18.75MG	N88576	001	May 23, 1984	Feb	DISC	
	@	30MG	N85417	001		Feb	DISC	
	@	30MG	N86732	002		Feb	DISC	
	@	30MG	N87215	001		Feb	DISC	
	@	37.5MG	N87915	001	Dec 22, 1983	Feb	DISC	
	@	37.5MG	N87918	001	Dec 22, 1983	Feb	DISC	
	@	37.5MG	N87930	001	Oct 14, 1983	Feb	DISC	
	@	37.5MG	N88610	001	Jun 04, 1984	Feb	DISC	
	@	37.5MG	N88611	001	Jun 04, 1984	Feb	DISC	
	@	37.5MG	N88625	001	Aug 23, 1984	Feb	DISC	
	@ ABLE	15MG	N40497	001	Mar 13, 2003	May	DISC	
	@	30MG	N40403	001	Aug 30, 2001	May	DISC	
	@	30MG	N40427	001	Aug 30, 2001	May	DISC	
	@ CAMALL	15MG	N86735	001		Feb	DISC	
	@	30MG	N87226	001		Feb	DISC	
	TABLET; ORAL							
	ONA MAST							
	@ MAST MM	8MG	N86260	001		Feb	DISC	
	PHENTERMINE HCL							
	@ ABC HOLDING	8MG	N83923	001		Feb	DISC	
	@	8MG	N85319	001		Feb	DISC	
	@	37.5MG	N87805	001	Dec 06, 1982	Feb	DISC	
	@	37.5MG	N88596	001	Apr 04, 1984	Feb	DISC	
	@ ABLE	37.5MG	N40402	001	Aug 30, 2001	May	DISC	
AA	LANNETT	37.5MG	N40555	001	Apr 15, 2005	Mar	NEWA	
	PHENTERMINE RESIN COMPLEX							
	CAPSULE, EXTENDED RELEASE; ORAL							
	IONAMIN							
	UCB	EQ 15MG BASE	N11613	004		Mar	CAHN	
	+	EQ 30MG BASE	N11613	002		Mar	CAHN	
	PHENYTOIN SODIUM							
	INJECTABLE; INJECTION							
	PHENYTOIN							
AP	+ ELKINS SINN	50MG/ML	N84307	001		Mar	CTEC	
	PHENYTOIN SODIUM							
AP	HOSPIRA	50MG/ML	N89521	001	Mar 17, 1987	Mar	CMFD	
AP		50MG/ML	N89744	001	Dec 18, 1987	Mar	CMFD	
	PIROXICAM							
	CAPSULE; ORAL							
	PIROXICAM							
AB	TEVA PHARMS	10MG	N74103	001	Aug 28, 1992	Mar	CAHN	
AB		20MG	N74103	002	Aug 28, 1992	Mar	CAHN	
	POTASSIUM CHLORIDE							
	INJECTABLE; INJECTION							
	POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER							
AP	HOSPIRA	14.9MG/ML	N20161	005	Nov 30, 1992	Mar	CMFD	
AP		745MG/100ML	N20161	001	Nov 30, 1992	Mar	CMFD	
	POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER							
AP	HOSPIRA	1.49GM/100ML	N20161	002	Nov 30, 1992	Mar	CMFD	

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE; ORAL

UROCIT-K

		MISSION PHARMA	5MEQ	N19071	001	Aug 30, 1985	Jan	CTNA
	+		10MEQ	N19071	002	Aug 31, 1992	Jan	CTNA

POTASSIUM PERCHLORATE

CAPSULE; ORAL

PERCHLORACAP

		@ MALLINCKRODT	200MG	N17551	001		Jun	DISC

PRAMLINTIDE ACETATE

INJECTABLE; SUBCUTANEOUS

SYMLIN

	+	AMYLIN	EQ 3MG BASE/5ML (EQ 0.6MG BASE/ML)	N21332	001	Mar 16, 2005	Mar	NEWA

PREDNISOLONE

SYRUP; ORAL

PREDNISOLONE

AA		IVAX PHARMS	15MG/5ML	N40287	001	May 28, 1999	Jan	CAHN
AA		TEVA PHARMS	15MG/5ML	N40322	001	Jan 19, 2000	Mar	CAHN

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

PEDIAPRED

AA	+	UCB	EQ 5MG BASE/5ML	N19157	001	May 28, 1986	Mar	CAHN

PREDNISOLONE SODIUM PHOSPHATE

AA		KV PHARM	EQ 5MG BASE/5ML	N76982	001	May 24, 2005	May	NEWA
AA			EQ 15MG BASE/5ML	N76988	001	May 24, 2005	May	NEWA
AA		PHARM ASSOC	EQ 15MG BASE/5ML	N76913	001	Apr 25, 2005	Apr	NEWA

PREDNISONE

TABLET; ORAL

PREDNISONE

AB		TRIGEN	1MG	N40611	001	Jun 06, 2005	May	NEWA
AB			20MG	N40362	003	Jun 29, 2005	Jun	NEWA

PREGABALIN

CAPSULE; ORAL

LYRICA

		CP PHARMS	25MG	N21446	001	Dec 30, 2004	Jun	CAHN
			50MG	N21446	002	Dec 30, 2004	Jun	CAHN
			75MG	N21446	003	Dec 30, 2004	Jun	CAHN
			100MG	N21446	004	Dec 30, 2004	Jun	CAHN
			150MG	N21446	005	Dec 30, 2004	Jun	CAHN
			200MG	N21446	006	Dec 30, 2004	Jun	CAHN
			225MG	N21446	007	Dec 30, 2004	Jun	CAHN
	+		300MG	N21446	008	Dec 30, 2004	Jun	CAHN

PRIMIDONE

TABLET; ORAL

MYSOLINE

AB	+	VALEANT	50MG	N09170	003		Apr	CAHN
AB			250MG	N09170	002		Apr	CAHN

TABLET; ORAL
PRIMIDONE

AB		VINTAGE PHARMS	50MG	N40586	001	Feb 24, 2005	Feb	NEWA
AB			250MG	N40586	002	Feb 24, 2005	Feb	NEWA

PROCHLORPERAZINE

SUPPOSITORY; RECTAL
COMPAZINE

		GLAXOSMITHKLINE	2.5MG	N11127	003		May	CTEC
			5MG	N11127	001		May	CTEC

PROCHLORPERAZINE

		@ ABLE	2.5MG	N40407	001	Jul 11, 2001	May	DISC
		@	5MG	N40407	002	Jul 11, 2001	May	DISC
		@	25MG	N40407	003	Jul 11, 2001	May	DISC

PROCHLORPERAZINE MALEATE

TABLET; ORAL
PROCHLORPERAZINE MALEATE

AB		TEVA PHARMS	EQ 5MG BASE	N40120	001	Jul 11, 1996	Mar	CAHN
AB			EQ 10MG BASE	N40120	002	Jul 11, 1996	Mar	CAHN

PROGESTERONE

INJECTABLE; INJECTION
PROGESTERONE

AO	+	WATSON LABS (UTAH)	50MG/ML	N17362	002		Feb	CAHN

PROMETHAZINE HYDROCHLORIDE

SUPPOSITORY; RECTAL
PHENERGAN

	+	WYETH PHARMS INC	50MG	N11689	001		May	CTEC
		@	50MG	N11689	001		Jun	DISC

PROMETHAZINE HCL

		@ ABLE	12.5MG	N40504	001	Apr 11, 2003	May	DISC
		@	25MG	N40504	002	Apr 11, 2003	May	DISC
		@	50MG	N40449	001	Feb 27, 2003	May	DISC

PROMETHEGAN

>D>	BR	G AND W LABS	50MG	N87165	001	Aug 14, 1987	Jul	CTEC
>A>			50MG	N87165	001	Aug 14, 1987	Jul	CTEC

TABLET; ORAL
PHENERGAN

	+	WYETH PHARMS INC	25MG	N07935	003		May	CTEC
		@	50MG	N07935	004		May	DISC

PROMETHAZINE HCL

		ABLE	12.5MG	N40558	001	Jul 01, 2004	Jan	CTEC
		@	12.5MG	N40558	001	Jul 01, 2004	May	DISC
		@	25MG	N40558	002	Jul 01, 2004	May	DISC
		@	50MG	N40558	003	Jul 01, 2004	May	DISC

PROPOFOL

INJECTABLE; INJECTION
PROPOFOL

AB		BEDFORD	10MG/ML	N74848	001	Apr 19, 2005	Mar	NEWA

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL
DARVON

>D>		@ AAIPHARMA LLC	32MG	N10997	001		Jul	CAHN
>D>	AA	+	65MG	N10997	003		Jul	CAHN
>A>		@ XANODYNE PHARM	32MG	N10997	001		Jul	CAHN
>A>	AA	+	65MG	N10997	003		Jul	CAHN

PROPOXYPHENE NAPSYLATE

TABLET; ORAL
DARVON-N

>D>		+ AAIPHARMA LLC	100MG	N16862	002		Jul	CAHN
>A>		+ XANODYNE PHARM	100MG	N16862	002		Jul	CAHN

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
INDERAL

	AB	WYETH PHARMS INC	10MG	N16418	001		Apr	CRLD

PYRIDOSTIGMINE BROMIDE

TABLET; ORAL
PYRIDOSTIGMINE BROMIDE

>A>		BARR	30MG	N40512	002	Jul 20, 2005	Jul	NEWA

QUAZEPAM

TABLET; ORAL
DORAL

		@ MEDPOINTE PHARM HLC	7.5MG	N18708	003	Feb 26, 1987	May	DISC

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL
QUINAPRIL HCL

	AB	EON	EQ 5MG BASE	N76803	001	Mar 02, 2005	Feb	NEWA
	AB		EQ 10MG BASE	N76803	002	Mar 02, 2005	Feb	NEWA
	AB		EQ 20MG BASE	N76803	003	Mar 02, 2005	Feb	NEWA
	AB		EQ 40MG BASE	N76803	004	Mar 02, 2005	Feb	NEWA
	AB	PAR PHARM	EQ 5MG BASE	N76036	001	Jan 28, 2005	Jan	NEWA
	AB		EQ 10MG BASE	N76036	002	Jan 28, 2005	Jan	NEWA
	AB		EQ 20MG BASE	N76036	003	Jan 28, 2005	Jan	NEWA
	AB		EQ 40MG BASE	N76036	004	Jan 28, 2005	Jan	NEWA

QUINIDINE SULFATE

TABLET, EXTENDED RELEASE; ORAL
QUINIDINE SULFATE

		+ TEVA PHARMS	300MG	N40045	001	Jun 30, 1994	Mar	CAHN

>A> RAMELTEON

>A> TABLET; ORAL
>A> ROZEREM

>A>		+ TAKEDA GLOBAL	8MG	N21782	001	Jul 22, 2005	Jul	NEWA

RANITIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
RANITIDINE HCL

	AP	BEN VENUE	EQ 25MG BASE/ML	N74777	001	Mar 02, 2005	Feb	NEWA

TABLET; ORAL
RANITIDINE HCL

>A>	AB	DR REDDYS LABS INC	EQ 150MG BASE	N76705	001	Jul 27, 2005	Jul	NEWA
>A>	AB		EQ 300MG BASE	N76705	002	Jul 27, 2005	Jul	NEWA

RESERPINE; TRICHLORMETHIAZIDE

TABLET; ORAL
NAQUIVAL

		@ SCHERING	0.1MG;4MG	N12265	003		Feb	DISC

RIBAVIRIN

TABLET; ORAL
COPEGUS

		ROCHE	400MG	N21511	002	Jun 21, 2005	Jun	NEWA

RIFAMPIN

CAPSULE; ORAL
RIMACTANE

>A>	AB	AMIDE PHARM	300MG	N50429	001		Jul	CAHN
>D>	AB	SANDOZ	300MG	N50429	001		Jul	CAHN

SILDENAFIL CITRATE

TABLET; ORAL
REVATIO

	+	PFIZER	EQ 20MG BASE	N21845	001	Jun 03, 2005	Jun	NEWA

VIAGRA

		PFIZER IRELAND	EQ 25MG BASE	N20895	001	Mar 27, 1998	Jun	CPOT
			EQ 50MG BASE	N20895	002	Mar 27, 1998	Jun	CPOT
	+		EQ 100MG BASE	N20895	003	Mar 27, 1998	Jun	CPOT

SIROLIMUS

TABLET; ORAL
RAPAMUNE

	+	WYETH PHARMS INC	2MG	N21110	002	Aug 22, 2002	May	CRLD
		@	5MG	N21110	003	Feb 23, 2004	May	DISC

SODIUM BENZOATE; SODIUM PHENYLACETATE

SOLUTION; IV (INFUSION)
AMMONUL

	+	UCYCLYD	10%;10% (5GM/50ML;5GM/50ML)	N20645	001	Feb 17, 2005	Feb	NEWA

SODIUM CHLORIDE

SOLUTION; IRRIGATION
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

	AT	HOSPIRA	450MG/100ML	N18380	001		Mar	CMFD

SOMATREM

INJECTABLE; INJECTION
PROTROPIN

		@ GENENTECH	5MG/VIAL	N19107	001	Oct 17, 1985	Mar	DISC
		@	10MG/VIAL	N19107	002	Oct 24, 1989	Mar	DISC

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION
BIO-TROPIN

>A>		@ FERRING	4.8MG/VIAL	N19774	001	May 25, 1995	Jul	CAHN

			INJECTABLE; INJECTION						
			BIO-TROPIN						
>D>			@ SAVIENT PHARMS	4.8MG/VIAL	N19774	001	May 25, 1995	Jul	CAHN
			TEV-TROPIN						
>A>	BX	+	FERRING	5MG/ML	N19774	002	Jan 04, 2002	Jul	CAHN
>D>	BX	+	SAVIENT PHARMS	5MG/ML	N19774	002	Jan 04, 2002	Jul	CAHN
			INJECTABLE; SUBCUTANEOUS						
			SEROSTIM LQ						
			SERONO	6MG/0.05VIAL	N20604	005	Feb 11, 2005	Feb	NEWA
			@	6MG/0.5ML	N20604	005	Feb 11, 2005	Jun	DISC
			SUCCINYLCHOLINE CHLORIDE						
			INJECTABLE; INJECTION						
			ANECTINE						
			@ SABEX 2002	500MG/VIAL	N08453	001		May	DISC
			@	1GM/VIAL	N08453	004		May	DISC
			SULFAMETHOXAZOLE; TRIMETHOPRIM						
			TABLET; ORAL						
			SULFAMETHOXAZOLE AND TRIMETHOPRIM						
	AB		INTERPHARM	400MG;80MG	N76899	001	Jan 27, 2005	Jan	NEWA
	AB			800MG;160MG	N76899	002	Jan 27, 2005	Jan	NEWA
			SULINDAC						
			TABLET; ORAL						
			SULINDAC						
			@ WARNER CHILCOTT	150MG	N72710	001	Mar 25, 1991	Jun	DISC
			@	200MG	N72711	001	Mar 25, 1991	Jun	DISC
			TACROLIMUS						
			CAPSULE; ORAL						
			PROGRAF						
			ASTELLAS	EQ 1MG BASE	N50708	001	Apr 08, 1994	May	CRLD
		+	FUJISAWA HLTHCARE	EQ 1MG BASE	N50708	001	Apr 08, 1994	Jan	CRLD
			TAMOXIFEN CITRATE						
			TABLET; ORAL						
			TAMOXIFEN CITRATE						
			@ PHARMACHEMIE	EQ 10MG BASE	N74539	001	Mar 31, 2003	Feb	DISC
			TECHNETIUM TC-99M MEDRONATE KIT						
			INJECTABLE; INJECTION						
			OSTEOLITE						
			@ CIS	N/A	N17972	001		May	DISC
			TECHNETIUM TC-99M TEBOROXIME KIT						
			INJECTABLE; INJECTION						
			CARDIOTEC						
			@ BRACCO	N/A	N19928	001	Dec 19, 1990	Jun	DISC
			TECHNETIUM TC-99M TETROFOSMIN KIT						
			INJECTABLE; INJECTION						
>A>			MYOVIEW						
>A>			GE HEALTHCARE	N/A	N20372	001	Feb 09, 1996	Jul	CTNA
>D>			MYOVIEW 30ML						
>D>			GE HEALTHCARE	N/A	N20372	001	Feb 09, 1996	Jul	CTNA

		INJECTABLE; INJECTION							
>A>		MYOVIEW 30ML							
>A>		GE HEALTHCARE	N/A		N20372	002	Jul 07, 2005	Jul	NEWA
			N/A		N20372	001	Feb 09, 1996	Jun	CTNA
		TELITHROMYCIN							
		TABLET; ORAL							
		KETEK							
		AVENTIS PHARMS	300MG		N21144	002	Feb 09, 2005	Feb	NEWA
		TERBINAFINE HYDROCHLORIDE							
		CREAM; TOPICAL							
		LAMISIL							
		@ NOVARTIS	1%		N20192	001	Dec 30, 1992	Jun	DISC
		TERBUTALINE SULFATE							
		TABLET; ORAL							
		TERBUTALINE SULFATE							
	AB	LANNETT	2.5MG		N77152	001	Mar 25, 2005	Mar	NEWA
	AB		5MG		N77152	002	Mar 25, 2005	Mar	NEWA
		TERCONAZOLE							
		CREAM; VAGINAL							
		TERCONAZOLE							
	AB	ALTANA	0.4%		N76712	001	Feb 18, 2005	Jan	NEWA
		TESTOSTERONE							
		GEL; TOPICAL							
		TESTIM							
	BX	+ AUXILIUM PHARMS	1%		N21454	001	Oct 31, 2002	Jun	CAHN
		TESTOSTERONE CYPIONATE							
		INJECTABLE; INJECTION							
		TESTOSTERONE CYPIONATE							
	AO	PADDOCK	200MG/ML		N40530	001	Jan 31, 2005	Jan	NEWA
		TETRACYCLINE HYDROCHLORIDE							
		CAPSULE; ORAL							
		SUMYCIN							
		@ APOTHECON	250MG		N60429	001		Mar	DISC
		@	500MG		N60429	003		Mar	DISC
		TETRACYCLINE HCL							
	AB	+ IVAX PHARMS	500MG		N60704	002		Mar	CRLD
		@ MAST MM	250MG		N62085	001		Feb	DISC
		THEOPHYLLINE							
		CAPSULE, EXTENDED RELEASE; ORAL							
		THEOPHYLLINE							
		INWOOD LABS	125MG		N40052	002	Feb 14, 1994	Apr	CTEC
		TABLET, EXTENDED RELEASE; ORAL							
		THEOPHYLLINE							
		@ ABLE	300MG		N40548	001	Apr 30, 2004	May	DISC
		@	400MG		N40543	001	Apr 27, 2004	May	DISC
		@	450MG		N40546	001	Apr 30, 2004	May	DISC
		@	600MG		N40539	001	Apr 27, 2004	May	DISC

TABLET, EXTENDED RELEASE; ORAL
UNIPHYL

+	PURDUE FREDERICK	400MG	N87571	001	Sep 01, 1982	May	CTEC
+		600MG	N40086	001	Apr 15, 1996	May	CTEC

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE; ORAL
THIORIDAZINE HCL

AA	+	TEVA PHARMS	30MG/ML	N89602	001	Nov 09, 1987	Mar	CAHN
AA	+		100MG/ML	N89603	001	Nov 09, 1987	Mar	CAHN

THIOTHIXENE HYDROCHLORIDE

CONCENTRATE; ORAL
THIOTHIXENE HCL

AA		TEVA PHARMS	EQ 5MG BASE/ML	N71554	001	Oct 16, 1987	Mar	CAHN

TIGECYCLINE

INJECTABLE; IV (INFUSION)
TYGACIL

+	WYETH PHARMS INC	50MG/VIAL	N21821	001	Jun 15, 2005	Jun	NEWA

TIPRANAVIR

CAPSULE; ORAL
APTIVUS

+	BOEHRINGER INGELHEIM	250MG	N21814	001	Jun 22, 2005	Jun	NEWA

TOLTERODINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL
DETROL LA

	PHARMACIA AND UPJOHN	2MG	N21228	001	Dec 22, 2000	Apr	CRLD

TOREMIFENE CITRATE

TABLET; ORAL
FARESTON

+	GTX INC	EQ 60MG BASE	N20497	001	May 29, 1997	Jan	CAHN

TORSEMIDE

TABLET; ORAL
TORSEMIDE

AB		APOTEX	5MG	N76894	001	May 31, 2005	May	NEWA
AB			10MG	N76894	002	May 31, 2005	May	NEWA
AB			20MG	N76894	003	May 31, 2005	May	NEWA
AB			100MG	N76894	004	May 31, 2005	May	NEWA
AB		ROXANE	5MG	N76943	001	Mar 01, 2005	Feb	NEWA
AB			10MG	N76943	002	Mar 01, 2005	Feb	NEWA
AB			20MG	N76943	003	Mar 01, 2005	Feb	NEWA

TRAMADOL HYDROCHLORIDE

TABLET, ORALLY DISINTEGRATING; ORAL
TRAMADOL HYDROCLORIDE

+	BIOVAIL	50MG	N21693	001	May 05, 2005	May	NEWA

TRETINOIN

CREAM; TOPICAL
RENOVA

+	JOHNSON AND JOHNSON	0.05%	N19963	001	Dec 29, 1995	May	CDFR

		SOLUTION; TOPICAL						
		TRETINOIN						
	AT	TEVA PHARMS	0.05%	N74873	001	Jun 19, 1998	Mar	CAHN
		TRIAMCINOLONE ACETONIDE						
		AEROSOL, METERED; INHALATION						
		AZMACORT						
	+	KOS LIFE	0.1MG/INH	N18117	001	Apr 23, 1982	Jun	CAHN
		CREAM; TOPICAL						
		ARISTOCORT						
		@ ASTELLAS	0.025%	N83017	003		Jun	DISC
		@	0.1%	N83016	004		Jun	DISC
		@	0.5%	N83015	002		Jun	DISC
>D>		ARISTOCORT A						
>D>	AT	ASTELLAS	0.025%	N83017	004		Jul	DISC
>A>		@	0.025%	N83017	004		Jul	DISC
>D>	AT		0.1%	N83016	005		Jul	DISC
>A>		@	0.1%	N83016	005		Jul	DISC
>D>	AT		0.5%	N83015	003		Jul	DISC
>A>		@	0.5%	N83015	003		Jul	DISC
		OINTMENT; TOPICAL						
		ARISTOCORT						
		@ ASTELLAS	0.1%	N80750	004		Jun	DISC
>D>		ARISTOCORT A						
>D>	AT	ASTELLAS	0.1%	N80750	003		Jul	DISC
>A>		@	0.1%	N80750	003		Jul	DISC
>D>	AT		0.1%	N88780	001	Oct 01, 1984	Jul	DISC
>A>		@	0.1%	N88780	001	Oct 01, 1984	Jul	DISC
		TRICHLORMETHIAZIDE						
		TABLET; ORAL						
		NAQUA						
		@ SCHERING	2MG	N12265	001		Feb	DISC
		@	4MG	N12265	002		Feb	DISC
		TRICHLORMETHIAZIDE						
		@ ABC HOLDING	4MG	N85568	001		Feb	DISC
		@ PAR PHARM	2MG	N87007	001		Feb	DISC
		@	4MG	N87005	001		Feb	DISC
		TRIMETHOPRIM HYDROCHLORIDE						
		SOLUTION; ORAL						
		PRIMSOL						
		@ TARO PHARMS NORTH	EQ 25MG BASE/5ML	N74374	001	Jun 23, 1995	Jan	CAHN
	+		EQ 50MG BASE/5ML	N74973	001	Jan 24, 2000	Jan	CAHN
		UROKINASE						
		INJECTABLE; INJECTION						
		ABBOKINASE						
		@ ABBOTT	5,000 IU/VIAL	N21846	003		Jun	DISC
		@	9,000 IU/VIAL	N21846	002		Jun	DISC
		URSODIOL						
		CAPSULE; ORAL						
		URSODIOL						
	AB	TEVA PHARMS	300MG	N75592	001	May 25, 2000	Mar	CAHN

VALPROIC ACID

SYRUP; ORAL

VALPROIC ACID

>A>	AA	APOTEX	250MG/5ML	N77105	001	Jul 29, 2005	Jul	NEWA
	AA	TEVA PHARMS	250MG/5ML	N73178	001	Aug 25, 1992	Mar	CAHN

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

VERELAN PM

		ELAN DRUG	100MG	N20943	001	Nov 25, 1998	May	CAHN
			200MG	N20943	002	Nov 25, 1998	May	CAHN
	+		300MG	N20943	003	Nov 25, 1998	May	CAHN
		ELAN PHARM	100MG	N20943	001	Nov 25, 1998	Mar	CRLD
			200MG	N20943	002	Nov 25, 1998	Mar	CRLD

INJECTABLE; INJECTION

VERAPAMIL HCL

	@	HOSPIRA	2.5MG/ML	N70739	001	May 06, 1987	May	DISC
	@		2.5MG/ML	N70740	001	May 06, 1987	May	DISC

VINBLASTINE SULFATE

INJECTABLE; INJECTION

VINBLASTINE SULFATE

	+	BEDFORD	10MG/VIAL	N89395	001	Apr 09, 1987	Jun	CTEC
	@	MAYNE PHARMA USA	10MG/VIAL	N89565	001	Aug 18, 1987	Jun	DISC

VINORELBINE TARTRATE

INJECTABLE; INJECTION

VINORELBINE TARTRATE

	AP	AM PHARM	EQ 10MG BASE/ML	N76849	001	Apr 18, 2005	Mar	NEWA
	AP	MAYNE PHARMA USA	EQ 10MG BASE/ML	N76827	001	Jun 02, 2005	May	NEWA

ZICONOTIDE

INJECTABLE; INTRATHECAL

PRIALT

>D>	+	ELAN PHARMS	100MG/1ML (100MG/ML)	N21060	002	Dec 28, 2004	Jul	CPOT
>A>	+		100UGM/1ML(100MG/ML)	N21060	002	Dec 28, 2004	Jul	CPOT
>D>	+		200MG/2ML (100MG/ML)	N21060	003	Dec 28, 2004	Jul	DISC
>A>	@		200UGM/2ML (100MG/ML)	N21060	003	Dec 28, 2004	Jul	DISC
>D>	+		500MG/20ML (25MG/ML)	N21060	001	Dec 28, 2004	Jul	CPOT
>D>	+		500MG/5ML (100MG/ML)	N21060	004	Dec 28, 2004	Jul	CPOT
>A>	+		500UGM/20ML(25MG/ML)	N21060	001	Dec 28, 2004	Jul	CPOT
>A>	+		500UGM/5ML(100MG/ML)	N21060	004	Dec 28, 2004	Jul	CPOT

ZIPRASIDONE HYDROCHLORIDE

CAPSULE; ORAL

GEODON

	+	PFIZER	EQ 20MG BASE	N20825	001	Feb 05, 2001	May	CPOT
			EQ 40MG BASE	N20825	002	Feb 05, 2001	May	CPOT
			EQ 60MG BASE	N20825	003	Feb 05, 2001	May	CPOT
			EQ 80MG BASE	N20825	004	Feb 05, 2001	May	CPOT

ASPIRIN

TABLET; ORAL
BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN

		BAYER	500MG	N21317	001	Oct 18, 2001	Mar CMFD

BENTOQUATAM

LOTION; TOPICAL
IVY BLOCK

	+	STAND HOMEOPATH	5%	N20532	001	Aug 26, 1996	Apr CAHN

CHLORHEXIDINE GLUCONATE

CLOTH; TOPICAL
CHLORHEXIDINE GLUCONATE

	+	SAGE PRODS	2%	N21669	001	Apr 25, 2005	Apr NEWA

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SPONGE; TOPICAL
CHLORAPREP ONE-STEP FREPP

	+	MEDI FLEX INC	2%;70%	N20832	001	Jul 14, 2000	Apr CTNA

CHLORAPREP SINGLE SWABSTICK

>A>	+	MEDI FLEX HOSP	2%;70%	N21555	002	May 10, 2005	Jul NEWA

CHLORAPREP WITH TINT

	+	MEDI FLEX INC	2%;70%	N20832	002	May 03, 2005	Apr NEWA

SWAB; TOPICAL
CHLORASCRUB MAXI SWABSTICK

	+	NICE PAK	3.15%;70%	N21524	003	Jun 03, 2005	Jun NEWA

CHLORASCRUB SWAB

		NICE PAK	3.15%;70%	N21524	001	Jun 03, 2005	Jun NEWA

CHLORASCRUB SWABSTICK

		NICE PAK	3.15%;70%	N21524	002	Jun 03, 2005	Jun NEWA

CLOTRIMAZOLE

TABLET; VAGINAL
GYNIX

		TEVA PHARMS	100MG	N73249	001	Feb 13, 1998	Mar CAHN

DEXTROMETHORPHAN POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL
DELSYM

	+	UCB	EQ 30MG HBR/5ML	N18658	001	Oct 08, 1982	Apr CAHN

EPINEPHRINE

AEROSOL, METERED; INHALATION
PRIMATENE MIST

>D>	+	WHITEHALL ROBINS	0.2MG/INH	N16126	001		Jul CAHN
>A>	+	WYETH CONS	0.2MG/INH	N16126	001		Jul CAHN

EPINEPHRINE BITARTRATE

AEROSOL, METERED; INHALATION
BRONITIN MIST

>D>		WHITEHALL ROBINS	0.3MG/INH	N16126	002		Jul CAHN
>A>		WYETH CONS	0.3MG/INH	N16126	002		Jul CAHN

FAMOTIDINE

TABLET; ORAL

FAMOTIDINE

	PERRIGO	10MG	N75400	001	Mar 18, 2005	Mar	NEWA
	WOCKHARDT	10MG	N77146	001	Mar 07, 2005	Feb	NEWA

IBUPROFEN

CAPSULE; ORAL

IBUPROFEN

+	BANNER PHARMACAPS	200MG	N21472	001	Oct 18, 2002	May	CRLD

TABLET; ORAL

IBUPROFEN

	PERRIGO R AND D	200MG	N77349	001	Jun 21, 2005	May	NEWA

LOPERAMIDE HYDROCHLORIDE

SOLUTION; ORAL

IMODIUM A-D

+	MCNEIL	1MG/7.5ML	N19487	002	Jul 08, 2004	Apr	NEWA

LORATADINE

SYRUP; ORAL

CLARITIN HIVES RELIEF

@	SCHERING	1MG/ML	N20641	003	Nov 19, 2003	Jan	DISC

MICONAZOLE NITRATE

CREAM; VAGINAL

MICONAZOLE 3

	TARO	4%	N76773	001	Mar 02, 2005	Feb	NEWA

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL

NICOTINE POLACRILEX

@	WATSON LABS	EQ 2MG BASE	N76568	001	Jul 29, 2004	Apr	DISC
@		EQ 4MG BASE	N76569	002	Jul 29, 2004	Apr	DISC

NICOTINE POLACRILEX (MINT)

	WATSON LABS	EQ 2MG BASE	N76569	001	Jul 29, 2004	Apr	CTNA
		EQ 4MG BASE	N76568	002	Jul 29, 2004	Apr	CTNA

POTASSIUM IODIDE

TABLET; ORAL

IOSAT

>D>	ANBEX	130MG	N18664	001	Oct 14, 1982	Jul	CRLD
>A> +		130MG	N18664	001	Oct 14, 1982	Jul	CRLD

>D> THYRO-BLOCK

>D> +	MEDPOINTE PHARM HLC	130MG	N18307	001		Jul	DISC
>A> @		130MG	N18307	001		Jul	DISC

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 07 JULY 2005

NO JULY 2005 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

http://www.fda.gov/orphan/designat/list.htm

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO JULY 2005 ADDITIONS

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATON DATE		PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE - TRIZIVIR						
021205 001	4724232	Sep 17, 2005			U-248	
	4818538	Sep 17, 2005		DP		
	4828838	Sep 17, 2005		DP		
	4833130	Sep 17, 2005			U-248	
	4837208	Sep 17, 2005			U-248	
	5034394	Jun 26, 2009	DS	DP		
	5034394*PED	Dec 26, 2009				
	5047407	Nov 17, 2009	DS	DP	U-248	
	5047407*PED	May 17, 2010				
	5905082	May 18, 2016	DS	DP	U-248	
	5905082*PED	Nov 18, 2016				
	6180639	Jan 30, 2018		DP	U-248	
	6180639*PED	Jul 30, 2018			U-248	
	6294540	May 14, 2018	DS	DP	U-65	
	6294540*PED	Nov 14, 2018			U-65	
	6417191	Mar 28, 2016		DP	U-248	
ALBUTEROL SULFATE - ALBUTEROL SULFATE HFA						
021457 001	5605674	Feb 25, 2014		DP		
	5695743	Jul 06, 2010		DP	U-491	
	5766573	Nov 28, 2009			U-356	
	6352684	Nov 28, 2009		DP		
ALENDRONATE SODIUM; CHOLECALCIFEROL - FOSAMAX PLUS D						
021762 001	4621077	Aug 06, 2007			U-648	
	4621077*PED	Feb 06, 2008				
	5358941	Dec 02, 2012		DP		
	5358941*PED	Jun 02, 2013				
	5681590	Dec 02, 2012		DP		
	5681590*PED	Jun 02, 2013				
	5994329	Jul 17, 2018			U-647	
	5994329*PED	Jan 17, 2019				
	6090410	Dec 02, 2012		DP		
	6090410*PED	Jun 02, 2013		DP		
ALPRAZOLAM - NIRAVAM						
021726 001	6024981	Apr 09, 2018		DP		
	6221392	Apr 09, 2018		DP		
ALPRAZOLAM - NIRAVAM						
021726 002	6024981	Apr 09, 2018		DP		
	6221392	Apr 09, 2018		DP		
ALPRAZOLAM - NIRAVAM						
021726 003	6024981	Apr 09, 2018		DP		
	6221392	Apr 09, 2018		DP		
ALPRAZOLAM - NIRAVAM						
021726 004	6024981	Apr 09, 2018		DP		
	6221392	Apr 09, 2018		DP		
ALPRAZOLAM - XANAX						
018276 004	5061494	Dec 12, 2008				
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 10						
021303 001					**>A>** NPP	Jul 21, 2008
					>A> PED	Jan 21, 2009
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 15						
021303 006					**>A>** NPP	Jul 21, 2008
					>A> PED	Jan 21, 2009
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 20						
021303 002					**>A>** NPP	Jul 21, 2008
					>A> PED	Jan 21, 2009
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 25						
021303 004					**>A>** NPP	Jul 21, 2008
					>A> PED	Jan 21, 2009

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATON DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 30					
021303 003				>A> NPP	Jul 21, 2008
				>A> PED	Jan 21, 2009
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 5					
021303 005				>A> NPP	Jul 21, 2008
				>A> PED	Jan 21, 2009
ARIPIPRAZOLE - ABILIFY					
021713 001				I-437	Sep 29, 2007
				I-401	Aug 28, 2006
				NCE	Nov 15, 2007
ARSENIC TRIOXIDE - TRISENOX					
021248 001	6855339	Nov 10, 2018	U-617		
	6861076	Nov 10, 2018	U-617		
	6884439	Nov 10, 2018	U-651		
ATOMOXETINE HYDROCHLORIDE - STRATTERA					
021411 007	5658590	Jan 11, 2015	U-494	NCE	Nov 26, 2007
	5658590*PED	Jul 11, 2015		PED	May 26, 2008
ATOMOXETINE HYDROCHLORIDE - STRATTERA					
021411 008	5658590	Jan 11, 2015	U-494	NCE	Nov 26, 2007
	5658590*PED	Jul 11, 2015		PED	May 26, 2008
BEXAROTENE - TARGRETIN					
021055 001	6043279	Apr 22, 2012	U-509		
	6320074	Apr 22, 2012 DS	U-509		
BEXAROTENE - TARGRETIN					
021056 001	6043279	Apr 22, 2012	U-510		
	6320074	Apr 22, 2012 DS	U-510		
BIVALIRUDIN - ANGIOMAX					
020873 001				I-458	Jun 13, 2008
BORTEZOMIB - VELCADE					
021602 001				I-452	Mar 25, 2008
BROMFENAC SODIUM - XIBROM					
021664 001				NP	Mar 24, 2008
BUDESONIDE - ENTOCORT EC					
021324 001	6423340	Nov 15, 2010		I-454	Apr 29, 2008
	6423340*PED	May 11, 2011			
BUDESONIDE - PULMICORT RESPULES					
020929 001	6899099	Dec 23, 2018	U-645		
CALCIPOTRIENE - DOVONEX					
020554 001	5763426	Jun 09, 2015 DS	DP		
CALCIPOTRIENE - DOVONEX					
020611 001	5763426	Jun 09, 2015 DS	DP		
CANDESARTAN CILEXETIL - ATACAND					
020838 001	5196444	Jun 04, 2012 DS	DP U-660	I-456	May 18, 2008
	5196444	Jun 04, 2012 DS	DP U-3	I-455	May 18, 2008
	5534534	Jul 09, 2013	DP	I-448	Feb 22, 2008
	5705517	Apr 18, 2011 DS	DP U-660		
CANDESARTAN CILEXETIL - ATACAND					
020838 002	5196444	Jun 04, 2012 DS	DP U-660	I-456	May 18, 2008
	5196444	Jun 04, 2012 DS	DP U-3	I-455	May 18, 2008
	5534534	Jul 09, 2013	DP	I-448	Feb 22, 2008
	5705517	Apr 18, 2011 DS	DP U-660		
CANDESARTAN CILEXETIL - ATACAND					
020838 003	5196444	Jun 04, 2012 DS	DP U-660	I-456	May 18, 2008
	5196444	Jun 04, 2012 DS	DP U-3	I-455	May 18, 2008
	5534534	Jul 09, 2013	DP	I-448	Feb 22, 2008
	5705517	Apr 18, 2011 DS	DP U-660		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATON DATE		PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CANDESARTAN CILEXETIL - ATACAND								
020838 004		5196444	Jun 04, 2012	DS	DP	U-660	I-456	May 18, 2008
		5196444	Jun 04, 2012	DS	DP	U-3	I-455	May 18, 2008
		5534534	Jul 09, 2013		DP		I-448	Feb 22, 2008
		5705517	Apr 18, 2011	DS	DP	U-660		
CAPECITABINE - XELODA								
020896 001							I-461	Jun 15, 2008
CAPECITABINE - XELODA								
020896 002							I-461	Jun 15, 2008
CARBAMAZEPINE - CARBATROL								
020712 003		5326570	Jul 05, 2011			U-215		
		5912013	Jun 15, 2016			U-277		
CARBAMAZEPINE - EQUETRO								
021710 001		5326570	Jul 23, 2011		DP	U-627		
		5912013	Jun 15, 2016		DP			
CARBAMAZEPINE - EQUETRO								
021710 002		5326570	Jul 23, 2011		DP	U-627		
		5912013	Jun 15, 2016		DP			
CARBAMAZEPINE - EQUETRO								
021710 003		5326570	Jul 23, 2011		DP	U-627		
		5912013	Jun 15, 2016		DP			
CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 100								
021485 002		5446194	Oct 19, 2013	DS				
CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 150								
021485 003		5446194	Oct 19, 2013	DS				
CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 50								
021485 001		5446194	Oct 19, 2013	DS				
CELECOXIB - CELEBREX								
020998 001	**>A>**	5466823	Nov 30, 2013	DS			**>A>** I-466	Jul 29, 2008
	>A>	5563165	Nov 30, 2013		DP			
	>A>	5760068	Jun 02, 2015			U-672		
	>A>	5760068	Jun 02, 2015			U-299		
CELECOXIB - CELEBREX								
020998 002	**>A>**	5466823	Nov 30, 2013	DS			**>A>** I-466	Jul 29, 2008
	>A>	5563165	Nov 30, 2013		DP			
	>A>	5760068	Jun 02, 2015			U-672		
	>A>	5760068	Jun 02, 2015			U-299		
CELECOXIB - CELEBREX								
020998 003	**>A>**	5466823	Nov 30, 2013	DS			**>A>** I-466	Jul 29, 2008
	>A>	5563165	Nov 30, 2013		DP			
	>A>	5760068	Jun 02, 2015			U-672		
	>A>	5760068	Jun 02, 2015			U-299		
CETRORELIX - CETROTIDE								
021197 001		6863891	Feb 19, 2013			U-426		
CETRORELIX - CETROTIDE								
021197 002		6863891	Feb 19, 2013			U-426		
CHLORHEXIDINE GLUCONATE - CHLORHEXIDINE GLUCONATE								
021669 001							NDF	Apr 25, 2008
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP FREPP								
020832 001		5538353	Aug 25, 2015		DP			
		5690958	Sep 30, 2016		DP			
		5752363	Apr 22, 2017		DP			
		5772346	Apr 22, 2017		DP			
		6536975	Nov 10, 2020		DP			
		D386849	Nov 25, 2011		DP			
		D396911	Aug 11, 2012		DP			
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP SEPP								
021555 001		5690958	Sep 30, 2016		DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATON DATE		PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT								
020832 002		5538353	Aug 25, 2015		DP		NP	May 03, 2008
		5690958	Sep 30, 2016		DP			
		6536975	Nov 10, 2020		DP			
		6729786	Mar 14, 2023		DP			
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORASCRUB SWAB								
021524 001							NP	Jun 03, 2008
CIPROFLOXACIN HYDROCHLORIDE - PROQUIN XR								
021744 001		5972389	Sep 19, 2016		DP	U-663	NDF	May 19, 2008
		6340475	Sep 19, 2016		DP	U-663		
		6488962	Jun 20, 2020		DP			
		6635280	Sep 19, 2016	DS		U-663		
CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE - CIPRO HC								
020805 001		4844902	Feb 11, 2008		DP			
		5843930	Jul 06, 2015			U-646		
CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE - CIPRO XR								
021473 001							NC	Dec 13, 2005
							PED	Jun 13, 2006
CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE - CIPRO XR								
021473 002							NC	Dec 13, 2005
							PED	Jun 13, 2006
CLOFARABINE - CLOLAR								
021673 001		4918179	Jun 14, 2005	DS				
		5384310	May 23, 2009	DS	DP			
		5661136	Aug 26, 2014			U-626		
COLESTIPOL HYDROCHLORIDE - COLESTID								
020222 001		5490987	Feb 13, 2013		DP			
DAPSONE - ACZONE								
021794 001							**>A>** NDF	Jul 07, 2008
DAPTOMYCIN - CUBICIN								
021572 001		6852689	Sep 24, 2019			U-282		
DAPTOMYCIN - CUBICIN								
021572 002		6852689	Sep 24, 2019			U-282		
DARIFENACIN HYDROBROMIDE - ENABLEX								
021513 001		5096890	Mar 13, 2010	DS	DP	U-631		
		6106864	Aug 21, 2016		DP	U-630		
DARIFENACIN HYDROBROMIDE - ENABLEX								
021513 002		5096890	Mar 13, 2010	DS	DP	U-631		
		6106864	Aug 21, 2016		DP	U-630		
DELAVIRDINE MESYLATE - RESCRIPTOR								
020705 002		6177101	Jun 07, 2019					
DESIRUDIN RECOMBINANT - IPRIVASK								
021271 001							NCE	Apr 04, 2008
DESLORATADINE - CLARINEX								
021165 001		4659716	Apr 21, 2006			U-427		
		4659716*PED	Oct 21, 2006			U-427		
DESLORATADINE - CLARINEX								
021300 001		4659716	Apr 21, 2006		DP	U-611		
		4659716*PED	Oct 21, 2006					
DESLORATADINE - CLARINEX								
021312 001	**>A>**	4659716	Apr 21, 2006		DP	U-427		
		4659716*PED	Oct 21, 2006			U-427		
	>A>	6100274	Jul 07, 2019		DP			
DESLORATADINE; PSEUDOEPHEDRINE SULFATE - CLARINEX D 24 HOUR								
021605 001		4659716	Apr 21, 2006		DP	U-644	NCE	Dec 21, 2006
		4659716*PED	Oct 21, 2006				NC	Mar 03, 2008
		6100274	Jul 07, 2019		DP		PED	Jun 21, 2007
		6100274*PED	Jan 07, 2020					
DESMOPRESSIN ACETATE - DESMOPRESSIN ACETATE								
076470 001							**>A>** PC	Dec 28, 2005

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATON DATE			PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DESMOPRESSIN ACETATE - DESMOPRESSIN ACETATE								
076470 002							**>A>** PC	Dec 28, 2005
DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR								
021802 001							**>A>** NDF	May 26, 2008
DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR								
021802 002							**>A>** NDF	May 26, 2008
DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR								
021802 003							**>A>** NDF	May 26, 2008
DEXRAZOXANE HYDROCHLORIDE - DEXRAZOXANE								
076068 001							PC	Aug 27, 2005
DEXRAZOXANE HYDROCHLORIDE - DEXRAZOXANE								
076068 002							PC	Oct 19, 2005
DEXTROMETHORPHAN POLISTIREX - DELSYM								
018658 001	5980882	Apr	16,	2017	DP			
DICLOFENAC SODIUM; MISOPROSTOL - ARTHROTEC								
020607 001	5698225	May	03,	2010		U-392		
DICLOFENAC SODIUM; MISOPROSTOL - ARTHROTEC								
020607 002	5698225	May	03,	2010		U-392		
DIVALPROEX SODIUM - DEPAKOTE ER								
021168 001	6720004	Dec	18,	2018	DP			
DIVALPROEX SODIUM - DEPAKOTE ER								
021168 002	6720004	Dec	18,	2018	DP			
DOFETILIDE - TIKOSYN								
020931 001	4959366	Sep	25,	2012	DS	DP U-652		
DOFETILIDE - TIKOSYN								
020931 002	4959366	Sep	25,	2012	DS	DP U-652		
DOFETILIDE - TIKOSYN								
020931 003	4959366	Sep	25,	2012	DS	DP U-652		
DOXAZOSIN MESYLATE - CARDURA XL								
021269 001							NDF	Feb 22, 2008
DOXAZOSIN MESYLATE - CARDURA XL								
021269 002	4837111	Mar	21,	2008	DP		NDF	Feb 22, 2008
DOXERCALCIFEROL - HECTOROL								
020862 001	6903083	Jul	18,	2021	DS	DP		
DOXERCALCIFEROL - HECTOROL								
020862 002	6903083	Jul	18,	2021	DS	DP		
DOXERCALCIFEROL - HECTOROL								
021027 001	6903083	Jul	18,	2021	DS	DP		
ENOXAPARIN SODIUM - LOVENOX								
020164 001	RE38743	Feb	14,	2012	DS	DP U-545		
ENOXAPARIN SODIUM - LOVENOX								
020164 002	RE38743	Feb	14,	2012	DS	DP U-545		
ENOXAPARIN SODIUM - LOVENOX								
020164 003	RE38743	Feb	14,	2012	DS	DP U-545		
ENOXAPARIN SODIUM - LOVENOX								
020164 004	RE38743	Feb	14,	2012	DS	DP U-545		
ENOXAPARIN SODIUM - LOVENOX								
020164 005	RE38743	Feb	14,	2012	DS	DP U-545		
ENOXAPARIN SODIUM - LOVENOX								
020164 006	RE38743	Feb	14,	2012	DS	DP U-545		
ENOXAPARIN SODIUM - LOVENOX								
020164 007	RE38743	Feb	14,	2012	DS	DP U-545		
ENOXAPARIN SODIUM - LOVENOX								
020164 008	RE38743	Feb	14,	2012	DS	DP U-545		
ENOXAPARIN SODIUM - LOVENOX								
020164 009	RE38743	Feb	14,	2012	DS	DP U-545		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATON DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ENTACAPONE - COMTAN					
020796 001	5446194	Oct 19, 2013	DS		
ENTECAVIR - BARACLUDE					
021797 001	5206244	Oct 18, 2010	DS	NCE	Mar 29, 2010
ENTECAVIR - BARACLUDE					
021797 002	5206244	Oct 18, 2010	DS	NCE	Mar 29, 2010
ENTECAVIR - BARACLUDE					
021798 001	5206244	Oct 18, 2010	DS	NCE	Mar 29, 2010
EPINEPHRINE; LIDOCAINE HYDROCHLORIDE - LIDOSITE TOPICAL SYSTEM KIT					
021504 001	6862473	Sep 30, 2013	DP		
EPLERENONE - INSPRA					
021437 001	4559332	Apr 09, 2006	DS DP U-537		
	6863902	Apr 10, 2020	DP U-664		
EPLERENONE - INSPRA					
021437 002	4559332	Apr 09, 2006	DS DP U-537		
	6863902	Apr 10, 2020	DP U-664		
EPLERENONE - INSPRA					
021437 003	4559332	Apr 09, 2006	DS DP U-537		
	6863902	Apr 10, 2020	DP U-664		
ERLOTINIB HYDROCHLORIDE - TARCEVA					
021743 001	5747498	Mar 30, 2015	DS DP U-659		
	6900221	Nov 09, 2020	DS DP U-659		
ERLOTINIB HYDROCHLORIDE - TARCEVA					
021743 002	5747498	Mar 30, 2015	DS DP U-659		
	6900221	Nov 09, 2020	DS DP U-659		
ERLOTINIB HYDROCHLORIDE - TARCEVA					
021743 003	5747498	Mar 30, 2015	DS DP U-659		
	6900221	Nov 09, 2020	DS DP U-659		
ERTAPENEM SODIUM - INVANZ					
021337 001	5478820	Feb 02, 2013	DS DP U-160	NPP	May 18, 2008
	5478820*PED	Aug 02, 2013		NCE	Nov 21, 2006
	5652233	Feb 02, 2013	DS DP U-160	PED	Nov 18, 2008
	5652233*PED	Aug 02, 2013		PED	May 21, 2007
	5952323	May 15, 2017	DP		
	5952323*PED	Nov 15, 2017			
ESCITALOPRAM OXALATE - LEXAPRO					
021323 001	**>A>** 6916941	Jul 25, 2022	DS DP		
	>A> 6916941*PED	Jan 25, 2023	DS DP		
ESCITALOPRAM OXALATE - LEXAPRO					
021323 002	**>A>** 6916941	Jul 25, 2022	DS DP		
	>A> 6916941*PED	Jan 25, 2023	DS DP		
ESCITALOPRAM OXALATE - LEXAPRO					
021323 003	**>A>** 6916941	Jul 25, 2022	DS DP		
	>A> 6916941*PED	Jan 25, 2023	DS DP		
ESMOLOL HYDROCHLORIDE - ESMOLOL HCL					
076323 001				PC	May 01, 2005
ESOMEPRAZOLE MAGNESIUM - NEXIUM					
021153 001	4738974	Apr 19, 2006	DS DP U-635		
	4738974	Apr 19, 2006	DS DP U-373		
	4738974*PED	Oct 19, 2006	U-373		
	6875872	May 27, 2014	DS		
	6875872*PED	Nov 27, 2014			
ESOMEPRAZOLE MAGNESIUM - NEXIUM					
021153 002	4738974	Apr 19, 2006	DS DP U-635		
	4738974	Apr 19, 2006	DS DP U-373		
	4738974*PED	Oct 19, 2006	U-373		
	6875872	May 27, 2014	DS		
	6875872*PED	Nov 27, 2014			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATON DATE			PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ESOMEPRAZOLE SODIUM - NEXIUM IV								
021689 001	5877192	May	27, 2014			U-643	NE	Mar 31, 2008
	5877192*PED	Nov	27, 2014					
	6143771	May	27, 2014		DP	U-643		
ESOMEPRAZOLE SODIUM - NEXIUM IV								
021689 002	5877192	May	27, 2014			U-643	NE	Mar 31, 2008
	5877192*PED	Nov	27, 2014					
	6143771	May	27, 2014		DP	U-643		
ESTROGENS, CONJUGATED SYNTHETIC A - CENESTIN								
020992 001							**>A>** I-466	Jul 29, 2008
ESTROGENS, CONJUGATED SYNTHETIC A - CENESTIN								
020992 002							**>A>** I-466	Jul 29, 2008
ESTROGENS, CONJUGATED SYNTHETIC A - CENESTIN								
020992 003							**>A>** I-466	Jul 29, 2008
ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVIA								
021443 001	6660726	Mar	08, 2021	DS	DP	U-284	NP	Dec 20, 2007
	6660726	Mar	08, 2021	DS	DP	U-196		
	6855703	Feb	12, 2021	DS	DP	U-284		
ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVIA								
021443 002	6660726	Mar	08, 2021	DS	DP	U-284	NP	Dec 20, 2007
	6660726	Mar	08, 2021	DS	DP	U-196		
	6855703	Feb	12, 2021	DS	DP	U-284		
ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVIA								
021443 003	6660726	Mar	08, 2021	DS	DP	U-284		
	6660726	Mar	08, 2021	DS	DP	U-196		
	6855703	Feb	12, 2021	DS	DP	U-284		
ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVIA								
021443 004	6660726	Mar	08, 2021	DS	DP	U-284		
	6660726	Mar	08, 2021	DS	DP	U-196		
	6855703	Feb	12, 2021	DS	DP	U-284		
ESZOPICLONE - LUNESTA								
021476 001	6319926	Jan	16, 2012			U-620		
	6444673	Jan	16, 2012	DS	DP			
	6864257	Aug	30, 2012			U-629		
ESZOPICLONE - LUNESTA								
021476 002	6319926	Jan	16, 2012			U-620		
	6444673	Jan	16, 2012	DS	DP			
	6864257	Aug	30, 2012			U-629		
ESZOPICLONE - LUNESTA								
021476 003	6319926	Jan	16, 2012			U-620		
	6444673	Jan	16, 2012	DS	DP			
	6864257	Aug	30, 2012			U-629		
ETHINYL ESTRADIOL; NORGESTIMATE - ORTHO CYCLEN-21								
019653 001							M-41	May 13, 2008
							PED	Nov 13, 2008
ETHINYL ESTRADIOL; NORGESTIMATE - ORTHO CYCLEN-28								
019653 002							M-41	May 13, 2008
							PED	Nov 13, 2008
ETHINYL ESTRADIOL; NORGESTIMATE - ORTHO TRI-CYCLEN								
019697 001							M-41	May 13, 2008
							PED	Nov 13, 2008
ETHINYL ESTRADIOL; NORGESTIMATE - ORTHO TRI-CYCLEN								
019697 002							M-41	May 13, 2008
							PED	Nov 13, 2008
EXEMESTANE - AROMASIN								
020753 001	4808616	Apr	01, 2011	DS	DP	U-658		
EXENATIDE SYNTHETIC - BYETTA								
021773 001	5424286	May	24, 2013			U-653	NCE	Apr 28, 2010
	6858576	Jan	06, 2017			U-656		
	6872700	Jan	14, 2020			U-654		
	6902744	Jan	14, 2020		DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATON DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EXENATIDE SYNTHETIC - BYETTA					
021773 002	5424286	May 24, 2013	U-653	NCE	Apr 28, 2010
	6858576	Jan 06, 2017	U-656		
	6872700	Jan 14, 2020	U-654		
	6902744	Jan 14, 2020	DP		
FAMOTIDINE - FLUXID					
021712 001	6024981	Apr 09, 2018	DP		
	6221392	Apr 09, 2018	DP		
FAMOTIDINE - FLUXID					
021712 002	6024981	Apr 09, 2018	DP		
	6221392	Apr 09, 2018	DP		
FENTANYL - DURAGESIC-12					
019813 005				NPP	May 20, 2006
				PED	Nov 20, 2006
FENTANYL CITRATE - ACTIQ					
020747 001	5785989	May 01, 2005			
FENTANYL CITRATE - ACTIQ					
020747 002	5785989	May 01, 2005			
FENTANYL CITRATE - ACTIQ					
020747 003	5785989	May 01, 2005			
FENTANYL CITRATE - ACTIQ					
020747 004	5785989	May 01, 2005			
FENTANYL CITRATE - ACTIQ					
020747 005	5785989	May 01, 2005			
FENTANYL CITRATE - ACTIQ					
020747 006	5785989	May 01, 2005			
FLUOCINOLONE ACETONIDE - RETISERT					
021737 001				NDF	Apr 08, 2008
FLUOCINONIDE - VANOS					
021758 001	6765001	Dec 21, 2021	DP	NP	Feb 11, 2008
FLUTICASONE PROPIONATE - CUTIVATE					
021152 001				NDF	Mar 31, 2008
				PED	Sep 30, 2008
FLUTICASONE PROPIONATE - FLOVENT DISKUS 100					
020833 002	6536427	Mar 01, 2011	DP		
	6536427*PED	Sep 01, 2011	DP		
FLUTICASONE PROPIONATE - FLOVENT DISKUS 250					
020833 003	6536427	Mar 01, 2011	DP		
	6536427*PED	Sep 01, 2011	DP		
FLUTICASONE PROPIONATE - FLOVENT DISKUS 50					
020833 001	6536427	Mar 01, 2011	DP		
	6536427*PED	Sep 01, 2011	DP		
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 100/50					
021077 001	6536427	Mar 01, 2011	DP		
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 250/50					
021077 002	6536427	Mar 01, 2011	DP		
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 500/50					
021077 003	6536427	Mar 01, 2011	DP		
FONDAPARINUX SODIUM - ARIXTRA					
021345 001				I-457	May 26, 2008
FONDAPARINUX SODIUM - ARIXTRA					
021345 002				I-457	May 26, 2008
FONDAPARINUX SODIUM - ARIXTRA					
021345 003				I-457	May 26, 2008
FONDAPARINUX SODIUM - ARIXTRA					
021345 004				I-457	May 26, 2008
GADODIAMIDE - OMNISCAN					
020123 001	5362475	Nov 08, 2011	DS		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATON DATE	PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
GALANTAMINE HYDROBROMIDE - REMINYL							
021169 001		6358527	Jun 06, 2017	DP	U-322		
GALANTAMINE HYDROBROMIDE - REMINYL							
021169 002		6358527	Jun 06, 2017	DP	U-322		
GALANTAMINE HYDROBROMIDE - REMINYL							
021169 003		6358527	Jun 06, 2017	DP	U-322		
GALANTAMINE HYDROBROMIDE - REMINYL							
021615 001		4663318	Dec 14, 2008		U-322		
GALANTAMINE HYDROBROMIDE - REMINYL							
021615 002		4663318	Dec 14, 2008		U-322		
GALANTAMINE HYDROBROMIDE - REMINYL							
021615 003		4663318	Dec 14, 2008		U-322		
GATIFLOXACIN - ZYMAR							
021493 001	**>A>**	4980470	Dec 15, 2009	DS	DP		
GEMCITABINE HYDROCHLORIDE - GEMZAR							
020509 001		4808614	May 15, 2010	DS		I-428	May 19, 2007
		4808614*PED	Nov 15, 2010			M-40	Apr 26, 2008
		5464826	Nov 07, 2012		U-146	PED	Oct 26, 2008
		5464826*PED	May 07, 2013			PED	Nov 19, 2007
GEMCITABINE HYDROCHLORIDE - GEMZAR							
020509 002		4808614	May 15, 2010	DS		I-428	May 19, 2007
		4808614*PED	Nov 15, 2010			M-40	Apr 26, 2008
		5464826	Nov 07, 2012		U-146	PED	Oct 26, 2008
		5464826*PED	May 07, 2013			PED	Nov 19, 2007
GLIMEPIRIDE - AMARYL							
020496 001		4379785	Apr 06, 2005		U-118		
		4379785*PED	Oct 06, 2005				
GLIMEPIRIDE - AMARYL							
020496 002		4379785	Apr 06, 2005		U-118		
		4379785*PED	Oct 06, 2005				
GLIMEPIRIDE - AMARYL							
020496 003		4379785	Apr 06, 2005		U-118		
		4379785*PED	Oct 06, 2005				
GLIPIZIDE - GLUCOTROL XL							
020329 001		5545413	Jul 02, 2008		U-111		
GLIPIZIDE - GLUCOTROL XL							
020329 002		5545413	Jul 02, 2008		U-111		
GLIPIZIDE - GLUCOTROL XL							
020329 003		5545413	Jul 02, 2008		U-111		
GLYBURIDE - GLYNASE							
020051 001		4735805	Mar 11, 2007				
GLYBURIDE - GLYNASE							
020051 002		4735805	Mar 11, 2007				
GLYBURIDE - GLYNASE							
020051 003		4735805	Mar 11, 2007				
GLYBURIDE - GLYNASE							
020051 004		4735805	Mar 11, 2007				
GRANISETRON HYDROCHLORIDE - KYTRIL							
020239 003		4886808	Dec 29, 2007	DS	DP U-89	I-369	Aug 16, 2005
GRANISETRON HYDROCHLORIDE - KYTRIL							
020239 004						I-369	Aug 16, 2005
HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE - BIDIL							
020727 001	**>A>**	4868179	Apr 22, 2007		U-71	NC	Jun 23, 2008
	>A>	6465463	Sep 08, 2020		U-71		
	>A>	6784177	Sep 08, 2020		U-71		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATON DATE		PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
HYDROCHLOROTHIAZIDE; IRBESARTAN - AVALIDE								
020758 004		5270317	Sep 30, 2011	DS	DP			
		5270317*PED	Mar 30, 2012					
		5994348	Jun 07, 2015		DP			
		5994348*PED	Dec 07, 2015					
HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM - HYZAAR								
020387 001		5138069	Aug 11, 2009	DS				
		5153197	Oct 06, 2009		DP	U-3		
		5153197	Oct 06, 2009		DP	U-538		
HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM - HYZAAR								
020387 002		5138069	Aug 11, 2009	DS				
		5153197	Oct 06, 2009		DP	U-3		
		5153197	Oct 06, 2009		DP	U-538		
HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - BENICAR HCT								
021532 002		6878703	Nov 19, 2021			U-3		
HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - BENICAR HCT								
021532 003		6878703	Nov 19, 2021			U-3		
HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - BENICAR HCT								
021532 005		6878703	Nov 19, 2021			U-3		
IBANDRONATE SODIUM - BONIVA								
021455 002		4927814	Jul 09, 2007	DS	DP	U-642	D-96	Mar 24, 2008
		6294196	Oct 07, 2019		DP		NS	Mar 24, 2008
							NCE	May 16, 2008
IMATINIB MESYLATE - GLEEVEC								
021335 001		5521184	Jan 04, 2015					
		6894051	May 23, 2019	DS	DP	U-649		
IMATINIB MESYLATE - GLEEVEC								
021335 002		5521184	Jan 04, 2015					
		6894051	May 23, 2019	DS	DP	U-649		
IMATINIB MESYLATE - GLEEVEC								
021588 001		5521184	Jan 04, 2015					
		6894051	May 23, 2019	DS	DP	U-649		
IMATINIB MESYLATE - GLEEVEC								
021588 002		5521184	Jan 04, 2015					
		6894051	May 23, 2019	DS	DP	U-649		
INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30								
021172 001		5618913	Apr 08, 2014				NCE	Jun 07, 2005
		5618913*PED	Oct 08, 2014				PED	Dec 07, 2005
		5866538	Jun 19, 2017		DP			
INSULIN ASPART RECOMBINANT - NOVOLOG								
020986 001		5618913	Apr 08, 2014				NCE	Jun 07, 2005
		5618913*PED	Oct 08, 2014				PED	Dec 07, 2005
		5866538	Jun 20, 2017					
		5866538*PED	Dec 20, 2017					
INSULIN DETEMIR RECOMBINANT - LEVEMIR								
021536 001	**>A>**	5750497	May 12, 2015	DS	DP	U-668	NCE	Jun 16, 2010
	>A>	5866538	Jun 20, 2017		DP			
	>A>	6011007	Feb 02, 2014	DS	DP	U-668		
	>A>	6869930	Feb 02, 2014	DS	DP	U-668		
IRON SUCROSE - VENOFER								
021135 001							I-459	Jun 17, 2008
IRON SUCROSE - VENOFER								
021135 002							I-459	Jun 17, 2008
IRON SUCROSE - VENOFER								
021135 003							I-459	Jun 17, 2008
ITRACONAZOLE - ITRACONAZOLE								
076104 001							PC	Aug 08, 2005
LANSOPRAZOLE - PREVACID								
021428 001		6328994	May 17, 2019					

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATON DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LANSOPRAZOLE - PREVACID					
021428 002	6328994	May 17, 2019			
LETROZOLE - FEMARA					
020726 001				I-446	Oct 29, 2007
LEUPROLIDE ACETATE - ELIGARD					
021731 001	4938763	Oct 03, 2008	DP U-621		
	5278201	Jan 11, 2011	DP		
	5324519	Jun 28, 2011	DP		
	5599552	Feb 04, 2014	DP U-621		
	5739176	Oct 03, 2008	DP U-621		
	6395293	Sep 28, 2013	DP		
	6565874	Oct 28, 2018	DP U-621		
	6626870	Mar 27, 2020	DP		
	6773714	Oct 28, 2018	U-621		
	RE37950	Oct 03, 2008	DP U-621		
LEVALBUTEROL TARTRATE - XOPENEX HFA					
021730 001	5225183	Jul 06, 2010	DP	NP	Mar 11, 2008
	5362755	Nov 08, 2011	U-636		
	5439670	Jul 06, 2010	DP		
	5547994	Aug 20, 2013	U-636		
	5605674	Feb 25, 2014	DP		
	5695743	Jul 06, 2010	DP U-636		
	5760090	Jan 05, 2010	U-636		
	5836299	Nov 17, 2017	DP		
	5844002	Jan 05, 2010	U-636		
	6083993	Jan 05, 2010	U-636		
	6352684	Nov 28, 2009	DP		
LEVETIRACETAM - KEPPRA					
021035 001	4837223	May 14, 2005	DP	NPP	Jun 21, 2008
	4943639	Jul 14, 2008 DS			
LEVETIRACETAM - KEPPRA					
021035 002	4837223	May 14, 2005	DP	NPP	Jun 21, 2008
	4943639	Jul 14, 2008 DS			
LEVETIRACETAM - KEPPRA					
021035 003	4837223	May 14, 2005	DP	NPP	Jun 21, 2008
	4943639	Jul 14, 2008 DS			
LEVETIRACETAM - KEPPRA					
021505 001	4837223	May 14, 2005	DP	NPP	Jun 21, 2008
	4943639	Jul 14, 2008 DS			
LEVOFLOXACIN - LEVAQUIN					
020634 001				**>A>** D-100	Aug 04, 2008
LEVOFLOXACIN - LEVAQUIN					
020634 002				**>A>** D-100	Aug 04, 2008
LEVOFLOXACIN - LEVAQUIN					
020634 003				**>A>** D-100	Aug 04, 2008
LEVOFLOXACIN - LEVAQUIN					
020635 001				**>A>** D-100	Aug 04, 2008
LEVOFLOXACIN - LEVAQUIN					
020635 004				**>A>** D-100	Aug 04, 2008
LEVOFLOXACIN - LEVAQUIN					
021721 001				**>A>** D-100	Aug 04, 2008
LEVOFLOXACIN - LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER					
020635 002				**>A>** D-100	Aug 04, 2008
LEVOFLOXACIN - LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER					
020635 003				**>A>** D-100	Aug 04, 2008
LEVOFLOXACIN - LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER					
020635 005				**>A>** D-100	Aug 04, 2008

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATON DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LINEZOLID - ZYVOX					
021130 001	5688792	Nov 18, 2014	DS U-319	I-431	Jun 23, 2007
	5688792*PED	May 18, 2015		I-402	Jul 22, 2006
	6514529	Mar 15, 2021	DP	NPP	Dec 19, 2005
	6514529*PED	Sep 15, 2021		NCE	Apr 18, 2005
	6559305	Jan 29, 2021	DS	PED	Dec 23, 2007
	6559305*PED	Jul 29, 2021		PED	Jan 22, 2007
				PED	Jun 19, 2006
				PED	Oct 18, 2005
LINEZOLID - ZYVOX					
021130 002	5688792	Nov 18, 2014	DS U-319	I-431	Jun 23, 2007
	5688792*PED	May 18, 2015		I-402	Jul 22, 2006
	6514529	Mar 15, 2021	DP	NPP	Dec 19, 2005
	6514529*PED	Sep 15, 2021		NCE	Apr 18, 2005
	6559305	Jan 29, 2021	DS	PED	Dec 23, 2007
	6559305*PED	Jul 29, 2021		PED	Jan 22, 2007
				PED	Jun 19, 2006
				PED	Oct 18, 2005
LINEZOLID - ZYVOX					
021131 001	5688792	Nov 18, 2014	U-319	I-431	Jun 23, 2007
	5688792*PED	May 18, 2015		I-402	Jul 22, 2006
	6559305	Jan 29, 2021	DS	NPP	Dec 19, 2005
	6559305*PED	Jul 29, 2021		NCE	Apr 18, 2005
				PED	Dec 23, 2007
				PED	Jan 22, 2007
				PED	Jun 19, 2006
				PED	Oct 18, 2005
LINEZOLID - ZYVOX					
021132 001	5688792	Nov 18, 2014	DS U-319	I-431	Jun 23, 2007
	5688792*PED	May 18, 2015		I-402	Jul 22, 2006
	6559305	Jan 29, 2021	DS	NPP	Dec 19, 2005
	6559305*PED	Jul 29, 2021		NCE	Apr 18, 2005
				PED	Dec 23, 2007
				PED	Jan 22, 2007
				PED	Jun 19, 2006
				PED	Oct 18, 2005
LOPINAVIR; RITONAVIR - KALETRA					
021226 001				D-99	Apr 29, 2008
LOPINAVIR; RITONAVIR - KALETRA					
021251 001	**>A>** 6911214	Nov 28, 2021	DP	D-99	Apr 29, 2008
LOVASTATIN - ALTOPREV					
021316 001	6485748	Dec 12, 2017	DP		
LOVASTATIN - ALTOPREV					
021316 002	6485748	Dec 12, 2017	DP		
LOVASTATIN - ALTOPREV					
021316 003	6485748	Dec 12, 2017	DP		
LOVASTATIN - ALTOPREV					
021316 004	6485748	Dec 12, 2017	DP		
MEDROXYPROGESTERONE ACETATE - DEPO-SUBQ PROVERA 104					
021583 001	6495534	May 15, 2020	DP	I-451	Mar 25, 2008
MELOXICAM - MOBIC					
020938 001				I-430	Jul 16, 2007
				NCE	Apr 13, 2005
				PED	Jan 16, 2008
				PED	Oct 13, 2005
MELOXICAM - MOBIC					
020938 002				I-430	Jul 16, 2007
				NCE	Apr 13, 2005
				PED	Jan 16, 2008
				PED	Oct 13, 2005

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATON DATE		PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MELOXICAM - MOBIC								
021530 001		6184220	Mar 25, 2019		DP		I-430	Jul 16, 2007
		6184220*PED	Sep 25, 2019				NCE	Apr 13, 2005
							PED	Jan 16, 2008
							PED	Oct 13, 2005
MEMANTINE HYDROCHLORIDE - NAMENDA								
021627 001							NCE	Oct 16, 2008
METFORMIN HYDROCHLORIDE - FORTAMET								
021574 001		6866866	Mar 17, 2021		DP			
METFORMIN HYDROCHLORIDE - FORTAMET								
021574 002		6866866	Mar 17, 2021		DP			
METFORMIN HYDROCHLORIDE - GLUMETZA								
021748 001	>A>	6340475	Sep 19, 2016	DS	DP	U-669	NP	Jun 03, 2008
	>A>	6488962	Jun 20, 2020	DS	DP			
	>A>	6723340	Oct 25, 2021	DS	DP			
METFORMIN HYDROCHLORIDE - GLUMETZA								
021748 002	>A>	6340475	Sep 19, 2016	DS	DP	U-669	NP	Jun 03, 2008
	>A>	6488962	Jun 20, 2020	DS	DP			
	>A>	6723340	Oct 25, 2021	DS	DP			
METFORMIN HYDROCHLORIDE - METFORMIN HCL								
076863 001							PC	Apr 12, 2005
METFORMIN HYDROCHLORIDE - RIOMET								
021591 001		6890957	Sep 14, 2023		DP			
METHYLPHENIDATE HYDROCHLORIDE - CONCERTA								
021121 001		6919373	Jul 31, 2017			U-666		
		6919373*PED	Jan 31, 2018					
	>A>	6930129	Jul 31, 2017			U-666		
	>A>	6930129*PED	Jan 31, 2018					
METHYLPHENIDATE HYDROCHLORIDE - CONCERTA								
021121 002		6919373	Jul 31, 2017			U-666		
		6919373*PED	Jan 31, 2018					
	>A>	6930129	Jul 31, 2017			U-666		
	>A>	6930129*PED	Jan 31, 2018					
METHYLPHENIDATE HYDROCHLORIDE - CONCERTA								
021121 003		6919373	Jul 31, 2017			U-666		
		6919373*PED	Jan 31, 2018					
	>A>	6930129	Jul 31, 2017			U-666		
	>A>	6930129*PED	Jan 31, 2018					
METHYLPHENIDATE HYDROCHLORIDE - CONCERTA								
021121 004		6919373	Jul 31, 2017			U-666		
		6919373*PED	Jan 31, 2018					
	>A>	6930129	Jul 31, 2017			U-666		
	>A>	6930129*PED	Jan 31, 2018					
METHYLPHENIDATE HYDROCHLORIDE - RITALIN LA								
021284 001		6228398	Nov 01, 2019		DP	U-472		
METHYLPHENIDATE HYDROCHLORIDE - RITALIN LA								
021284 002		6228398	Nov 01, 2019		DP	U-472		
METHYLPHENIDATE HYDROCHLORIDE - RITALIN LA								
021284 003		6228398	Nov 01, 2019		DP	U-472		
METHYLPHENIDATE HYDROCHLORIDE - RITALIN LA								
021284 004		6228398	Nov 01, 2019		DP			
METOCLOPRAMIDE HYDROCHLORIDE - METOCLOPRAMIDE								
021793 001	>A>	6024981	Apr 09, 2018		DP			
	>A>	6221392	Apr 09, 2018		DP			
METOCLOPRAMIDE HYDROCHLORIDE - METOCLOPRAMIDE								
021793 002	>A>	6024981	Apr 09, 2018		DP			
	>A>	6221392	Apr 09, 2018		DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATON DATE		PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METOPROLOL SUCCINATE - TOPROL-XL							
019962 001	4927640	May 22, 2007		DP		D-95	Feb 15, 2008
	4957745	Sep 18, 2007		DP	U-107		
	5001161	Sep 18, 2007		DP			
	5081154	Sep 18, 2007	DS				
METOPROLOL SUCCINATE - TOPROL-XL							
019962 002	4927640	May 22, 2007		DP		D-95	Feb 15, 2008
	4957745	Sep 18, 2007		DP	U-107		
	5001161	Sep 18, 2007		DP			
	5081154	Sep 18, 2007	DS				
METOPROLOL SUCCINATE - TOPROL-XL							
019962 003	4927640	May 22, 2007		DP		D-95	Feb 15, 2008
	4957745	Sep 18, 2007		DP	U-107		
	5001161	Sep 18, 2007		DP			
	5081154	Sep 18, 2007	DS				
METOPROLOL SUCCINATE - TOPROL-XL							
019962 004	4927640	May 22, 2007		DP		D-95	Feb 15, 2008
	4957745	Sep 18, 2007		DP	U-107		
	5001161	Sep 18, 2007		DP	U-107		
	5081154	Sep 18, 2007	DS		U-107		
METRONIDAZOLE - METROGEL							
021789 001						NP	Jun 30, 2008
MICAFUNGIN SODIUM - MYCAMINE							
021506 002	5376634	Dec 27, 2011	DS	DP		NCE	Mar 16, 2010
	6107458	Sep 29, 2015	DS	DP	U-650		
	6265536	Sep 29, 2015	DS	DP	U-650		
	6774104	Jan 08, 2021		DP	U-650		
MODAFINIL - PROVIGIL							
020717 001						I-449	Jan 23, 2007
MODAFINIL - PROVIGIL							
020717 002						I-449	Jan 23, 2007
MOMETASONE FUROATE - ASMANEX TWISTHALER							
021067 001	5394868	Jun 25, 2012		DP		NP	Mar 30, 2008
	5687710	Nov 18, 2014		DP			
	5829434	Nov 03, 2015		DP			
	5889015	Jan 27, 2014			U-645		
	6057307	Jan 27, 2014		DP	U-645		
	6240918	Feb 20, 2017		DP			
	6365581	Jan 27, 2014			U-645		
	6503537	Mar 17, 2018		DP			
	6677322	Jan 27, 2014			U-645		
MOMETASONE FUROATE - MOMETASONE FUROATE							
077180 001						PC	Nov 19, 2005
MOMETASONE FUROATE MONOHYDRATE - NASONEX							
020762 001	5837699	Jan 27, 2014		DP	U-625		
	6127353	Oct 03, 2017	DS	DP			
	6723713	Jan 27, 2014			U-625		
MONTELUKAST SODIUM - SINGULAIR							
020829 002						**>A>** I-465	Aug 27, 2008
MONTELUKAST SODIUM - SINGULAIR							
020830 001						**>A>** I-465	Aug 27, 2008
MONTELUKAST SODIUM - SINGULAIR							
020830 002						**>A>** I-465	Aug 27, 2008
MONTELUKAST SODIUM - SINGULAIR							
021409 001						**>A>** I-465	Aug 27, 2008
NATEGLINIDE - STARLIX							
021204 001	6844008	Nov 14, 2017		DP	U-214		
	RE34878	Sep 08, 2009					
NATEGLINIDE - STARLIX							
021204 002	6844008	Nov 14, 2017		DP	U-214		
	RE34878	Sep 08, 2009					

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATON DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NITAZOXANIDE - ALINIA					
021498 001				I-460	Jun 16, 2008
OCTREOTIDE ACETATE - OCTREOTIDE ACETATE					
076330 001				PC	Nov 20, 2005
OCTREOTIDE ACETATE - OCTREOTIDE ACETATE					
076330 002				PC	Nov 20, 2005
OCTREOTIDE ACETATE - OCTREOTIDE ACETATE (PRESERVATIVE FREE)					
076313 001				PC	Oct 02, 2005
OCTREOTIDE ACETATE - OCTREOTIDE ACETATE (PRESERVATIVE FREE)					
076313 002				PC	Oct 02, 2005
OCTREOTIDE ACETATE - OCTREOTIDE ACETATE (PRESERVATIVE FREE)					
076313 003				PC	Oct 02, 2005
OCTREOTIDE ACETATE - SANDOSTATIN					
019667 005	**>A>** 5753618	May 19, 2015			
OLANZAPINE - ZYPREXA					
021253 001				**>A>** I-463	Aug 03, 2008
OLMESARTAN MEDOXOMIL - BENICAR					
021286 001	6878703	Nov 19, 2021	U-3		
OLMESARTAN MEDOXOMIL - BENICAR					
021286 003	6878703	Nov 19, 2021	U-3		
OLMESARTAN MEDOXOMIL - BENICAR					
021286 004	6878703	Nov 19, 2021	U-3		
OMEPRAZOLE - ZEGERID					
021706 001	5840737	Jul 16, 2016	DS U-624	**>A>** NP	Dec 21, 2007
	5840737	Jul 16, 2016	DS U-623		
	6489346	Jul 16, 2016	DS DP U-624		
	6489346	Jul 16, 2016	DS DP U-623		
	6645988	Jul 16, 2016	DS DP		
	6699885	Jul 16, 2016	U-624		
	6699885	Jul 16, 2016	U-623		
	6780882	Jul 16, 2016	DS DP		
ONDANSETRON HYDROCHLORIDE - ZOFRAN					
020007 001				D-98	Mar 25, 2008
				D-97	Mar 25, 2008
				PED	Sep 25, 2008
				PED	Sep 25, 2008
ONDANSETRON HYDROCHLORIDE - ZOFRAN PRESERVATIVE FREE					
020007 003				D-98	Mar 25, 2008
				D-97	Mar 25, 2008
				PED	Sep 25, 2008
				PED	Sep 25, 2008
OXALIPLATIN - ELOXATIN					
021759 001				I-441	Nov 04, 2007
				NCE	Aug 09, 2007
OXALIPLATIN - ELOXATIN					
021759 002				I-441	Nov 04, 2007
				NCE	Aug 09, 2007
OXANDROLONE - OXANDRIN					
013718 001				M-42	Jun 20, 2008
OXANDROLONE - OXANDRIN					
013718 002				M-42	Jun 20, 2008
OXCARBAZEPINE - TRILEPTAL					
021014 001				NCE	Jan 14, 2005
				PED	Jul 14, 2005
OXCARBAZEPINE - TRILEPTAL					
021014 002				NCE	Jan 14, 2005
				PED	Jul 14, 2005
OXCARBAZEPINE - TRILEPTAL					
021014 003				NCE	Jan 14, 2005
				PED	Jul 14, 2005

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATON DATE	PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OXCARBAZEPINE - TRILEPTAL						
021285 001					NCE	Jan 14, 2005
					PED	Jul 14, 2005
OXYBUTYNIN CHLORIDE - DITROPAN XL						
020897 001	**>A>** 6919092	May 22, 2015	DP	U-667		
	>A> 6919092*PED	Nov 22, 2015				
OXYBUTYNIN CHLORIDE - DITROPAN XL						
020897 002	**>A>** 6919092	May 22, 2015	DP	U-667		
	>A> 6919092*PED	Nov 22, 2015				
OXYBUTYNIN CHLORIDE - DITROPAN XL						
020897 003	**>A>** 6919092	May 22, 2015	DP	U-667		
	>A> 6919092*PED	Nov 22, 2015				
OXYCODONE HYDROCHLORIDE - OXYCODONE HCL						
075923 001					PC	Dec 04, 2005
OXYCODONE HYDROCHLORIDE - OXYCODONE HCL						
075923 002					PC	Dec 04, 2005
OXYCODONE HYDROCHLORIDE - OXYCODONE HCL						
075923 003					PC	Dec 04, 2005
OXYCODONE HYDROCHLORIDE - OXYCODONE HCL						
075923 004					PC	Dec 04, 2005
PACLITAXEL - ABRAXANE						
021660 001	5439686	Feb 22, 2013	DP		NP	Jan 07, 2008
	5498421	Mar 12, 2013	DP	U-634		
	6096331	Feb 22, 2013	DP	U-633		
	6506405	Feb 22, 2013	DP	U-633		
	6537579	Feb 22, 2013		U-632		
	6749868	Feb 22, 2013	DP			
	6753006	Feb 22, 2013	DP			
PARICALCITOL - ZEMPLAR						
021606 001	**>A>** 5246925	Apr 17, 2012		U-671	NDF	May 26, 2008
	>A> 5246925*PED	Oct 17, 2012				
	>A> 5587497	Dec 24, 2013	DS			
	>A> 5587497*PED	Jun 24, 2014				
PARICALCITOL - ZEMPLAR						
021606 002	**>A>** 5246925	Apr 17, 2012		U-671	NDF	May 26, 2008
	>A> 5246925*PED	Oct 17, 2012				
	>A> 5587497	Dec 24, 2013	DS			
	>A> 5587497*PED	Jun 24, 2014				
PARICALCITOL - ZEMPLAR						
021606 003	**>A>** 5246925	Apr 17, 2012		U-671	NDF	May 26, 2008
	>A> 5246925*PED	Oct 17, 2012				
	>A> 5587497	Dec 24, 2013	DS			
	>A> 5587497*PED	Jun 24, 2014				
PAROXETINE MESYLATE - PEXEVA						
021299 001	**>A>** 6703408	Oct 21, 2022	DP			
PAROXETINE MESYLATE - PEXEVA						
021299 002	**>A>** 6703408	Oct 21, 2022	DP			
PAROXETINE MESYLATE - PEXEVA						
021299 003	**>A>** 6703408	Oct 21, 2022	DP			
PAROXETINE MESYLATE - PEXEVA						
021299 004	**>A>** 6703408	Oct 21, 2022	DP			
PEGAPTANIB SODIUM - MACUGEN						
021756 001	5919455	Oct 27, 2013	DS			
	5932462	Aug 03, 2016	DS			
	6011020	Jan 04, 2017	DS			
	6051698	Oct 17, 2012	DS			
	6113906	Oct 27, 2013	DS			
	6147204	Jun 11, 2010	DS			
	6426335	Jun 11, 2010		U-622		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATON DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PERFLUTREN - DEFINITY					
021064 001	6033645	Jun 19, 2016	U-665		
	6146657	Dec 22, 2009 DS			
	6528039	Apr 05, 2011 DS			
	6773696	Apr 05, 2011 DS			
PRAMLINTIDE ACETATE - SYMLIN					
021332 001	5175145	Dec 29, 2009	U-637	NCE	Mar 16, 2010
	5686411	Nov 11, 2014 DS	DP U-638		
	5814600	Sep 29, 2015	U-639		
	5998367	Mar 08, 2011 DS	DP		
	6114304	Sep 05, 2017	U-640		
	6410511	Jan 09, 2018	DP		
	6608029	Sep 07, 2013	U-641		
	6610824	Mar 08, 2011 DS			
PREGABALIN - LYRICA					
021446 001	5563175	Oct 08, 2013	U-661		
	6001876	Jul 16, 2017	U-55		
	6197819	Mar 06, 2018 DS	DP		
PREGABALIN - LYRICA					
021446 002	5563175	Oct 08, 2013	U-661		
	6001876	Jul 16, 2017	U-55		
	6197819	Mar 06, 2018 DS	DP		
PREGABALIN - LYRICA					
021446 003	5563175	Oct 08, 2013	U-661		
	6001876	Jul 16, 2017	U-55		
	6197819	Mar 06, 2018 DS	DP		
PREGABALIN - LYRICA					
021446 004	5563175	Oct 08, 2013	U-661		
	6001876	Jul 16, 2017	U-55		
	6197819	Mar 06, 2018 DS	DP		
PREGABALIN - LYRICA					
021446 005	5563175	Oct 08, 2013	U-661		
	6001876	Jul 16, 2017	U-55		
	6197819	Mar 06, 2018 DS	DP		
PREGABALIN - LYRICA					
021446 006	5563175	Oct 08, 2013	U-661		
	6001876	Jul 16, 2017	U-55		
	6197819	Mar 06, 2018 DS	DP		
PREGABALIN - LYRICA					
021446 007	5563175	Oct 08, 2013	U-661		
	6001876	Jul 16, 2017	U-55		
	6197819	Mar 06, 2018 DS	DP		
PREGABALIN - LYRICA					
021446 008	5563175	Oct 08, 2013	U-661		
	6001876	Jul 16, 2017	U-55		
	6197819	Mar 06, 2018 DS	DP		
RALOXIFENE HYDROCHLORIDE - EVISTA					
020815 001	6894064	Mar 10, 2017	DP U-657		
	6906086	Jul 28, 2012	U-662		
	6906086	Jul 28, 2012	U-657		
RAMELTEON - ROZEREM					
021782 001				**>A>** NCE	Jul 22, 2010
RIBAVIRIN - COPEGUS					
021511 001				I-447	Feb 25, 2008
RIBAVIRIN - COPEGUS					
021511 002				**>A>** I-447	Feb 25, 2008
				>A> NP	Dec 03, 2005
RISPERIDONE - RISPERDAL					
021444 004	4804663	Dec 29, 2007 DS	DP U-543		
	5648093	Jul 15, 2014	DP		
	6224905	Jun 10, 2017	DP		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATON DATE		PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RISPERIDONE - RISPERDAL								
021444 005		4804663	Dec 29, 2007	DS	DP	U-543		
		5648093	Jul 15, 2014		DP			
		6224905	Jun 10, 2017		DP			
ROPINIROLE HYDROCHLORIDE - REQUIP								
020658 001		4452808	Dec 07, 2007	DS	DP		>A> I-464	May 04, 2008
ROPINIROLE HYDROCHLORIDE - REQUIP								
020658 002		4452808	Dec 07, 2007	DS	DP		>A> I-464	May 04, 2008
ROPINIROLE HYDROCHLORIDE - REQUIP								
020658 003		4452808	Dec 07, 2007	DS	DP		>A> I-464	May 04, 2008
ROPINIROLE HYDROCHLORIDE - REQUIP								
020658 004		4452808	Dec 07, 2007	DS	DP		>A> I-464	May 04, 2008
ROPINIROLE HYDROCHLORIDE - REQUIP								
020658 005		4452808	Dec 07, 2007	DS	DP		>A> I-464	May 04, 2008
ROPINIROLE HYDROCHLORIDE - REQUIP								
020658 006		4452808	Dec 07, 2007	DS	DP		>A> I-464	May 04, 2008
ROPINIROLE HYDROCHLORIDE - REQUIP								
020658 007		4452808	Dec 07, 2007	DS	DP		>A> I-464	May 04, 2008
ROSIGLITAZONE MALEATE - AVANDIA								
021071 002		5002953	Aug 30, 2008	DS	DP	U-628	I-453	Feb 28, 2008
		5002953	Aug 30, 2008	DS	DP	U-329		
		5741803	Apr 21, 2015	DS	DP	U-628		
		5741803	Apr 21, 2015	DS	DP	U-329		
ROSIGLITAZONE MALEATE - AVANDIA								
021071 003		5002953	Aug 30, 2008	DS	DP	U-628	I-453	Feb 28, 2008
		5002953	Aug 30, 2008	DS	DP	U-329		
		5741803	Apr 21, 2015	DS	DP	U-628		
		5741803	Apr 21, 2015	DS	DP	U-329		
ROSIGLITAZONE MALEATE - AVANDIA								
021071 004		5002953	Aug 30, 2008	DS	DP	U-628	I-453	Feb 28, 2008
		5002953	Aug 30, 2008	DS	DP	U-329		
		5741803	Apr 21, 2015	DS	DP	U-628		
		5741803	Apr 21, 2015	DS	DP	U-329		
ROSUVASTATIN CALCIUM - CRESTOR								
021366 002		6858618	Dec 17, 2021			U-618		
ROSUVASTATIN CALCIUM - CRESTOR								
021366 003		6858618	Dec 17, 2021			U-618		
ROSUVASTATIN CALCIUM - CRESTOR								
021366 004		6858618	Dec 17, 2021			U-618		
ROSUVASTATIN CALCIUM - CRESTOR								
021366 005		6858618	Dec 17, 2021			U-618		
SILDENAFIL CITRATE - REVATIO								
021845 001	>A>	5250534	Mar 27, 2012	DS	DP		NP	Jun 03, 2008
SIROLIMUS - RAPAMUNE								
021083 001		5536729	Sep 30, 2013		DP		NPP	Mar 11, 2008
							PED	Sep 11, 2008
SIROLIMUS - RAPAMUNE								
021110 001		5989591	Mar 11, 2018		DP		NPP	Mar 11, 2008
							PED	Sep 11, 2008
SIROLIMUS - RAPAMUNE								
021110 002		5989591	Mar 11, 2018		DP		NPP	Mar 11, 2008
							PED	Sep 11, 2008

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATON DATE		PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SIROLIMUS - RAPAMUNE							
021110 003	5100899	Jun 06, 2009			U-290	NPP	Mar 11, 2008
	5100899*PED	Dec 06, 2009				PED	Sep 11, 2008
	5212155	May 18, 2010			U-291		
	5212155*PED	Nov 18, 2010					
	5403833	Apr 04, 2012			U-293		
	5403833*PED	Oct 04, 2012					
	5989591	Mar 11, 2018		DP			
	5989591*PED	Sep 11, 2018					
SODIUM BENZOATE; SODIUM PHENYLACETATE - AMMONUL							
020645 001						NDF	Feb 17, 2008
						ODE	Feb 17, 2012
SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE							
020280 001	4968299	Jun 28, 2008		DP			
	6152897	Nov 20, 2018		DP			
SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE							
020280 002	4968299	Jun 28, 2008		DP			
	6152897	Nov 20, 2018		DP			
SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE							
020280 003	4968299	Jun 28, 2008		DP			
	6152897	Nov 20, 2018		DP			
SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE							
020280 005	4968299	Jun 28, 2008		DP			
	6152897	Nov 20, 2018		DP			
SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE							
020280 008	4968299	Jun 28, 2008		DP			
	6152897	Nov 20, 2018		DP			
SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE							
020280 009	4968299	Jun 28, 2008		DP			
	6152897	Nov 20, 2018		DP			
SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE							
020280 010	4968299	Jun 28, 2008		DP			
SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE							
020280 011	4968299	Jun 28, 2008		DP			
SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE							
020280 012	4968299	Jun 28, 2008		DP			
SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE							
020280 013	4968299	Jun 28, 2008		DP			
SOMATROPIN RECOMBINANT - NUTROPIN							
020168 001						**>A>** I-462	Jun 28, 2008
SOMATROPIN RECOMBINANT - NUTROPIN							
020168 002						**>A>** I-462	Jun 28, 2008
SOMATROPIN RECOMBINANT - NUTROPIN AQ							
020522 001						**>A>** I-462	Jun 28, 2008
SOMATROPIN RECOMBINANT - NUTROPIN AQ PEN							
020522 002						**>A>** I-462	Jun 28, 2008
TELITHROMYCIN - KETEK							
021144 002	5635485	Apr 21, 2015	DS	DP	U-578	NCE	Apr 01, 2009
	D459798	Sep 24, 2015		DP			
TEMOZOLOMIDE - TEMODAR							
021029 001	5260291	Aug 11, 2013	DS	DP	U-619	I-450	Mar 15, 2008
	5260291*PED	Feb 11, 2014				ODE	Mar 15, 2012
TEMOZOLOMIDE - TEMODAR							
021029 002	5260291	Aug 11, 2013	DS	DP	U-619	I-450	Mar 15, 2008
	5260291*PED	Feb 11, 2014				ODE	Mar 15, 2012
TEMOZOLOMIDE - TEMODAR							
021029 003	5260291	Aug 11, 2013	DS	DP	U-619	I-450	Mar 15, 2008
	5260291*PED	Feb 11, 2014				ODE	Mar 15, 2012

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATON DATE	PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TEMOZOLOMIDE - TEMODAR						
021029 004	5260291	Aug 11, 2013	DS	DP U-619	I-450	Mar 15, 2008
	5260291*PED	Feb 11, 2014			ODE	Mar 15, 2012
THALIDOMIDE - THALOMID						
020785 001	6869399	Oct 23, 2020		U-371		
	>A> 6908432	Aug 28, 2018		U-371		
THALIDOMIDE - THALOMID						
020785 002	6869399	Oct 23, 2020		U-371		
	>A> 6908432	Aug 28, 2018		U-371		
THALIDOMIDE - THALOMID						
020785 003	6869399	Oct 23, 2020		U-371		
	>A> 6908432	Aug 28, 2018		U-371		
TIGECYCLINE - TYGACIL						
021821 001	**>A>** 5494903	Aug 13, 2012	DS	DP	NCE	Jun 15, 2010
	>A> 5529990	Jun 25, 2013		U-282		
TIOTROPIUM BROMIDE MONOHYDRATE - SPIRIVA						
021395 001	**>A>** 6908928	Nov 25, 2022	DS	DP U-566		
TIPRANAVIR - APTIVUS						
021814 001	**>A>** 5852195	Dec 22, 2015	DS		NCE	Jun 22, 2010
	>A> 6147095	Oct 29, 2019		U-670		
	>A> 6169181	May 06, 2014	DS			
	>A> 6231887	Jul 27, 2018		DP		
TOLTERODINE TARTRATE - DETROL LA						
021228 001	6911217	Aug 26, 2019		DP U-544		
	6911217*PED	Feb 26, 2020		DP U-544		
TOLTERODINE TARTRATE - DETROL LA						
021228 002	6911217	Aug 26, 2019		DP U-544		
	6911217*PED	Feb 26, 2020		DP U-544		
TOPIRAMATE - TOPAMAX						
020505 001					I-41	Aug 11, 2007
TOPIRAMATE - TOPAMAX						
020505 002					I-41	Aug 11, 2007
TOPIRAMATE - TOPAMAX						
020505 003					I-41	Aug 11, 2007
TOPIRAMATE - TOPAMAX						
020505 004					I-41	Aug 11, 2007
TOPIRAMATE - TOPAMAX						
020505 005					I-41	Aug 11, 2007
TOPIRAMATE - TOPAMAX						
020505 006					I-41	Aug 11, 2007
TOPIRAMATE - TOPAMAX SPRINKLE						
020844 001					I-41	Aug 11, 2007
TOPIRAMATE - TOPAMAX SPRINKLE						
020844 002					I-41	Aug 11, 2007
TOPIRAMATE - TOPAMAX SPRINKLE						
020844 003					I-41	Aug 11, 2007
VORICONAZOLE - VFEND						
021266 001	5567817	May 24, 2016	DS	DP U-540		
VORICONAZOLE - VFEND						
021266 002	5567817	May 24, 2016	DS	DP U-540		
VORICONAZOLE - VFEND						
021267 001	5567817	May 24, 2016	DS	DP U-540		
VORICONAZOLE - VFEND						
021630 001	5567817	May 24, 2016	DS	DP U-540		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATON DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ZICONOTIDE - PRIALT					
021060 001	5364842	Dec 30, 2011	U-55		
	5364842	Dec 30, 2011	U-48		
	5795864	Jun 27, 2015	DP		
	5859186	Dec 30, 2011	U-55		
	5859186	Dec 30, 2011	U-48		
ZICONOTIDE - PRIALT					
021060 002	5364842	Dec 30, 2011	U-55		
	5364842	Dec 30, 2011	U-48		
	5795864	Jun 27, 2015	DP		
	5859186	Dec 30, 2011	U-55		
	5859186	Dec 30, 2011	U-48		
ZICONOTIDE - PRIALT					
021060 003	5364842	Dec 30, 2011	U-55		
	5364842	Dec 30, 2011	U-48		
	5795864	Jun 27, 2015	DP		
	5859186	Dec 30, 2011	U-55		
	5859186	Dec 30, 2011	U-48		
ZICONOTIDE - PRIALT					
021060 004	5364842	Dec 30, 2011	U-55		
	5364842	Dec 30, 2011	U-48		
	5795864	Jun 27, 2015	DP		
	5859186	Dec 30, 2011	U-55		
	5859186	Dec 30, 2011	U-48		

Footnote:
1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents submitted on FDA Form 3542 and listed after August 18, 2003 will have one to three patent codes indicating specific patent claims as submitted by the sponsor:
DS = Drug Substance claim
DP = Drug Product claim
U and number = Method of Use claim (may be multiple). Specific Method of use claims are listed at http://www.fda.gov/cder/orange/patex.htm
3. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.
4. *PED and PED represent pediatric exclusivity. Patents with pediatric exclusivity granted after August 18, 2003 will be indicated with *PED as was done prior to August 18, 2003. Patents with *PED added after August 18, 2003 will not contain any information relative to the patent itself other than the *PED extension. Information related specifically to the patent will be conveyed on the original patent only.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 25th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm

The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm